<!DOCTYPE html>
<!--[if lt IE 7]> <html lang='en' class='no-js lt-ie10 lt-ie9 lt-ie8 lt-ie7'> <![endif]-->
<!--[if IE 7]>    <html lang='en' class='no-js lt-ie10 lt-ie9 lt-ie8'> <![endif]-->
<!--[if IE 8]>    <html lang='en' class='no-js lt-ie10 lt-ie9'> <![endif]-->
<!--[if IE 9]>    <html lang='en' class='no-js lt-ie10'> <![endif]-->
<!--[if (gt IE 9)|!(IE)]><!-->
<html class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage no-websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients no-cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths" style="" lang="en"><!--<![endif]--><head><script src="https://js-agent.newrelic.com/nr-1167.min.js"></script><script type="text/javascript" src="//api-public.addthis.com/url/shares.json?url=http%3A%2F%2Fwww.jci.org%2Farticles%2Fview%2F44423&amp;callback=_ate.cbs.rcb_it750"></script><script type="text/javascript" src="//graph.facebook.com/?id=http%3A%2F%2Fwww.jci.org%2Farticles%2Fview%2F44423&amp;fields=og_object%7Bengagement%7D&amp;callback=_ate.cbs.rcb_3e480"></script><script type="text/javascript" src="//api-public.addthis.com/url/shares.json?url=https%3A%2F%2Fwww.jci.org%2Farticles%2Fview%2F44423&amp;callback=_ate.cbs.rcb_e8ja0"></script><script type="text/javascript" src="//graph.facebook.com/?id=https%3A%2F%2Fwww.jci.org%2Farticles%2Fview%2F44423&amp;fields=og_object%7Bengagement%7D&amp;callback=_ate.cbs.rcb_6ex50"></script><script src="amp4ads-host-v0.js"></script><script src="pubads_impl_rendering_2020030501.js"></script><script type="text/javascript" async="" src="analytics.js"></script><script type="text/javascript" src="300lo.json"></script><script type="text/javascript" src="_ate.config_resp"></script><script type="text/javascript" src="moatframe.js"></script><meta class="foundation-mq-small"><meta class="foundation-mq-small-only"><meta class="foundation-mq-medium"><meta class="foundation-mq-medium-only"><meta class="foundation-mq-large"><meta class="foundation-mq-large-only"><meta class="foundation-mq-xlarge"><meta class="foundation-mq-xlarge-only"><meta class="foundation-mq-xxlarge"><meta class="foundation-data-attribute-namespace">
<meta charset="utf-8">
<script async="" src="gtm.js"></script><script async="" type="text/javascript" src="gpt.js"></script><script>window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"27b438aa5b","applicationID":"77504","transactionName":"cV9cEEdeCA5cExpTQkZZUQhQQksUUARC","queueTime":0,"applicationTime":663,"agent":""}</script>
<script>(window.NREUM||(NREUM={})).loader_config={licenseKey:"27b438aa5b",applicationID:"77504"};window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var i=n[t]={exports:{}};e[t][0].call(i.exports,function(n){var i=e[t][1][n];return r(i||n)},i,i.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var i=0;i<t.length;i++)r(t[i]);return r}({1:[function(e,n,t){function r(){}function i(e,n,t){return function(){return o(e,[u.now()].concat(f(arguments)),n?null:this,t),n?void 0:this}}var o=e("handle"),a=e(4),f=e(5),c=e("ee").get("tracer"),u=e("loader"),s=NREUM;"undefined"==typeof window.newrelic&&(newrelic=s);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],l="api-",d=l+"ixn-";a(p,function(e,n){s[n]=i(l+n,!0,"api")}),s.addPageAction=i(l+"addPageAction",!0),s.setCurrentRouteName=i(l+"routeName",!0),n.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(e,n){var t={},r=this,i="function"==typeof n;return o(d+"tracer",[u.now(),e,t],r),function(){if(c.emit((i?"":"no-")+"fn-start",[u.now(),r,i],t),i)try{return n.apply(this,arguments)}catch(e){throw c.emit("fn-err",[arguments,this,e],t),e}finally{c.emit("fn-end",[u.now()],t)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(e,n){m[n]=i(d+n)}),newrelic.noticeError=function(e,n){"string"==typeof e&&(e=new Error(e)),o("err",[e,u.now(),!1,n])}},{}],2:[function(e,n,t){function r(e,n){var t=e.getEntries();t.forEach(function(e){"first-paint"===e.name?c("timing",["fp",Math.floor(e.startTime)]):"first-contentful-paint"===e.name&&c("timing",["fcp",Math.floor(e.startTime)])})}function i(e,n){var t=e.getEntries();t.length>0&&c("lcp",[t[t.length-1]])}function o(e){if(e instanceof s&&!l){var n,t=Math.round(e.timeStamp);n=t>1e12?Date.now()-t:u.now()-t,l=!0,c("timing",["fi",t,{type:e.type,fid:n}])}}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var a,f,c=e("handle"),u=e("loader"),s=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){a=new PerformanceObserver(r),f=new PerformanceObserver(i);try{a.observe({entryTypes:["paint"]}),f.observe({entryTypes:["largest-contentful-paint"]})}catch(p){}}if("addEventListener"in document){var l=!1,d=["click","keydown","mousedown","pointerdown","touchstart"];d.forEach(function(e){document.addEventListener(e,o,!1)})}}},{}],3:[function(e,n,t){function r(e,n){if(!i)return!1;if(e!==i)return!1;if(!n)return!0;if(!o)return!1;for(var t=o.split("."),r=n.split("."),a=0;a<r.length;a++)if(r[a]!==t[a])return!1;return!0}var i=null,o=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var f=navigator.userAgent,c=f.match(a);c&&f.indexOf("Chrome")===-1&&f.indexOf("Chromium")===-1&&(i="Safari",o=c[1])}n.exports={agent:i,version:o,match:r}},{}],4:[function(e,n,t){function r(e,n){var t=[],r="",o=0;for(r in e)i.call(e,r)&&(t[o]=n(r,e[r]),o+=1);return t}var i=Object.prototype.hasOwnProperty;n.exports=r},{}],5:[function(e,n,t){function r(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,i=t-n||0,o=Array(i<0?0:i);++r<i;)o[r]=e[n+r];return o}n.exports=r},{}],6:[function(e,n,t){n.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(e,n,t){function r(){}function i(e){function n(e){return e&&e instanceof r?e:e?c(e,f,o):o()}function t(t,r,i,o){if(!l.aborted||o){e&&e(t,r,i);for(var a=n(i),f=v(t),c=f.length,u=0;u<c;u++)f[u].apply(a,r);var p=s[y[t]];return p&&p.push([b,t,r,a]),a}}function d(e,n){h[e]=v(e).concat(n)}function m(e,n){var t=h[e];if(t)for(var r=0;r<t.length;r++)t[r]===n&&t.splice(r,1)}function v(e){return h[e]||[]}function g(e){return p[e]=p[e]||i(t)}function w(e,n){u(e,function(e,t){n=n||"feature",y[t]=n,n in s||(s[n]=[])})}var h={},y={},b={on:d,addEventListener:d,removeEventListener:m,emit:t,get:g,listeners:v,context:n,buffer:w,abort:a,aborted:!1};return b}function o(){return new r}function a(){(s.api||s.feature)&&(l.aborted=!0,s=l.backlog={})}var f="nr@context",c=e("gos"),u=e(4),s={},p={},l=n.exports=i();l.backlog=s},{}],gos:[function(e,n,t){function r(e,n,t){if(i.call(e,n))return e[n];var r=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:r,writable:!0,enumerable:!1}),r}catch(o){}return e[n]=r,r}var i=Object.prototype.hasOwnProperty;n.exports=r},{}],handle:[function(e,n,t){function r(e,n,t,r){i.buffer([e],r),i.emit(e,n,t)}var i=e("ee").get("handle");n.exports=r,r.ee=i},{}],id:[function(e,n,t){function r(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:a(e,o,function(){return i++})}var i=1,o="nr@id",a=e("gos");n.exports=r},{}],loader:[function(e,n,t){function r(){if(!x++){var e=E.info=NREUM.info,n=d.getElementsByTagName("script")[0];if(setTimeout(s.abort,3e4),!(e&&e.licenseKey&&e.applicationID&&n))return s.abort();u(y,function(n,t){e[n]||(e[n]=t)}),c("mark",["onload",a()+E.offset],null,"api");var t=d.createElement("script");t.src="https://"+e.agent,n.parentNode.insertBefore(t,n)}}function i(){"complete"===d.readyState&&o()}function o(){c("mark",["domContent",a()+E.offset],null,"api")}function a(){return O.exists&&performance.now?Math.round(performance.now()):(f=Math.max((new Date).getTime(),f))-E.offset}var f=(new Date).getTime(),c=e("handle"),u=e(4),s=e("ee"),p=e(3),l=window,d=l.document,m="addEventListener",v="attachEvent",g=l.XMLHttpRequest,w=g&&g.prototype;NREUM.o={ST:setTimeout,SI:l.setImmediate,CT:clearTimeout,XHR:g,REQ:l.Request,EV:l.Event,PR:l.Promise,MO:l.MutationObserver};var h=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1167.min.js"},b=g&&w&&w[m]&&!/CriOS/.test(navigator.userAgent),E=n.exports={offset:f,now:a,origin:h,features:{},xhrWrappable:b,userAgent:p};e(1),e(2),d[m]?(d[m]("DOMContentLoaded",o,!1),l[m]("load",r,!1)):(d[v]("onreadystatechange",i),l[v]("onload",r)),c("mark",["firstbyte",f],null,"api");var x=0,O=e(6)},{}],"wrap-function":[function(e,n,t){function r(e){return!(e&&e instanceof Function&&e.apply&&!e[a])}var i=e("ee"),o=e(5),a="nr@original",f=Object.prototype.hasOwnProperty,c=!1;n.exports=function(e,n){function t(e,n,t,i){function nrWrapper(){var r,a,f,c;try{a=this,r=o(arguments),f="function"==typeof t?t(r,a):t||{}}catch(u){l([u,"",[r,a,i],f])}s(n+"start",[r,a,i],f);try{return c=e.apply(a,r)}catch(p){throw s(n+"err",[r,a,p],f),p}finally{s(n+"end",[r,a,c],f)}}return r(e)?e:(n||(n=""),nrWrapper[a]=e,p(e,nrWrapper),nrWrapper)}function u(e,n,i,o){i||(i="");var a,f,c,u="-"===i.charAt(0);for(c=0;c<n.length;c++)f=n[c],a=e[f],r(a)||(e[f]=t(a,u?f+i:i,o,f))}function s(t,r,i){if(!c||n){var o=c;c=!0;try{e.emit(t,r,i,n)}catch(a){l([a,t,r,i])}c=o}}function p(e,n){if(Object.defineProperty&&Object.keys)try{var t=Object.keys(e);return t.forEach(function(t){Object.defineProperty(n,t,{get:function(){return e[t]},set:function(n){return e[t]=n,n}})}),n}catch(r){l([r])}for(var i in e)f.call(e,i)&&(n[i]=e[i]);return n}function l(n){try{e.emit("internal-error",n)}catch(t){}}return e||(e=i),t.inPlace=u,t.flag=a,t}},{}]},{},["loader"]);</script>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
<meta content="The Journal of Clinical Investigation" name="AUTHOR">
<!-- Set the viewport width to device width for mobile -->
<meta content="width=device-width, initial-scale=1.0" name="viewport">
<link href="https://www.jci.org/rss" rel="alternate" title="JCI New Article RSS" type="application/rss+xml">
<meta name="csrf-param" content="authenticity_token">
<meta name="csrf-token" content="DHHDTJMu5SEx5cv+Y9yBLqCBblzytlS3gEyEf+T0QMD/353eEcVkGAR0F8pN9TeIo5ogS8jV3vaPVn0Nu662xA==">
<meta name="citation_title" content="Advances and challenges in malaria vaccine development">
<meta name="citation_author" content="Peter D. Crompton">
<meta name="citation_author" content="Susan K. Pierce">
<meta name="citation_author" content="Louis H. Miller">

<meta name="citation_journal_title" content="The Journal of Clinical Investigation">
<meta name="citation_journal_abbrev" content="J Clin Invest">
<meta name="citation_publisher" content="American Society for Clinical Investigation">
<meta name="citation_issue" content="12">
<meta name="citation_volume" content="120">
<meta name="citation_doi" content="10.1172/JCI44423">
<meta name="citation_pmid" content="21123952">
<meta name="citation_firstpage" content="4168">
<meta name="citation_lastpage" content="4178">
<meta name="citation_publication_date" content="2010/12/01">
<meta name="citation_html_url" content="http://www.jci.org/articles/view/44423">
<meta name="citation_pdf_url" content="http://www.jci.org/articles/view/44423/files/pdf">
<meta name="citation_xml_url" content="http://www.jci.org/articles/view/44423/xml">
<meta name="citation_issn" content="0021-9738">
<meta name="citation_fulltext_world_readable" content="">
<meta name="citation_reference" content="citation_title=The global distribution of clinical episodes of Plasmodium falciparum malaria.;citation_author=RW Snow;citation_author=CA Guerra;citation_author=AM Noor;citation_author=HY Myint;citation_author=SI Hay;citation_journal_title=Nature.;citation_volume=434;citation_issue=7030;citation_pages=214-217;citation_year=2005;">
<meta name="citation_reference" content="citation_title=Changes in the burden of malaria in sub-Saharan Africa.;citation_author=WP O’Meara;citation_author=JN Mangeni;citation_author=R Steketee;citation_author=B Greenwood;citation_journal_title=Lancet Infect Dis.;citation_volume=10;citation_issue=8;citation_pages=545-555;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Increasing incidence of malaria in the Negro River basin, Brazilian Amazon.;citation_author=AC Cabral;citation_author=NF Fe;citation_author=MC Suarez-Mutis;citation_author=MN Boia;citation_author=FA Carvalho-Costa;citation_journal_title=Trans R Soc Trop Med Hyg.;citation_volume=104;citation_issue=8;citation_pages=556-562;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Artemisinin resistance: current status and scenarios for containment.;citation_author=AM Dondorp;citation_journal_title=Nat Rev Microbiol.;citation_volume=8;citation_issue=4;citation_pages=272-280;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Reduced efficacy of insecticide-treated nets and indoor residual spraying for malaria control in pyrethroid resistance area, Benin.;citation_author=R N’Guessan;citation_author=V Corbel;citation_author=M Akogbeto;citation_author=M Rowland;citation_journal_title=Emerg Infect Dis.;citation_volume=13;citation_issue=2;citation_pages=199-206;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Genome sequence of the human malaria parasite Plasmodium falciparum.;citation_author=MJ Gardner;citation_journal_title=Nature.;citation_volume=419;citation_issue=6906;citation_pages=498-511;citation_year=2002;">
<meta name="citation_reference" content="citation_title=A proteomic view of the Plasmodium falciparum life cycle.;citation_author=L Florens;citation_journal_title=Nature.;citation_volume=419;citation_issue=6906;citation_pages=520-526;citation_year=2002;">
<meta name="citation_reference" content="citation_title=Antigenic variation in Plasmodium falciparum.;citation_author=A Scherf;citation_author=JJ Lopez-Rubio;citation_author=L Riviere;citation_journal_title=Annu Rev Microbiol.;citation_volume=62;citation_pages=445-470;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Immunity to malaria: more questions than answers.;citation_author=J Langhorne;citation_author=FM Ndungu;citation_author=AM Sponaas;citation_author=K Marsh;citation_journal_title=Nat Immunol.;citation_volume=9;citation_issue=7;citation_pages=725-732;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Immune effector mechanisms in malaria.;citation_author=K Marsh;citation_author=S Kinyanjui;citation_journal_title=Parasite Immunol.;citation_volume=28;citation_issue=1–2;citation_pages=51-60;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Immunity to non-cerebral severe malaria is acquired after one or two infections.;citation_author=S Gupta;citation_author=RW Snow;citation_author=CA Donnelly;citation_author=K Marsh;citation_author=C Newbold;citation_journal_title=Nat Med.;citation_volume=5;citation_issue=3;citation_pages=340-343;citation_year=1999;">
<meta name="citation_reference" content="citation_title=Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria.;citation_author=JK Baird;citation_journal_title=Am J Trop Med Hyg.;citation_volume=45;citation_issue=1;citation_pages=65-76;citation_year=1991;">
<meta name="citation_reference" content="citation_title=Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria.;citation_author=JK Baird;citation_journal_title=Am J Trop Med Hyg.;citation_volume=49;citation_issue=6;citation_pages=707-719;citation_year=1993;">
<meta name="citation_reference" content="citation_title=The pre-erythrocytic stage of Plasmodium falciparum.;citation_author=HE Shortt;citation_author=NH Fairley;citation_author=G Covell;citation_author=PG Shute;citation_author=PC Garnham;citation_journal_title=Trans R Soc Trop Med Hyg.;citation_volume=44;citation_issue=4;citation_pages=405-419;citation_year=1951;">
<meta name="citation_reference" content="citation_title=Sidelights on malaria in man obtained by subinoculation experiments.;citation_author=NH Fairley;citation_journal_title=Trans R Soc Trop Med Hyg.;citation_volume=40;citation_issue=5;citation_pages=621-676;citation_year=1947;">
<meta name="citation_reference" content="citation_title=The RTS,S malaria vaccine.;citation_author=S Casares;citation_author=TD Brumeanu;citation_author=TL Richie;citation_journal_title=Vaccine.;citation_volume=28;citation_issue=31;citation_pages=4880-4894;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection.;citation_author=JA Simpson;citation_author=L Aarons;citation_author=WE Collins;citation_author=GM Jeffery;citation_author=NJ White;citation_journal_title=Parasitology.;citation_volume=124;citation_issue=pt 3;citation_pages=247-263;citation_year=2002;">
<meta name="citation_reference" content="citation_title=A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray.;citation_author=PD Crompton;citation_journal_title=Proc Natl Acad Sci U S A.;citation_volume=107;citation_issue=15;citation_pages=6958-6963;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice.;citation_author=A Pinzon-Charry;citation_journal_title=J Clin Invest.;citation_volume=120;citation_issue=8;citation_pages=2967-2978;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.;citation_author=DJ Pombo;citation_journal_title=Lancet.;citation_volume=360;citation_issue=9333;citation_pages=610-617;citation_year=2002;">
<meta name="citation_reference" content="citation_title=The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections.;citation_author=GE Weiss;citation_journal_title=PLoS Pathog.;citation_volume=6;citation_issue=5;citation_pages=e1000912-;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Gamma-globulin and acquired immunity to human malaria.;citation_author=S Cohen;citation_author=IA McGregor;citation_author=S Carrington;citation_journal_title=Nature.;citation_volume=192;citation_pages=733-737;citation_year=1961;">
<meta name="citation_reference" content="citation_title=Evidence for environmental modulation of gametocytogenesis in Plasmodium falciparum in continuous culture.;citation_author=R Carter;citation_author=LH Miller;citation_journal_title=Bull World Health Organ.;citation_volume=57;citation_issue=suppl 1;citation_pages=37-52;citation_year=1979;">
<meta name="citation_reference" content="citation_title=Malaria transmission-blocking vaccines — how can their development be supported?;citation_author=R Carter;citation_author=KN Mendis;citation_author=LH Miller;citation_author=L Molineaux;citation_author=A Saul;citation_journal_title=Nat Med.;citation_volume=6;citation_issue=3;citation_pages=241-244;citation_year=2000;">
<meta name="citation_reference" content="citation_title=Protection against a malaria challenge by sporozoite inoculation.;citation_author=M Roestenberg;citation_journal_title=N Engl J Med.;citation_volume=361;citation_issue=5;citation_pages=468-477;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei.;citation_author=RS Nussenzweig;citation_author=J Vanderberg;citation_author=H Most;citation_author=C Orton;citation_journal_title=Nature.;citation_volume=216;citation_issue=5111;citation_pages=160-162;citation_year=1967;">
<meta name="citation_reference" content="citation_title=Development of a sporozoite malaria vaccine.;citation_author=V Nussenzweig;citation_author=RS Nussenzweig;citation_journal_title=Am J Trop Med Hyg.;citation_volume=35;citation_issue=4;citation_pages=678-688;citation_year=1986;">
<meta name="citation_reference" content="citation_title=Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum.;citation_author=JB Dame;citation_journal_title=Science.;citation_volume=225;citation_issue=4662;citation_pages=593-599;citation_year=1984;">
<meta name="citation_reference" content="citation_title=Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.;citation_author=DM Gordon;citation_journal_title=J Infect Dis.;citation_volume=171;citation_issue=6;citation_pages=1576-1585;citation_year=1995;">
<meta name="citation_reference" content="citation_title=A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.;citation_author=JA Stoute;citation_journal_title=N Engl J Med.;citation_volume=336;citation_issue=2;citation_pages=86-91;citation_year=1997;">
<meta name="citation_reference" content="citation_title=Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.;citation_author=KE Kester;citation_journal_title=J Infect Dis.;citation_volume=183;citation_issue=4;citation_pages=640-647;citation_year=2001;">
<meta name="citation_reference" content="citation_title=A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults.;citation_author=KE Kester;citation_journal_title=Vaccine.;citation_volume=25;citation_issue=29;citation_pages=5359-5366;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research.;citation_author=KE Kester;citation_journal_title=Vaccine.;citation_volume=26;citation_issue=18;citation_pages=2191-2202;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.;citation_author=KE Kester;citation_journal_title=J Infect Dis.;citation_volume=200;citation_issue=3;citation_pages=337-346;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.;citation_author=AI Olotu;citation_author=G Fegan;citation_author=P Bejon;citation_journal_title=J Infect Dis.;citation_volume=201;citation_issue=6;citation_pages=970-971;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.;citation_author=KA Bojang;citation_journal_title=Lancet.;citation_volume=358;citation_issue=9297;citation_pages=1927-1934;citation_year=2001;">
<meta name="citation_reference" content="citation_title=Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.;citation_author=ME Polhemus;citation_journal_title=PLoS One.;citation_volume=4;citation_issue=7;citation_pages=e6465-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.;citation_author=PL Alonso;citation_journal_title=Lancet.;citation_volume=364;citation_issue=9443;citation_pages=1411-1420;citation_year=2004;">
<meta name="citation_reference" content="citation_title=Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.;citation_author=PL Alonso;citation_journal_title=Lancet.;citation_volume=366;citation_issue=9502;citation_pages=2012-2018;citation_year=2005;">
<meta name="citation_reference" content="citation_title=Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.;citation_author=J Sacarlal;citation_journal_title=J Infect Dis.;citation_volume=200;citation_issue=3;citation_pages=329-336;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.;citation_author=S Abdulla;citation_journal_title=N Engl J Med.;citation_volume=359;citation_issue=24;citation_pages=2533-2544;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.;citation_author=P Bejon;citation_journal_title=N Engl J Med.;citation_volume=359;citation_issue=24;citation_pages=2521-2532;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.;citation_author=C Guinovart;citation_journal_title=PLoS One.;citation_volume=4;citation_issue=4;citation_pages=e5165-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.;citation_author=JJ Aponte;citation_journal_title=Lancet.;citation_volume=370;citation_issue=9598;citation_pages=1543-1551;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.;citation_author=B Genton;citation_journal_title=Vaccine.;citation_volume=28;citation_issue=40;citation_pages=6573-6580;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.;citation_author=M Walther;citation_journal_title=Infect Immun.;citation_volume=74;citation_issue=5;citation_pages=2706-2716;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.;citation_author=M Walther;citation_journal_title=Vaccine.;citation_volume=23;citation_issue=7;citation_pages=857-864;citation_year=2005;">
<meta name="citation_reference" content="citation_title=A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.;citation_author=J Kubler-Kielb;citation_journal_title=Proc Natl Acad Sci U S A.;citation_volume=107;citation_issue=3;citation_pages=1172-1177;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.;citation_author=SL Hoffman;citation_journal_title=Hum Vaccin.;citation_volume=6;citation_issue=1;citation_pages=97-106;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Genetically engineered, attenuated whole-cell vaccine approaches for malaria.;citation_author=AM Vaughan;citation_author=R Wang;citation_author=SH Kappe;citation_journal_title=Hum Vaccin.;citation_volume=6;citation_issue=1;citation_pages=107-113;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Prime-boost vectored malaria vaccines: progress and prospects.;citation_author=AV Hill;citation_journal_title=Hum Vaccin.;citation_volume=6;citation_issue=1;citation_pages=78-83;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75.;citation_author=DF Clyde;citation_journal_title=Bull World Health Organ.;citation_volume=68;citation_issue=suppl;citation_pages=9-12;citation_year=1990;">
<meta name="citation_reference" content="citation_title=Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.;citation_author=SL Hoffman;citation_journal_title=J Infect Dis.;citation_volume=185;citation_issue=8;citation_pages=1155-1164;citation_year=2002;">
<meta name="citation_reference" content="citation_title=Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes.;citation_author=A Trimnell;citation_author=A Takagi;citation_author=M Gupta;citation_author=TL Richie;citation_author=SH Kappe;citation_author=R Wang;citation_journal_title=J Immunol.;citation_volume=183;citation_issue=9;citation_pages=5870-5878;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.;citation_author=DP Webster;citation_journal_title=Proc Natl Acad Sci U S A.;citation_volume=102;citation_issue=13;citation_pages=4836-4841;citation_year=2005;">
<meta name="citation_reference" content="citation_title=A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.;citation_author=P Bejon;citation_journal_title=PLoS Clin Trials.;citation_volume=1;citation_issue=6;citation_pages=e29-;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.;citation_author=A Sabchareon;citation_journal_title=Am J Trop Med Hyg.;citation_volume=45;citation_issue=3;citation_pages=297-308;citation_year=1991;">
<meta name="citation_reference" content="citation_title=Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes.;citation_author=H Bouharoun-Tayoun;citation_author=P Attanath;citation_author=A Sabchareon;citation_author=T Chongsuphajaisiddhi;citation_author=P Druilhe;citation_journal_title=J Exp Med.;citation_volume=172;citation_issue=6;citation_pages=1633-1641;citation_year=1990;">
<meta name="citation_reference" content="citation_title=Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.;citation_author=DI Baruch;citation_author=JA Gormely;citation_author=C Ma;citation_author=RJ Howard;citation_author=BL Pasloske;citation_journal_title=Proc Natl Acad Sci U S A.;citation_volume=93;citation_issue=8;citation_pages=3497-3502;citation_year=1996;">
<meta name="citation_reference" content="citation_title=Opsonic activity of human immune serum on in vitro phagocytosis of Plasmodium falciparum infected red blood cells by monocytes.;citation_author=A Celada;citation_author=A Cruchaud;citation_author=LH Perrin;citation_journal_title=Clin Exp Immunol.;citation_volume=47;citation_issue=3;citation_pages=635-644;citation_year=1982;">
<meta name="citation_reference" content="citation_title=Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses.;citation_author=H Groux;citation_author=J Gysin;citation_journal_title=Res Immunol.;citation_volume=141;citation_issue=6;citation_pages=529-542;citation_year=1990;">
<meta name="citation_reference" content="citation_title=Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.;citation_author=PC Bull;citation_author=BS Lowe;citation_author=M Kortok;citation_author=CS Molyneux;citation_author=CI Newbold;citation_author=K Marsh;citation_journal_title=Nat Med.;citation_volume=4;citation_issue=3;citation_pages=358-360;citation_year=1998;">
<meta name="citation_reference" content="citation_title=Naturally elicited antibodies to glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum require intact GPI structures for binding and are directed primarily against the conserved glycan moiety.;citation_author=RS Naik;citation_author=G Krishnegowda;citation_author=CF Ockenhouse;citation_author=DC Gowda;citation_journal_title=Infect Immun.;citation_volume=74;citation_issue=2;citation_pages=1412-1415;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria.;citation_author=L Schofield;citation_author=MC Hewitt;citation_author=K Evans;citation_author=MA Siomos;citation_author=PH Seeberger;citation_journal_title=Nature.;citation_volume=418;citation_issue=6899;citation_pages=785-789;citation_year=2002;">
<meta name="citation_reference" content="citation_title=Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.;citation_author=MD Edstein;citation_journal_title=Antimicrob Agents Chemother.;citation_volume=49;citation_issue=10;citation_pages=4421-4422;citation_year=2005;">
<meta name="citation_reference" content="citation_title=A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.;citation_author=I Sagara;citation_journal_title=Vaccine.;citation_volume=27;citation_issue=23;citation_pages=3090-3098;citation_year=2009;">
<meta name="citation_reference" content="citation_title=The safety and immunogenicity of recombinant EBA 175-RII NG malaria vaccine in healthy adults living in a non-endemic area.;citation_author=HM El Sahly;citation_journal_title=Clin Vaccine Immunol.;citation_volume=17;citation_issue=10;citation_pages=1552-1559;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Safety and immunogenicity of GMZ2 — a MSP3-GLURP fusion protein malaria vaccine candidate.;citation_author=M Esen;citation_journal_title=Vaccine.;citation_volume=27;citation_issue=49;citation_pages=6862-6868;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.;citation_author=CC Hermsen;citation_journal_title=Vaccine.;citation_volume=25;citation_issue=15;citation_pages=2930-2940;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.;citation_author=BR Ogutu;citation_journal_title=PLoS One.;citation_volume=4;citation_issue=3;citation_pages=e4708-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.;citation_author=B Genton;citation_journal_title=J Infect Dis.;citation_volume=185;citation_issue=6;citation_pages=820-827;citation_year=2002;">
<meta name="citation_reference" content="citation_title=Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.;citation_author=R Audran;citation_journal_title=Infect Immun.;citation_volume=73;citation_issue=12;citation_pages=8017-8026;citation_year=2005;">
<meta name="citation_reference" content="citation_title=Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.;citation_author=SB Sirima;citation_journal_title=PLoS One.;citation_volume=4;citation_issue=10;citation_pages=e7549-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.;citation_author=P Druilhe;citation_journal_title=PLoS Med.;citation_volume=2;citation_issue=11;citation_pages=e344-;citation_year=2005;">
<meta name="citation_reference" content="citation_title=Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.;citation_author=T Horii;citation_journal_title=Parasitol Int.;citation_volume=59;citation_issue=3;citation_pages=380-386;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults.;citation_author=RD Ellis;citation_journal_title=PLoS One.;citation_volume=5;citation_issue=1;citation_pages=e8787-;citation_year=2010;">
<meta name="citation_reference" content="citation_title=A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.;citation_author=I Sagara;citation_journal_title=Vaccine.;citation_volume=27;citation_issue=52;citation_pages=7292-7298;citation_year=2009;">
<meta name="citation_reference" content="citation_title=A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.;citation_author=E Malkin;citation_journal_title=Vaccine.;citation_volume=26;citation_issue=52;citation_pages=6864-6873;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Detecting signatures of balancing selection to identify targets of anti-parasite immunity.;citation_author=GD Weedall;citation_author=DJ Conway;citation_journal_title=Trends Parasitol.;citation_volume=26;citation_issue=7;citation_pages=363-369;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria.’;citation_author=SL Takala;citation_author=CV Plowe;citation_journal_title=Parasite Immunol.;citation_volume=31;citation_issue=9;citation_pages=560-573;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.;citation_author=SL Takala;citation_journal_title=Sci Transl Med.;citation_volume=1;citation_issue=2;citation_pages=2ra5-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Profiling humoral immune responses to P. falciparum infection with protein microarrays.;citation_author=DL Doolan;citation_journal_title=Proteomics.;citation_volume=8;citation_issue=22;citation_pages=4680-4694;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates.;citation_author=T Tsuboi;citation_journal_title=Infect Immun.;citation_volume=76;citation_issue=4;citation_pages=1702-1708;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.;citation_author=GW Agak;citation_journal_title=Vaccine.;citation_volume=26;citation_issue=16;citation_pages=1963-1971;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites.;citation_author=D Gaur;citation_author=DC Mayer;citation_author=LH Miller;citation_journal_title=Int J Parasitol.;citation_volume=34;citation_issue=13–14;citation_pages=1413-1429;citation_year=2004;">
<meta name="citation_reference" content="citation_title=Invasion of red blood cells by malaria parasites.;citation_author=AF Cowman;citation_author=BS Crabb;citation_journal_title=Cell.;citation_volume=124;citation_issue=4;citation_pages=755-766;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Pathogenicity, stability, and immunogenicity of a knobless clone of Plasmodium falciparum in Colombian owl monkeys.;citation_author=SG Langreth;citation_author=E Peterson;citation_journal_title=Infect Immun.;citation_volume=47;citation_issue=3;citation_pages=760-766;citation_year=1985;">
<meta name="citation_reference" content="citation_title=Surface alterations of erythrocytes in Plasmodium falciparum malaria. Antigenic variation, antigenic diversity, and the role of the spleen.;citation_author=M Hommel;citation_author=PH David;citation_author=LD Oligino;citation_journal_title=J Exp Med.;citation_volume=157;citation_issue=4;citation_pages=1137-1148;citation_year=1983;">
<meta name="citation_reference" content="citation_title=Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes.;citation_author=JH Leech;citation_author=JW Barnwell;citation_author=LH Miller;citation_author=RJ Howard;citation_journal_title=J Exp Med.;citation_volume=159;citation_issue=6;citation_pages=1567-1575;citation_year=1984;">
<meta name="citation_reference" content="citation_title=Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria.;citation_author=A Salanti;citation_journal_title=Mol Microbiol.;citation_volume=49;citation_issue=1;citation_pages=179-191;citation_year=2003;">
<meta name="citation_reference" content="citation_title=Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta.;citation_author=M Fried;citation_author=PE Duffy;citation_journal_title=Science.;citation_volume=272;citation_issue=5267;citation_pages=1502-1504;citation_year=1996;">
<meta name="citation_reference" content="citation_title=Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes.;citation_author=M Avril;citation_journal_title=Infect Immun.;citation_volume=78;citation_issue=5;citation_pages=2248-2256;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Differentiating the pathologies of cerebral malaria by postmortem parasite counts.;citation_author=TE Taylor;citation_journal_title=Nat Med.;citation_volume=10;citation_issue=2;citation_pages=143-145;citation_year=2004;">
<meta name="citation_reference" content="citation_title=Evidence for the importance of genetic structuring to the structural and functional specialization of the Plasmodium falciparum var gene family.;citation_author=SM Kraemer;citation_author=JD Smith;citation_journal_title=Mol Microbiol.;citation_volume=50;citation_issue=5;citation_pages=1527-1538;citation_year=2003;">
<meta name="citation_reference" content="citation_title=Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes.;citation_author=AT Jensen;citation_journal_title=J Exp Med.;citation_volume=199;citation_issue=9;citation_pages=1179-1190;citation_year=2004;">
<meta name="citation_reference" content="citation_title=Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.;citation_author=V Moorthy;citation_author=Z Reed;citation_author=PG Smith;citation_journal_title=Vaccine.;citation_volume=25;citation_issue=28;citation_pages=5115-5123;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera.;citation_author=PM Graves;citation_author=R Carter;citation_author=TR Burkot;citation_author=IA Quakyi;citation_author=N Kumar;citation_journal_title=Parasite Immunol.;citation_volume=10;citation_issue=2;citation_pages=209-218;citation_year=1988;">
<meta name="citation_reference" content="citation_title=Sexual-stage antibody responses to P. falciparum in endemic populations.;citation_author=JT Bousema;citation_author=CJ Drakeley;citation_author=RW Sauerwein;citation_journal_title=Curr Mol Med.;citation_volume=6;citation_issue=2;citation_pages=223-229;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum.;citation_author=DC Kaslow;citation_author=IA Quakyi;citation_author=DB Keister;citation_journal_title=Mol Biochem Parasitol.;citation_volume=32;citation_issue=1;citation_pages=101-103;citation_year=1989;">
<meta name="citation_reference" content="citation_title=A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.;citation_author=DR Chowdhury;citation_author=E Angov;citation_author=T Kariuki;citation_author=N Kumar;citation_journal_title=PLoS One.;citation_volume=4;citation_issue=7;citation_pages=e6352-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.;citation_author=IA Quakyi;citation_author=R Carter;citation_author=J Rener;citation_author=N Kumar;citation_author=MF Good;citation_author=LH Miller;citation_journal_title=J Immunol.;citation_volume=139;citation_issue=12;citation_pages=4213-4217;citation_year=1987;">
<meta name="citation_reference" content="citation_title=The conserved plant sterility gene HAP2 functions after attachment of fusogenic membranes in Chlamydomonas and Plasmodium gametes.;citation_author=Y Liu;citation_journal_title=Genes Dev.;citation_volume=22;citation_issue=8;citation_pages=1051-1068;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro.;citation_author=AM Blagborough;citation_author=RE Sinden;citation_journal_title=Vaccine.;citation_volume=27;citation_issue=38;citation_pages=5187-5194;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Efficacy model for mosquito stage transmission blocking vaccines for malaria.;citation_author=A Saul;citation_journal_title=Parasitology.;citation_volume=135;citation_issue=13;citation_pages=1497-1506;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex.;citation_author=Y Wu;citation_journal_title=Proc Natl Acad Sci U S A.;citation_volume=103;citation_issue=48;citation_pages=18243-18248;citation_year=2006;">
<meta name="citation_reference" content="citation_title=Vivax malaria: neglected and not benign.;citation_author=RN Price;citation_author=E Tjitra;citation_author=CA Guerra;citation_author=S Yeung;citation_author=NJ White;citation_author=NM Anstey;citation_journal_title=Am J Trop Med Hyg.;citation_volume=77;citation_issue=6 suppl;citation_pages=79-87;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Adult and child malaria mortality in India: a nationally representative mortality survey [published online ahead of print October 21, 2010].;citation_author=N Dhingra;citation_journal_title=Lancet.;citation_volume=;citation_pages=-;citation_year=;">
<meta name="citation_reference" content="citation_title=Neutralization of the infectivity of sporozoites of Plasmodium knowlesi by antibodies to a synthetic peptide.;citation_author=J Gysin;citation_author=J Barnwell;citation_author=DH Schlesinger;citation_author=V Nussenzweig;citation_author=RS Nussenzweig;citation_journal_title=J Exp Med.;citation_volume=160;citation_issue=3;citation_pages=935-940;citation_year=1984;">
<meta name="citation_reference" content="citation_title=Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.;citation_author=ML Plassmeyer;citation_journal_title=J Biol Chem.;citation_volume=284;citation_issue=39;citation_pages=26951-26963;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Structural and functional properties of region II-plus of the malaria circumsporozoite protein.;citation_author=P Sinnis;citation_author=P Clavijo;citation_author=D Fenyo;citation_author=BT Chait;citation_author=C Cerami;citation_author=V Nussenzweig;citation_journal_title=J Exp Med.;citation_volume=180;citation_issue=1;citation_pages=297-306;citation_year=1994;">
<meta name="citation_reference" content="citation_title=Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite protein.;citation_author=M Guttinger;citation_journal_title=EMBO J.;citation_volume=7;citation_issue=8;citation_pages=2555-2558;citation_year=1988;">
<meta name="citation_reference" content="citation_title=Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum.;citation_author=S Kumar;citation_journal_title=Nature.;citation_volume=334;citation_issue=6179;citation_pages=258-260;citation_year=1988;">
<meta name="citation_reference" content="citation_title=A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules.;citation_author=F Sinigaglia;citation_journal_title=Nature.;citation_volume=336;citation_issue=6201;citation_pages=778-780;citation_year=1988;">
<meta name="citation_reference" content="citation_title=Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.;citation_author=A Lalvani;citation_journal_title=J Infect Dis.;citation_volume=180;citation_issue=5;citation_pages=1656-1664;citation_year=1999;">
<meta name="citation_reference" content="citation_title=Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.;citation_author=P Sun;citation_journal_title=J Immunol.;citation_volume=171;citation_issue=12;citation_pages=6961-6967;citation_year=2003;">
<meta name="citation_reference" content="citation_title=Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.;citation_author=JF Cummings;citation_journal_title=Vaccine.;citation_volume=28;citation_issue=31;citation_pages=5135-5144;citation_year=2010;">
<meta name="citation_reference" content="citation_title=Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.;citation_author=MD Spring;citation_journal_title=PLoS One.;citation_volume=4;citation_issue=4;citation_pages=e5254-;citation_year=2009;">
<meta name="citation_reference" content="citation_title=Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.;citation_author=M Roestenberg;citation_journal_title=PLoS One.;citation_volume=3;citation_issue=12;citation_pages=e3960-;citation_year=2008;">
<meta name="citation_reference" content="citation_title=Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers.;citation_author=G Lawrence;citation_journal_title=Vaccine.;citation_volume=18;citation_issue=18;citation_pages=1925-1931;citation_year=2000;">
<meta name="citation_reference" content="citation_title=Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.;citation_author=Y Wu;citation_journal_title=PLoS One.;citation_volume=3;citation_issue=7;citation_pages=e2636-;citation_year=2008;">
<meta name="citation_reference" content="citation_title=A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.;citation_author=SL Okitsu;citation_journal_title=PLoS One.;citation_volume=2;citation_issue=12;citation_pages=e1278-;citation_year=2007;">
<meta name="citation_reference" content="citation_title=A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.;citation_author=B Genton;citation_journal_title=PLoS One.;citation_volume=2;citation_issue=10;citation_pages=e1018-;citation_year=2007;">
<meta name="citation_reference" content="citation_title=Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.;citation_author=FM Thompson;citation_journal_title=PLoS One.;citation_volume=3;citation_issue=1;citation_pages=e1493-;citation_year=2008;">



<meta name="DC.Format" content="text/html">
<meta name="DC.Language" content="en">
<meta content="Advances and challenges in malaria vaccine development" name="DC.Title">
<meta content="10.1172/JCI44423" name="DC.Identifier">
<meta content="2010-12-01" name="DC.Date">
<meta content="American Society for Clinical Investigation" name="DC.Publisher">
<meta content="Peter D. Crompton" name="DC.Contributor">
<meta content="Susan K. Pierce" name="DC.Contributor">
<meta content="Louis H. Miller" name="DC.Contributor">

<link rel="shortcut icon" type="image/x-icon" href="https://www.jci.org/assets/jci-favicon-b6f74d2a3ee91ddde987c4dcc25a92d19a3f49aaf2cc6f8b58190cf1e34e3785.ico">
<title>
JCI -
Advances and challenges in malaria vaccine development
</title>

<!--[if gt IE 8]><!--><link rel="stylesheet" media="all" href="application-2282a7fbb6123b783507c1a2aaa0fab6a4538875d9fc1f11.css"><!--<![endif]-->
<!--[if (lt IE 9)]>
<link rel="stylesheet" media="all" href="/assets/ie8/application-8344233743ad5fae6328b0a08482b9778961dfa02c8f980574689a50e97c13cb.css" />
<script src="/assets/ie8/ie8-head-bfd8231ba171b62724ed7348c9f7aef3cb95e7c031381a8875b6b0769bb2cd66.js"></script>
<![endif]-->

<style>
  @font-face {
    font-family: "klavika-bold";
    src: url("//dm5migu4zj3pb.cloudfront.net/fonts/klavika/eot/KlavikaWebBasicBold.eot");
    src:
      url("//dm5migu4zj3pb.cloudfront.net/fonts/klavika/eot/KlavikaWebBasicBold.eot?#iefix") format("embedded-opentype"),
      url("//dm5migu4zj3pb.cloudfront.net/fonts/klavika/woff/KlavikaWebBasicBold.woff") format("woff");
  }
  @font-face {
    font-family: "klavika-regular";
    src: url("//dm5migu4zj3pb.cloudfront.net/fonts/klavika/eot/KlavikaWebBasicRegular.eot");
    src:
      url("//dm5migu4zj3pb.cloudfront.net/fonts/klavika/eot/KlavikaWebBasicRegular.eot?#iefix") format("embedded-opentype"),
      url("//dm5migu4zj3pb.cloudfront.net/fonts/klavika/woff/KlavikaWebBasicRegular.woff") format("woff");
  }
  @font-face {
    font-family: "foundation-icons";
    src: url("//dm5migu4zj3pb.cloudfront.net/fonts/foundation-icons-3/foundation-icons.eot");
    src: url("//dm5migu4zj3pb.cloudfront.net/fonts/foundation-icons-3/foundation-icons.eot?#iefix") format("embedded-opentype"),
         url("//dm5migu4zj3pb.cloudfront.net/fonts/foundation-icons-3/foundation-icons.woff") format("woff"),
         url("//dm5migu4zj3pb.cloudfront.net/fonts/foundation-icons-3/foundation-icons.ttf") format("truetype"),
         url("//dm5migu4zj3pb.cloudfront.net/fonts/foundation-icons-3/foundation-icons.svg#fontcustom") format("svg");
    font-weight: normal;
    font-style: normal;
  }
</style>

<script>
  //Google Tag Manager Data Layer
  //Values must be set before GTM tags are triggered
  window.dataLayer = window.dataLayer || [];
  window.dataLayer.push({
    'siteName': 'content-jci',
    'ipAddress': '178.255.168.24',
    'environment': 'production',
  });
</script>
<script src="modernizr-34068bbe55efaed404fc5f26a12641757e9f4e5ba63d46a4720.js"></script>
<script type="text/javascript">
	var googletag = googletag || {};
	googletag.cmd = googletag.cmd || [];
	(function () {
		var gads = document.createElement('script');
		gads.async = true;
		gads.type = 'text/javascript';
		var useSSL = 'https:' == document.location.protocol;
		gads.src = (useSSL ? 'https:' : 'http:') + '//www.googletagservices.com/tag/js/gpt.js';
		var node = document.getElementsByTagName('script')[0];
		node.parentNode.insertBefore(gads, node);
	})();

	googletag.cmd.push(function () {

		// NOTE: This script manages google ads, more info at doc/GoogleAds.md

		var mapping = googletag.sizeMapping().addSize([800, 600], [300, 250]).addSize([640, 480], [260, 217]).build();
		var mapping2 = googletag.sizeMapping()
		   .addSize([1920, 1080], [728, 90])//All desktop like resolutions are set to 728x90
		   .addSize([800, 600], [728, 90])
		   .addSize([640, 480], [728, 90])
		   .addSize([0, 0], [320, 50]) //Smaller than 640x480 screens
		   .build();
			
		googletag.defineSlot('/82117132/jci-homepage-med-rectangle-left-col-top', [[300, 250],[260, 217]], 'jci-homepage-med-rectangle-left-col-top').defineSizeMapping(mapping).addService(googletag.pubads());

		googletag.defineSlot('/82117132/jci-article-interior-leaderboard-top', [[728, 90],[320, 50]], 'jci-article-interior-leaderboard-top').defineSizeMapping(mapping2).addService(googletag.pubads());
		googletag.defineSlot('/82117132/jci-article-interior-leaderboard-bottom', [728, 90], 'jci-article-interior-leaderboard-bottom').addService(googletag.pubads());
		googletag.defineSlot('/82117132/jci-article-interior-skyscraper-right-col', [160, 600], 'jci-article-interior-skyscraper-right-col').addService(googletag.pubads());
		googletag.defineSlot('/82117132/jci-interior-skyscraper-right-col', [160, 600], 'jci-interior-skyscraper-right-col').addService(googletag.pubads());

		// collapseEmptyDivs requires all slots be defined above.
		googletag.pubads().collapseEmptyDivs(true);
		googletag.enableServices();
	});
</script>

<style></style><style>.cke{visibility:hidden;}</style><meta class="foundation-mq-topbar"><script id="altmetric-embed-js" src="altmetric_badges-75bc9437b4bcd96622a3f013e4e9519d1b65ea847ab6.js"></script><style type="text/css">.at-icon{fill:#fff;border:0}.at-icon-wrapper{display:inline-block;overflow:hidden}a .at-icon-wrapper{cursor:pointer}.at-rounded,.at-rounded-element .at-icon-wrapper{border-radius:12%}.at-circular,.at-circular-element .at-icon-wrapper{border-radius:50%}.addthis_32x32_style .at-icon{width:2pc;height:2pc}.addthis_24x24_style .at-icon{width:24px;height:24px}.addthis_20x20_style .at-icon{width:20px;height:20px}.addthis_16x16_style .at-icon{width:1pc;height:1pc}#at16lb{display:none;position:absolute;top:0;left:0;width:100%;height:100%;z-index:1001;background-color:#000;opacity:.001}#at_complete,#at_error,#at_share,#at_success{position:static!important}.at15dn{display:none}#at15s,#at16p,#at16p form input,#at16p label,#at16p textarea,#at_share .at_item{font-family:arial,helvetica,tahoma,verdana,sans-serif!important;font-size:9pt!important;outline-style:none;outline-width:0;line-height:1em}* html #at15s.mmborder{position:absolute!important}#at15s.mmborder{position:fixed!important;width:250px!important}#at15s{background:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgaGAgAjAxEAlGFVJHIUCAAQDcngCUgqGMqwAAAABJRU5ErkJggg==);float:none;line-height:1em;margin:0;overflow:visible;padding:5px;text-align:left;position:absolute}#at15s a,#at15s span{outline:0;direction:ltr;text-transform:none}#at15s .at-label{margin-left:5px}#at15s .at-icon-wrapper{width:1pc;height:1pc;vertical-align:middle}#at15s .at-icon{width:1pc;height:1pc}.at4-icon{display:inline-block;background-repeat:no-repeat;background-position:top left;margin:0;overflow:hidden;cursor:pointer}.addthis_16x16_style .at4-icon,.addthis_default_style .at4-icon,.at4-icon,.at-16x16{width:1pc;height:1pc;line-height:1pc;background-size:1pc!important}.addthis_32x32_style .at4-icon,.at-32x32{width:2pc;height:2pc;line-height:2pc;background-size:2pc!important}.addthis_24x24_style .at4-icon,.at-24x24{width:24px;height:24px;line-height:24px;background-size:24px!important}.addthis_20x20_style .at4-icon,.at-20x20{width:20px;height:20px;line-height:20px;background-size:20px!important}.at4-icon.circular,.circular .at4-icon,.circular.aticon{border-radius:50%}.at4-icon.rounded,.rounded .at4-icon{border-radius:4px}.at4-icon-left{float:left}#at15s .at4-icon{text-indent:20px;padding:0;overflow:visible;white-space:nowrap;background-size:1pc;width:1pc;height:1pc;background-position:top left;display:inline-block;line-height:1pc}.addthis_vertical_style .at4-icon,.at4-follow-container .at4-icon{margin-right:5px}html>body #at15s{width:250px!important}#at15s.atm{background:none!important;padding:0!important;width:10pc!important}#at15s_inner{background:#fff;border:1px solid #fff;margin:0}#at15s_head{position:relative;background:#f2f2f2;padding:4px;cursor:default;border-bottom:1px solid #e5e5e5}.at15s_head_success{background:#cafd99!important;border-bottom:1px solid #a9d582!important}.at15s_head_success a,.at15s_head_success span{color:#000!important;text-decoration:none}#at15s_brand,#at15sptx,#at16_brand{position:absolute}#at15s_brand{top:4px;right:4px}.at15s_brandx{right:20px!important}a#at15sptx{top:4px;right:4px;text-decoration:none;color:#4c4c4c;font-weight:700}#at15sptx:hover{text-decoration:underline}#at16_brand{top:5px;right:30px;cursor:default}#at_hover{padding:4px}#at_hover .at_item,#at_share .at_item{background:#fff!important;float:left!important;color:#4c4c4c!important}#at_share .at_item .at-icon-wrapper{margin-right:5px}#at_hover .at_bold{font-weight:700;color:#000!important}#at_hover .at_item{width:7pc!important;padding:2px 3px!important;margin:1px;text-decoration:none!important}#at_hover .at_item.athov,#at_hover .at_item:focus,#at_hover .at_item:hover{margin:0!important}#at_hover .at_item.athov,#at_hover .at_item:focus,#at_hover .at_item:hover,#at_share .at_item.athov,#at_share .at_item:hover{background:#f2f2f2!important;border:1px solid #e5e5e5;color:#000!important;text-decoration:none}.ipad #at_hover .at_item:focus{background:#fff!important;border:1px solid #fff}.at15t{display:block!important;height:1pc!important;line-height:1pc!important;padding-left:20px!important;background-position:0 0;text-align:left}.addthis_button,.at15t{cursor:pointer}.addthis_toolbox a.at300b,.addthis_toolbox a.at300m{width:auto}.addthis_toolbox a{margin-bottom:5px;line-height:initial}.addthis_toolbox.addthis_vertical_style{width:200px}.addthis_button_facebook_like .fb_iframe_widget{line-height:100%}.addthis_button_facebook_like iframe.fb_iframe_widget_lift{max-width:none}.addthis_toolbox a.addthis_button_counter,.addthis_toolbox a.addthis_button_facebook_like,.addthis_toolbox a.addthis_button_facebook_send,.addthis_toolbox a.addthis_button_facebook_share,.addthis_toolbox a.addthis_button_foursquare,.addthis_toolbox a.addthis_button_linkedin_counter,.addthis_toolbox a.addthis_button_pinterest_pinit,.addthis_toolbox a.addthis_button_tweet{display:inline-block}.addthis_toolbox span.addthis_follow_label{display:none}.addthis_toolbox.addthis_vertical_style span.addthis_follow_label{display:block;white-space:nowrap}.addthis_toolbox.addthis_vertical_style a{display:block}.addthis_toolbox.addthis_vertical_style.addthis_32x32_style a{line-height:2pc;height:2pc}.addthis_toolbox.addthis_vertical_style .at300bs{margin-right:4px;float:left}.addthis_toolbox.addthis_20x20_style span{line-height:20px}.addthis_toolbox.addthis_32x32_style span{line-height:2pc}.addthis_toolbox.addthis_pill_combo_style .addthis_button_compact .at15t_compact,.addthis_toolbox.addthis_pill_combo_style a{float:left}.addthis_toolbox.addthis_pill_combo_style a.addthis_button_tweet{margin-top:-2px}.addthis_toolbox.addthis_pill_combo_style .addthis_button_compact .at15t_compact{margin-right:4px}.addthis_default_style .addthis_separator{margin:0 5px;display:inline}div.atclear{clear:both}.addthis_default_style .addthis_separator,.addthis_default_style .at4-icon,.addthis_default_style .at300b,.addthis_default_style .at300bo,.addthis_default_style .at300bs,.addthis_default_style .at300m{float:left}.at300b img,.at300bo img{border:0}a.at300b .at4-icon,a.at300m .at4-icon{display:block}.addthis_default_style .at300b,.addthis_default_style .at300bo,.addthis_default_style .at300m{padding:0 2px}.at300b,.at300bo,.at300bs,.at300m{cursor:pointer}.addthis_button_facebook_like.at300b:hover,.addthis_button_facebook_like.at300bs:hover,.addthis_button_facebook_send.at300b:hover,.addthis_button_facebook_send.at300bs:hover{opacity:1}.addthis_20x20_style .at15t,.addthis_20x20_style .at300bs{overflow:hidden;display:block;height:20px!important;width:20px!important;line-height:20px!important}.addthis_32x32_style .at15t,.addthis_32x32_style .at300bs{overflow:hidden;display:block;height:2pc!important;width:2pc!important;line-height:2pc!important}.at300bs{overflow:hidden;display:block;background-position:0 0;height:1pc;width:1pc;line-height:1pc!important}.addthis_default_style .at15t_compact,.addthis_default_style .at15t_expanded{margin-right:4px}#at_share .at_item{width:123px!important;padding:4px;margin-right:2px;border:1px solid #fff}#at16p{background:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgaGAgAjAxEAlGFVJHIUCAAQDcngCUgqGMqwAAAABJRU5ErkJggg==);z-index:10000001;position:absolute;top:50%;left:50%;width:300px;padding:10px;margin:0 auto;margin-top:-185px;margin-left:-155px;font-family:arial,helvetica,tahoma,verdana,sans-serif;font-size:9pt;color:#5e5e5e}#at_share{margin:0;padding:0}#at16pt{position:relative;background:#f2f2f2;height:13px;padding:5px 10px}#at16pt a,#at16pt h4{font-weight:700}#at16pt h4{display:inline;margin:0;padding:0;font-size:9pt;color:#4c4c4c;cursor:default}#at16pt a{position:absolute;top:5px;right:10px;color:#4c4c4c;text-decoration:none;padding:2px}#at15sptx:focus,#at16pt a:focus{outline:thin dotted}#at15s #at16pf a{top:1px}#_atssh{width:1px!important;height:1px!important;border:0!important}.atm{width:10pc!important;padding:0;margin:0;line-height:9pt;letter-spacing:normal;font-family:arial,helvetica,tahoma,verdana,sans-serif;font-size:9pt;color:#444;background:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgaGAgAjAxEAlGFVJHIUCAAQDcngCUgqGMqwAAAABJRU5ErkJggg==);padding:4px}.atm-f{text-align:right;border-top:1px solid #ddd;padding:5px 8px}.atm-i{background:#fff;border:1px solid #d5d6d6;padding:0;margin:0;box-shadow:1px 1px 5px rgba(0,0,0,.15)}.atm-s{margin:0!important;padding:0!important}.atm-s a:focus{border:transparent;outline:0;transition:none}#at_hover.atm-s a,.atm-s a{display:block;text-decoration:none;padding:4px 10px;color:#235dab!important;font-weight:400;font-style:normal;transition:none}#at_hover.atm-s .at_bold{color:#235dab!important}#at_hover.atm-s a:hover,.atm-s a:hover{background:#2095f0;text-decoration:none;color:#fff!important}#at_hover.atm-s .at_bold{font-weight:700}#at_hover.atm-s a:hover .at_bold{color:#fff!important}.atm-s a .at-label{vertical-align:middle;margin-left:5px;direction:ltr}.at_PinItButton{display:block;width:40px;height:20px;padding:0;margin:0;background-image:url(//s7.addthis.com/static/t00/pinit00.png);background-repeat:no-repeat}.at_PinItButton:hover{background-position:0 -20px}.addthis_toolbox .addthis_button_pinterest_pinit{position:relative}.at-share-tbx-element .fb_iframe_widget span{vertical-align:baseline!important}#at16pf{height:auto;text-align:right;padding:4px 8px}.at-privacy-info{position:absolute;left:7px;bottom:7px;cursor:pointer;text-decoration:none;font-family:helvetica,arial,sans-serif;font-size:10px;line-height:9pt;letter-spacing:.2px;color:#666}.at-privacy-info:hover{color:#000}.body .wsb-social-share .wsb-social-share-button-vert{padding-top:0;padding-bottom:0}.body .wsb-social-share.addthis_counter_style .addthis_button_tweet.wsb-social-share-button{padding-top:40px}.body .wsb-social-share.addthis_counter_style .addthis_button_facebook_like.wsb-social-share-button{padding-top:21px}@media print{#at4-follow,#at4-share,#at4-thankyou,#at4-whatsnext,#at4m-mobile,#at15s,.at4,.at4-recommended{display:none!important}}@media screen and (max-width:400px){.at4win{width:100%}}@media screen and (max-height:700px) and (max-width:400px){.at4-thankyou-inner .at4-recommended-container{height:122px;overflow:hidden}.at4-thankyou-inner .at4-recommended .at4-recommended-item:first-child{border-bottom:1px solid #c5c5c5}}</style><style type="text/css">.at-branding-logo{font-family:helvetica,arial,sans-serif;text-decoration:none;font-size:10px;display:inline-block;margin:2px 0;letter-spacing:.2px}.at-branding-logo .at-branding-icon{background-image:url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAMAAAC67D+PAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAAZQTFRF////+GlNUkcc1QAAAB1JREFUeNpiYIQDBjQmAwMmkwEM0JnY1WIxFyDAABGeAFEudiZsAAAAAElFTkSuQmCC")}.at-branding-logo .at-branding-icon,.at-branding-logo .at-privacy-icon{display:inline-block;height:10px;width:10px;margin-left:4px;margin-right:3px;margin-bottom:-1px;background-repeat:no-repeat}.at-branding-logo .at-privacy-icon{background-image:url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAkAAAAKCAMAAABR24SMAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABhQTFRF8fr9ot/xXcfn2/P5AKva////////AKTWodjhjAAAAAd0Uk5T////////ABpLA0YAAAA6SURBVHjaJMzBDQAwCAJAQaj7b9xifV0kUKJ9ciWxlzWEWI5gMF65KUTv0VKkjVeTerqE/x7+9BVgAEXbAWI8QDcfAAAAAElFTkSuQmCC")}.at-branding-logo span{text-decoration:none}.at-branding-logo .at-branding-addthis,.at-branding-logo .at-branding-powered-by{color:#666}.at-branding-logo .at-branding-addthis:hover{color:#333}.at-cv-with-image .at-branding-addthis,.at-cv-with-image .at-branding-addthis:hover{color:#fff}a.at-branding-logo:visited{color:initial}.at-branding-info{display:inline-block;padding:0 5px;color:#666;border:1px solid #666;border-radius:50%;font-size:10px;line-height:9pt;opacity:.7;transition:all .3s ease;text-decoration:none}.at-branding-info span{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}.at-branding-info:before{content:'i';font-family:Times New Roman}.at-branding-info:hover{color:#0780df;border-color:#0780df}</style><link rel="preload" href="integrator_002.js" as="script"><script type="text/javascript" src="integrator_002.js"></script><link rel="preload" href="integrator.js" as="script"><script type="text/javascript" src="integrator.js"></script><script src="pubads_impl_2020030501.js" async=""></script><link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-37/html/container.html"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="embed-a458e1093bac38cf5adc51eff02159de22f9e260b3636d0ecefba2.css"><script type="text/javascript" charset="utf-8" async="" src="layers.js"></script><style type="text/css">.at-share-dock.atss{top:auto;left:0;right:0;bottom:0;width:100%;max-width:100%;z-index:1000200;box-shadow:0 0 1px 1px #e2dfe2}.at-share-dock.at-share-dock-zindex-hide{z-index:-1!important}.at-share-dock.atss-top{bottom:auto;top:0}.at-share-dock a{width:auto;transition:none;color:#fff;text-decoration:none;box-sizing:content-box;-webkit-box-sizing:content-box;-moz-box-sizing:content-box}.at-share-dock a:hover{width:auto}.at-share-dock .at4-count{height:43px;padding:5px 0 0;line-height:20px;background:#fff;font-family:Helvetica neue,arial}.at-share-dock .at4-count span{width:100%}.at-share-dock .at4-count .at4-share-label{color:#848484;font-size:10px;letter-spacing:1px}.at-share-dock .at4-count .at4-counter{top:2px;position:relative;display:block;color:#222;font-size:22px}.at-share-dock.at-shfs-medium .at4-count{height:36px;line-height:1pc;padding-top:4px}.at-share-dock.at-shfs-medium .at4-count .at4-counter{font-size:18px}.at-share-dock.at-shfs-medium .at-share-btn .at-icon-wrapper,.at-share-dock.at-shfs-medium a .at-icon-wrapper{padding:6px 0}.at-share-dock.at-shfs-small .at4-count{height:26px;line-height:1;padding-top:3px}.at-share-dock.at-shfs-small .at4-count .at4-share-label{font-size:8px}.at-share-dock.at-shfs-small .at4-count .at4-counter{font-size:14px}.at-share-dock.at-shfs-small .at-share-btn .at-icon-wrapper,.at-share-dock.at-shfs-small a .at-icon-wrapper{padding:4px 0}</style><style type="text/css">div.at-share-close-control.ats-dark,div.at-share-open-control-left.ats-dark,div.at-share-open-control-right.ats-dark{background:#262b30}div.at-share-close-control.ats-light,div.at-share-open-control-left.ats-light,div.at-share-open-control-right.ats-light{background:#fff}div.at-share-close-control.ats-gray,div.at-share-open-control-left.ats-gray,div.at-share-open-control-right.ats-gray{background:#f2f2f2}.atss{position:fixed;top:20%;width:3pc;z-index:100020;background:none}.at-share-close-control{position:relative;width:3pc;overflow:auto}.at-share-open-control-left{position:fixed;top:20%;z-index:100020;left:0;width:22px}.at-share-close-control .at4-arrow.at-left{float:right}.atss-left{left:0;float:left;right:auto}.atss-right{left:auto;float:right;right:0}.atss-right.at-share-close-control .at4-arrow.at-right{position:relative;right:0;overflow:auto}.atss-right.at-share-close-control .at4-arrow{float:left}.at-share-open-control-right{position:fixed;top:20%;z-index:100020;right:0;width:22px;float:right}.atss-right .at-share-close-control .at4-arrow{float:left}.atss.atss-right a{float:right}.atss.atss-right .at4-share-title{float:right;overflow:hidden}.atss .at-share-btn,.atss a{position:relative;display:block;width:3pc;margin:0;outline-offset:-1px;text-align:center;float:left;transition:width .15s ease-in-out;overflow:hidden;background:#e8e8e8;z-index:100030;cursor:pointer}.at-share-btn::-moz-focus-inner{border:0;padding:0}.atss-right .at-share-btn{float:right}.atss .at-share-btn{border:0;padding:0}.atss .at-share-btn:focus,.atss .at-share-btn:hover,.atss a:focus,.atss a:hover{width:4pc}.atss .at-share-btn .at-icon-wrapper,.atss a .at-icon-wrapper{display:block;padding:8px 0}.atss .at-share-btn:last-child,.atss a:last-child{border:none}.atss .at-share-btn span .at-icon,.atss a span .at-icon{position:relative;top:0;left:0;display:block;background-repeat:no-repeat;background-position:50% 50%;width:2pc;height:2pc;line-height:2pc;border:none;padding:0;margin:0 auto;overflow:hidden;cursor:pointer;cursor:hand}.at4-share .at-custom-sidebar-counter{font-family:Helvetica neue,arial;vertical-align:top;margin-right:4px;display:inline-block;text-align:center}.at4-share .at-custom-sidebar-count{font-size:17px;line-height:1.25em;color:#222}.at4-share .at-custom-sidebar-text{font-size:9px;line-height:1.25em;color:#888;letter-spacing:1px}.at4-share .at4-share-count-container{position:absolute;left:0;right:auto;top:auto;bottom:0;width:100%;color:#fff;background:inherit}.at4-share .at4-share-count,.at4-share .at4-share-count-container{line-height:1pc;font-size:10px}.at4-share .at4-share-count{text-indent:0;font-family:Arial,Helvetica Neue,Helvetica,sans-serif;font-weight:200;width:100%;height:1pc}.at4-share .at4-share-count-anchor{padding-bottom:8px;text-decoration:none;transition:padding .15s ease-in-out .15s,width .15s ease-in-out}</style><style type="text/css">#at4-drawer-outer-container{top:0;width:20pc;position:fixed}#at4-drawer-outer-container.at4-drawer-inline{position:relative}#at4-drawer-outer-container.at4-drawer-inline.at4-drawer-right{float:right;right:0;left:auto}#at4-drawer-outer-container.at4-drawer-inline.at4-drawer-left{float:left;left:0;right:auto}#at4-drawer-outer-container.at4-drawer-shown,#at4-drawer-outer-container.at4-drawer-shown *{z-index:999999}#at4-drawer-outer-container,#at4-drawer-outer-container .at4-drawer-outer,#at-drawer{height:100%;overflow-y:auto;overflow-x:hidden}.at4-drawer-push-content-right-back{position:relative;right:0}.at4-drawer-push-content-right{position:relative;left:20pc!important}.at4-drawer-push-content-left-back{position:relative;left:0}.at4-drawer-push-content-left{position:relative;right:20pc!important}#at4-drawer-outer-container.at4-drawer-right{left:auto;right:-20pc}#at4-drawer-outer-container.at4-drawer-left{right:auto;left:-20pc}#at4-drawer-outer-container.at4-drawer-shown.at4-drawer-right{left:auto;right:0}#at4-drawer-outer-container.at4-drawer-shown.at4-drawer-left{right:auto;left:0}#at-drawer{top:0;z-index:9999999;height:100%;animation-duration:.4s}#at-drawer.drawer-push.at-right{right:-20pc}#at-drawer.drawer-push.at-left{left:-20pc}#at-drawer .at-recommended-label{padding:0 0 0 20px;color:#999;line-height:3pc;font-size:18px;font-weight:300;cursor:default}#at-drawer-arrow{width:30px;height:5pc}#at-drawer-arrow.ats-dark{background:#262b30}#at-drawer-arrow.ats-gray{background:#f2f2f2}#at-drawer-open-arrow{background-image:url(data:image/png;base64,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);background-repeat:no-repeat;width:13px;height:23px;margin:28px 0 0 8px}.at-left #at-drawer-open-arrow{background-position:0 -46px}.ats-dark #at-drawer-open-arrow{background-position:0 -23px}.ats-dark.at-left #at-drawer-open-arrow{background-position:0 -69px}#at-drawer-arrow.at4-drawer-modern-browsers{position:fixed;top:40%;background-repeat:no-repeat;background-position:0 0!important;z-index:9999999}.at4-drawer-inline #at-drawer-arrow{position:absolute}#at-drawer-arrow.at4-drawer-modern-browsers.at-right{right:0}#at-drawer-arrow.at4-drawer-modern-browsers.at-left{left:0}.at4-drawer-push-animation-left{transition:left .4s ease-in-out .15s}.at4-drawer-push-animation-right{transition:right .4s ease-in-out .15s}#at-drawer.drawer-push.at4-drawer-push-animation-right{right:0}#at-drawer.drawer-push.at4-drawer-push-animation-right-back{right:-20pc!important}#at-drawer.drawer-push.at4-drawer-push-animation-left{left:0}#at-drawer.drawer-push.at4-drawer-push-animation-left-back{left:-20pc!important}#at-drawer .at4-closebutton.drawer-close{content:'X';color:#999;display:block;position:absolute;margin:0;top:0;right:0;width:3pc;height:45px;line-height:45px;overflow:hidden;opacity:.5}#at-drawer.ats-dark .at4-closebutton.drawer-close{color:#fff}#at-drawer .at4-closebutton.drawer-close:hover{opacity:1}#at-drawer.ats-dark.at4-recommended .at4-logo-container a{color:#666}#at-drawer.at4-recommended .at4-recommended-vertical{padding:0}#at-drawer.at4-recommended .at4-recommended-item .sponsored-label{margin:2px 0 0 21px;color:#ddd}#at-drawer.at4-recommended .at4-recommended-vertical .at4-recommended-item{position:relative;padding:0;width:20pc;height:180px;margin:0}#at-drawer.at4-recommended .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-img a:after{content:'';position:absolute;top:0;left:0;right:0;bottom:0;background:rgba(0,0,0,.65);z-index:1000000;transition:all .2s ease-in-out}#at-drawer.at4-recommended .at4-recommended-vertical .at4-recommended-item.at-hover .at4-recommended-item-img a:after{background:rgba(0,0,0,.8)}#at-drawer .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-img,#at-drawer .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-img a,#at-drawer .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-img img{width:20pc;height:180px;float:none}#at-drawer .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption{width:100%;position:absolute;bottom:0;left:0;height:70px}#at-drawer .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption .at-h4{color:#fff;position:absolute;height:52px;top:0;left:20px;right:20px;margin:0;padding:0;line-height:25px;font-size:20px;font-weight:600;z-index:1000001;text-decoration:none;text-transform:none}#at-drawer.at4-recommended .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption .at-h4 a:hover{text-decoration:none}#at-drawer.at4-recommended .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption .at-h4 a:link{color:#fff}#at-drawer.at4-recommended .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption small{position:absolute;top:auto;bottom:10px;left:20px;width:auto;color:#ccc}#at-drawer.at4-recommended .at4-logo-container{margin-left:20px}#at-drawer.ats-dark.at4-recommended .at4-logo-container a:hover{color:#fff}#at-drawer.at4-recommended .at-logo{margin:0}</style><style type="text/css">.at4-follow.at-mobile{display:none!important}.at4-follow{position:fixed;top:0;right:0;font-weight:400;color:#666;cursor:default;z-index:10001}.at4-follow .at4-follow-inner{position:relative;padding:10px 24px 10px 15px}.at4-follow-inner,.at-follow-open-control{border:0 solid #c5c5c5;border-width:1px 0 1px 1px;margin-top:-1px}.at4-follow .at4-follow-container{margin-left:9pt}.at4-follow.at4-follow-24 .at4-follow-container{height:24px;line-height:23px;font-size:13px}.at4-follow.at4-follow-32 .at4-follow-container{width:15pc;height:2pc;line-height:2pc;font-size:14px}.at4-follow .at4-follow-container .at-follow-label{display:inline-block;height:24px;line-height:24px;margin-right:10px;padding:0;cursor:default;float:left}.at4-follow .at4-follow-container .at-icon-wrapper{height:24px;width:24px}.at4-follow.ats-transparent .at4-follow-inner,.at-follow-open-control.ats-transparent{border-color:transparent}.at4-follow.ats-dark .at4-follow-inner,.at-follow-open-control.ats-dark{background:#262b30;border-color:#000;color:#fff}.at4-follow.ats-dark .at-follow-close-control{background-color:#262b30}.at4-follow.ats-light .at4-follow-inner{background:#fff;border-color:#c5c5c5}.at4-follow.ats-gray .at4-follow-inner,.at-follow-open-control.ats-gray{background:#f2f2f2;border-color:#c5c5c5}.at4-follow.ats-light .at4-follow-close-control,.at-follow-open-control.ats-light{background:#e5e5e5}.at4-follow .at4-follow-inner .at4-follow-close-control{position:absolute;top:0;bottom:0;left:0;width:20px;cursor:pointer;display:none}.at4-follow .at4-follow-inner .at4-follow-close-control div{display:block;line-height:20px;text-indent:-9999em;margin-top:calc(50% + 1px);overflow:hidden}.at-follow-open-control div.at4-arrow.at-left{background-position:0 -2px}.at-follow-open-control{position:fixed;height:35px;top:0;right:0;padding-top:10px;z-index:10002}.at-follow-btn{margin:0 5px 5px 0;padding:0;outline-offset:-1px;display:inline-block;box-sizing:content-box;transition:all .2s ease-in-out}.at-follow-btn:focus,.at-follow-btn:hover{transform:translateY(-4px)}.at4-follow-24 .at-follow-btn{height:25px;line-height:0;width:25px}</style><style type="text/css">.at-follow-tbx-element .at300b,.at-follow-tbx-element .at300m{display:inline-block;width:auto;padding:0;margin:0 2px 5px;outline-offset:-1px;transition:all .2s ease-in-out}.at-follow-tbx-element .at300b:focus,.at-follow-tbx-element .at300b:hover,.at-follow-tbx-element .at300m:focus,.at-follow-tbx-element .at300m:hover{transform:translateY(-4px)}.at-follow-tbx-element .addthis_vertical_style .at300b,.at-follow-tbx-element .addthis_vertical_style .at300m{display:block}.at-follow-tbx-element .addthis_vertical_style .at300b .addthis_follow_label,.at-follow-tbx-element .addthis_vertical_style .at300b .at-icon-wrapper,.at-follow-tbx-element .addthis_vertical_style .at300m .addthis_follow_label,.at-follow-tbx-element .addthis_vertical_style .at300m .at-icon-wrapper{display:inline-block;vertical-align:middle;margin-right:5px}.at-follow-tbx-element .addthis_vertical_style .at300b:focus,.at-follow-tbx-element .addthis_vertical_style .at300b:hover,.at-follow-tbx-element .addthis_vertical_style .at300m:focus,.at-follow-tbx-element .addthis_vertical_style .at300m:hover{transform:none}</style><style type="text/css">.at4-jumboshare .at-share-btn{display:inline-block;margin-right:13px;margin-top:13px}.at4-jumboshare .at-share-btn .at-icon{float:left}.at4-jumboshare .at-share-btn .at300bs{display:inline-block;float:left;cursor:pointer}.at4-jumboshare .at4-mobile .at-share-btn .at-icon,.at4-jumboshare .at4-mobile .at-share-btn .at-icon-wrapper{margin:0;padding:0}.at4-jumboshare .at4-mobile .at-share-btn{padding:0}.at4-jumboshare .at4-mobile .at-share-btn .at-label{display:none}.at4-jumboshare .at4-count{font-size:60px;line-height:60px;font-family:Helvetica neue,arial;font-weight:700}.at4-jumboshare .at4-count-container{display:table-cell;text-align:center;min-width:200px;vertical-align:middle;border-right:1px solid #ccc;padding-right:20px}.at4-jumboshare .at4-share-container{display:table-cell;vertical-align:middle;padding-left:20px}.at4-jumboshare .at4-share-container.at-share-tbx-element{padding-top:0}.at4-jumboshare .at4-title{position:relative;font-size:18px;line-height:18px;bottom:2px}.at4-jumboshare .at4-spacer{height:1px;display:block;visibility:hidden;opacity:0}.at4-jumboshare .at-share-btn{display:inline-block;margin:0 2px;line-height:0;padding:0;overflow:hidden;text-decoration:none;text-transform:none;color:#fff;cursor:pointer;transition:all .2s ease-in-out;border:0;background-color:transparent}.at4-jumboshare .at-share-btn:focus,.at4-jumboshare .at-share-btn:hover{transform:translateY(-4px);color:#fff;text-decoration:none}.at4-jumboshare .at-label{font-family:helvetica neue,helvetica,arial,sans-serif;font-size:9pt;padding:0 15px 0 0;margin:0;height:2pc;line-height:2pc;background:none}.at4-jumboshare .at-share-btn:hover,.at4-jumboshare .at-share-btn:link{text-decoration:none}.at4-jumboshare .at-share-btn::-moz-focus-inner{border:0;padding:0}.at4-jumboshare.at-mobile .at-label{display:none}</style><style type="text/css">.at4-recommendedbox-outer-container{display:inline}.at4-recommended-outer{position:static}.at4-recommended{top:20%;margin:0;text-align:center;font-weight:400;font-size:13px;line-height:17px;color:#666}.at4-recommended.at-inline .at4-recommended-horizontal{text-align:left}.at4-recommended-recommendedbox{padding:0;z-index:inherit}.at4-recommended-recommended{padding:40px 0}.at4-recommended-horizontal{max-height:340px}.at4-recommended.at-medium .at4-recommended-horizontal{max-height:15pc}.at4-recommended.at4-minimal.at-medium .at4-recommended-horizontal{padding-top:10px;max-height:230px}.at4-recommended-text-only .at4-recommended-horizontal{max-height:130px}.at4-recommended-horizontal{padding-top:5px;overflow-y:hidden}.at4-minimal{background:none;color:#000;border:none!important;box-shadow:none!important}@media screen and (max-width:900px){.at4-recommended-horizontal .at4-recommended-item,.at4-recommended-horizontal .at4-recommended-item .at4-recommended-item-img{width:15pc}}.at4-recommended.at4-minimal .at4-recommended-horizontal .at4-recommended-item .at4-recommended-item-caption{padding:0 0 10px}.at4-recommended.at4-minimal .at4-recommended-horizontal .at4-recommended-item-caption{padding:20px 0 0!important}.addthis-smartlayers .at4-recommended .at-h3.at-recommended-label{margin:0;padding:0;font-weight:300;font-size:18px;line-height:24px;color:#464646;width:100%;display:inline-block;zoom:1}.addthis-smartlayers .at4-recommended.at-inline .at-h3.at-recommended-label{text-align:left}#at4-thankyou .addthis-smartlayers .at4-recommended.at-inline .at-h3.at-recommended-label{text-align:center}.at4-recommended .at4-recommended-item{display:inline-block;zoom:1;position:relative;background:#fff;border:1px solid #c5c5c5;width:200px;margin:10px}.addthis_recommended_horizontal .at4-recommended-item{border:none}.at4-recommended .at4-recommended-item .sponsored-label{color:#666;font-size:9px;position:absolute;top:-20px}.at4-recommended .at4-recommended-item-img .at-tli,.at4-recommended .at4-recommended-item-img a{position:absolute;left:0}.at4-recommended.at-inline .at4-recommended-horizontal .at4-recommended-item{margin:10px 20px 0 0}.at4-recommended.at-medium .at4-recommended-horizontal .at4-recommended-item{margin:10px 10px 0 0}.at4-recommended.at-medium .at4-recommended-item{width:140px;overflow:hidden}.at4-recommended .at4-recommended-item .at4-recommended-item-img{position:relative;text-align:center;width:100%;height:200px;line-height:0;overflow:hidden}.at4-recommended .at4-recommended-item .at4-recommended-item-img a{display:block;width:100%;height:200px}.at4-recommended.at-medium .at4-recommended-item .at4-recommended-item-img,.at4-recommended.at-medium .at4-recommended-item .at4-recommended-item-img a{height:140px}.at4-recommended .at4-recommended-item .at4-recommended-item-img img{position:absolute;top:0;left:0;min-height:0;min-width:0;max-height:none;max-width:none;margin:0;padding:0}.at4-recommended .at4-recommended-item .at4-recommended-item-caption{height:74px;overflow:hidden;padding:20px;text-align:left;-ms-box-sizing:content-box;-o-box-sizing:content-box;box-sizing:content-box}.at4-recommended.at-medium .at4-recommended-item .at4-recommended-item-caption{height:50px;padding:15px}.at4-recommended .at4-recommended-item .at4-recommended-item-caption .at-h4{height:54px;margin:0 0 5px;padding:0;overflow:hidden;word-wrap:break-word;font-size:14px;font-weight:400;line-height:18px;text-align:left}.at4-recommended.at-medium .at4-recommended-item .at4-recommended-item-caption .at-h4{font-size:9pt;line-height:1pc;height:33px}.at4-recommended .at4-recommended-item:hover .at4-recommended-item-caption .at-h4{text-decoration:underline}.at4-recommended a:link,.at4-recommended a:visited{text-decoration:none;color:#464646}.at4-recommended .at4-recommended-item .at4-recommended-item-caption .at-h4 a:hover{text-decoration:underline;color:#000}.at4-recommended .at4-recommended-item .at4-recommended-item-caption small{display:block;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;font-size:11px;color:#666}.at4-recommended.at-medium .at4-recommended-item .at4-recommended-item-caption small{font-size:9px}.at4-recommended .at4-recommended-vertical{padding:15px 0 0}.at4-recommended .at4-recommended-vertical .at4-recommended-item{display:block;width:auto;max-width:100%;height:60px;border:none;margin:0 0 15px;box-shadow:none;background:none}.at4-recommended-vertical .at4-recommended-item .at4-recommended-item-img,.at4-recommended-vertical .at4-recommended-item .at4-recommended-item-img img{width:60px;height:60px;float:left}.at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption{border-top:none;margin:0;height:60px;padding:3px 5px}.at4-recommended .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption .at-h4{height:38px;margin:0}.at4-recommended .at4-recommended-vertical .at4-recommended-item .at4-recommended-item-caption small{position:absolute;bottom:0}.at4-recommended .at-recommended-label.at-vertical{text-align:left}.at4-no-image-light-recommended,.at4-no-image-minimal-recommended{background-color:#f2f2f2!important}.at4-no-image-gray-recommended{background-color:#e6e6e5!important}.at4-no-image-dark-recommended{background-color:#4e555e!important}.at4-recommended .at4-recommended-item-placeholder-img{background-repeat:no-repeat!important;background-position:center!important;width:100%!important;height:100%!important}.at4-recommended-horizontal .at4-no-image-dark-recommended .at4-recommended-item-placeholder-img{background-image:url(data:image/png;base64,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)!important}.at4-recommended-vertical .at4-no-image-dark-recommended .at4-recommended-item-placeholder-img{background-image:url(data:image/png;base64,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)!important}.at4-recommended-horizontal .at4-no-image-gray-recommended .at4-recommended-item-placeholder-img,.at4-recommended-horizontal .at4-no-image-light-recommended .at4-recommended-item-placeholder-img,.at4-recommended-horizontal .at4-no-image-minimal-recommended .at4-recommended-item-placeholder-img{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACIAAAAfCAYAAACCox+xAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAyNpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+IDx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDUuNS1jMDE0IDc5LjE1MTQ4MSwgMjAxMy8wMy8xMy0xMjowOToxNSAgICAgICAgIj4gPHJkZjpSREYgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj4gPHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9IiIgeG1sbnM6eG1wPSJodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvIiB4bWxuczp4bXBNTT0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wL21tLyIgeG1sbnM6c3RSZWY9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC9zVHlwZS9SZXNvdXJjZVJlZiMiIHhtcDpDcmVhdG9yVG9vbD0iQWRvYmUgUGhvdG9zaG9wIENDIChNYWNpbnRvc2gpIiB4bXBNTTpJbnN0YW5jZUlEPSJ4bXAuaWlkOjAzREMyNTMyMTI0RjExRTM4NzAwREJDRjlCQzAyMUVFIiB4bXBNTTpEb2N1bWVudElEPSJ4bXAuZGlkOjAzREMyNTMzMTI0RjExRTM4NzAwREJDRjlCQzAyMUVFIj4gPHhtcE1NOkRlcml2ZWRGcm9tIHN0UmVmOmluc3RhbmNlSUQ9InhtcC5paWQ6OUU1RTJBODkxMjREMTFFMzg3MDBEQkNGOUJDMDIxRUUiIHN0UmVmOmRvY3VtZW50SUQ9InhtcC5kaWQ6OUU1RTJBOEExMjREMTFFMzg3MDBEQkNGOUJDMDIxRUUiLz4gPC9yZGY6RGVzY3JpcHRpb24+IDwvcmRmOlJERj4gPC94OnhtcG1ldGE+IDw/eHBhY2tldCBlbmQ9InIiPz6dfDQvAAABg0lEQVR42uyWS0vDQBDH82jaKNW0qUltbl68e/Di98eLBz+CCB5EBaWIpUat/4UJLMuame1j7SEDYbqbKfPLvHbDi8ur8+D/5T4K9kR6xrr27D+xgdS3N9d3PilQFmcNzN6mxkbdhxrQcoGofXkFAUAINcVzrG2vsP8KmJdtg7SlxoRQouBywOReQOAosUDoklPEpEU5XDciqeB/iRAig6pIO4P8CHysBBDqg0palrR2Alkwjj5RsDUDoRqhorpq6quifRkInKiIPLf4eWIgQoLoWbq0stXXn10DmDeoR2PsL/E84N0Hk5Wypc70dMkGGhzOoeb4gpjW34K6GEFljFkGu6XTZJUCEMQBVCHs6kI60MycB47FyUmo20oPvYJCzhVnvIsR3zg5ghoRTNpyHKTBBhIJTt6pFsoZ9iLDZswcB5uBULhnho0a66eazaFDca59Hym1e4guQ4rCO4Fu/T4Sw8Gk+c3MghN6H+8CRKVg4tB6fV8XI6/SgXQgHYir/AowAMU5TskhKVUNAAAAAElFTkSuQmCC)!important}.at4-recommended-vertical .at4-no-image-gray-recommended .at4-recommended-item-placeholder-img,.at4-recommended-vertical .at4-no-image-light-recommended .at4-recommended-item-placeholder-img,.at4-recommended-vertical .at4-no-image-minimal-recommended .at4-recommended-item-placeholder-img{background-image:url(data:image/png;base64,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)!important}#at-drawer.ats-dark,.at4-recommended.ats-dark .at4-recommended-horizontal .at4-recommended-item-caption,.at4-recommended.ats-dark .at4-recommended-vertical .at4-recommended-item-caption{background:#262b30}#at-drawer.ats-gray,.at4-recommended.ats-gray .at4-recommended-horizontal .at4-recommended-item-caption{background:#f2f2f2}#at-drawer.ats-light,.at4-recommended.ats-light .at4-recommended-horizontal .at4-recommended-item-caption{background:#fff}.at4-recommended.ats-dark .at4-recommended-vertical .at4-recommended-item{background:none}.at4-recommended.ats-dark .at4-recommended-item .at4-recommended-item-caption a:hover,.at4-recommended.ats-dark .at4-recommended-item .at4-recommended-item-caption a:link,.at4-recommended.ats-dark .at4-recommended-item .at4-recommended-item-caption a:visited,.at4-recommended.ats-dark .at4-recommended-item .at4-recommended-item-caption small,.at4-recommended.ats-dark .at4-recommended-item-caption,.at4-recommended.ats-dark .at-logo a:hover,.at4-recommended.ats-dark .at-recommended-label.at-vertical{color:#fff}.at4-recommended-vertical-logo{padding-top:0;text-align:left}.at4-recommended-vertical-logo .at4-logo-container{line-height:10px}.at4-recommended-horizontal-logo{text-align:center}.at4-recommended.at-inline .at4-recommended-horizontal-logo{text-align:left}#at4-thankyou .at4-recommended.at-inline .at4-recommended-horizontal{text-align:center}.at4-recommended .at-logo{margin:10px 0 0;padding:0;height:25px;overflow:auto;-ms-box-sizing:content-box;-o-box-sizing:content-box;box-sizing:content-box}.at4-recommended.at-inline .at4-recommended-horizontal .at-logo{text-align:left}.at4-recommended .at4-logo-container a.at-sponsored-link{color:#666}.at4-recommended-class .at4-logo-container a:hover,.at4-recommendedbox-outer-container .at4-recommended-recommendedbox .at4-logo-container a:hover{color:#000}</style><style type="text/css">.at-recommendedjumbo-outer-container{margin:0;padding:0;border:0;background:none;color:#000}.at-recommendedjumbo-footer{position:relative;width:100%;height:510px;overflow:hidden;transition:all .3s ease-in-out}.at-mobile .at-recommendedjumbo-footer{height:250px}.at-recommendedjumbo-footer #bg-link:after{content:'';position:absolute;top:0;left:0;right:0;bottom:0;background:rgba(0,0,0,.75)}.at-recommendedjumbo-footer:hover #bg-link:after{background:rgba(0,0,0,.85)}.at-recommendedjumbo-footer *,.at-recommendedjumbo-footer :after,.at-recommendedjumbo-footer :before{box-sizing:border-box}.at-recommendedjumbo-footer:hover #at-recommendedjumbo-footer-bg{animation:atRecommendedJumboAnimatedBackground 1s ease-in-out 1;animation-fill-mode:forwards}.at-recommendedjumbo-footer #at-recommendedjumbo-top-holder{position:absolute;top:0;padding:0 40px;width:100%}.at-mobile .at-recommendedjumbo-footer #at-recommendedjumbo-top-holder{padding:0 20px}.at-recommendedjumbo-footer .at-recommendedjumbo-footer-inner{position:relative;text-align:center;font-family:helvetica,arial,sans-serif;z-index:2;width:100%}.at-recommendedjumbo-footer #at-recommendedjumbo-label-holder{margin:40px 0 0;max-height:30px}.at-mobile .at-recommendedjumbo-footer #at-recommendedjumbo-label-holder{margin:20px 0 0;max-height:20px}.at-recommendedjumbo-footer #at-recommendedjumbo-label{font-weight:300;font-size:24px;line-height:24px;color:#fff;margin:0}.at-mobile .at-recommendedjumbo-footer #at-recommendedjumbo-label{font-weight:150;font-size:14px;line-height:14px}.at-recommendedjumbo-footer #at-recommendedjumbo-title-holder{margin:20px 0 0;min-height:3pc;max-height:78pt}.at-mobile .at-recommendedjumbo-footer #at-recommendedjumbo-title-holder{margin:10px 0 0;min-height:24px;max-height:54px}.at-recommendedjumbo-footer #at-recommendedjumbo-content-title{font-size:3pc;line-height:52px;font-weight:700;margin:0}.at-mobile .at-recommendedjumbo-footer #at-recommendedjumbo-content-title{font-size:24px;line-height:27px}.at-recommendedjumbo-footer a{text-decoration:none;color:#fff}.at-recommendedjumbo-footer a:visited{color:#fff}.at-recommendedjumbo-footer small{margin:20px 0 0;display:inline-block;height:2pc;line-height:2pc;font-size:14px;color:#ccc;cursor:default}.at-mobile .at-recommendedjumbo-footer small{margin:10px 0 0;height:14px;line-height:14px;font-size:9pt}.at-recommendedjumbo-footer .at-logo-container{position:absolute;bottom:20px;margin:auto;left:0;right:0}.at-mobile .at-recommendedjumbo-footer .at-logo-container{bottom:10px}.at-recommendedjumbo-footer a.at-sponsored-link{color:#ccc}.at-recommendedjumbo-footer div #at-recommendedjumbo-logo-link{padding:2px 0 0 11px;text-decoration:none;line-height:20px;font-family:helvetica,arial,sans-serif;font-size:9px;color:#ccc}@keyframes atRecommendedJumboAnimatedBackground{0%{transform:scale(1,1)}to{transform:scale(1.1,1.1)}}</style><style type="text/css">.at-resp-share-element{position:relative;padding:0;margin:0;font-size:0;line-height:0}.at-resp-share-element:after,.at-resp-share-element:before{content:" ";display:table}.at-resp-share-element.at-mobile .at4-share-count-container,.at-resp-share-element.at-mobile .at-label{display:none}.at-resp-share-element .at-share-btn{display:inline-block;*display:inline;*zoom:1;margin:0 2px 5px;padding:0;overflow:hidden;line-height:0;text-decoration:none;text-transform:none;color:#fff;cursor:pointer;transition:all .2s ease-in-out;border:0;font-family:helvetica neue,helvetica,arial,sans-serif;background-color:transparent}.at-resp-share-element .at-share-btn::-moz-focus-inner{border:0;padding:0}.at-resp-share-element .at-share-btn:focus,.at-resp-share-element .at-share-btn:hover{transform:translateY(-4px);color:#fff;text-decoration:none}.at-resp-share-element .at-share-btn .at-icon-wrapper{float:left}.at-resp-share-element .at-share-btn.at-share-btn.at-svc-compact:hover{transform:none}.at-resp-share-element .at-share-btn .at-label{font-family:helvetica neue,helvetica,arial,sans-serif;font-size:9pt;padding:0 15px 0 0;margin:0 0 0 5px;height:2pc;line-height:2pc;background:none}.at-resp-share-element .at-icon,.at-resp-share-element .at-label{cursor:pointer}.at-resp-share-element .at4-share-count-container{text-decoration:none;float:right;padding-right:15px;font-size:9pt}.at-mobile .at-resp-share-element .at-label{display:none}.at-resp-share-element.at-mobile .at-share-btn{margin-right:5px}.at-mobile .at-resp-share-element .at-share-btn{padding:5px;margin-right:5px}</style><style type="text/css">.at-share-tbx-element{position:relative;margin:0;color:#fff;font-size:0}.at-share-tbx-element,.at-share-tbx-element .at-share-btn{font-family:helvetica neue,helvetica,arial,sans-serif;padding:0;line-height:0}.at-share-tbx-element .at-share-btn{cursor:pointer;margin:0 5px 5px 0;display:inline-block;overflow:hidden;border:0;text-decoration:none;text-transform:none;background-color:transparent;color:inherit;transition:all .2s ease-in-out}.at-share-tbx-element .at-share-btn:focus,.at-share-tbx-element .at-share-btn:hover{transform:translateY(-4px);outline-offset:-1px;color:inherit}.at-share-tbx-element .at-share-btn::-moz-focus-inner{border:0;padding:0}.at-share-tbx-element .at-share-btn.at-share-btn.at-svc-compact:hover{transform:none}.at-share-tbx-element .at-icon-wrapper{vertical-align:middle}.at-share-tbx-element .at4-share-count,.at-share-tbx-element .at-label{margin:0 7.5px 0 2.5px;text-decoration:none;vertical-align:middle;display:inline-block;background:none;height:0;font-size:inherit;line-height:inherit;color:inherit}.at-share-tbx-element.at-mobile .at4-share-count,.at-share-tbx-element.at-mobile .at-label{display:none}.at-share-tbx-element .at_native_button{vertical-align:middle}.at-share-tbx-element .addthis_counter.addthis_bubble_style{margin:0 2px;vertical-align:middle;display:inline-block}.at-share-tbx-element .fb_iframe_widget{display:block}.at-share-tbx-element.at-share-tbx-native .at300b{vertical-align:middle}.at-style-responsive .at-share-btn{padding:5px}.at-style-jumbo{display:table}.at-style-jumbo .at4-spacer{height:1px;display:block;visibility:hidden;opacity:0}.at-style-jumbo .at4-count-container{display:table-cell;text-align:center;min-width:200px;vertical-align:middle;border-right:1px solid #ccc;padding-right:20px}.at-style-jumbo .at4-count{font-size:60px;line-height:60px;font-weight:700}.at-style-jumbo .at4-count-title{position:relative;font-size:18px;line-height:18px;bottom:2px}.at-style-jumbo .at-share-btn-elements{display:table-cell;vertical-align:middle;padding-left:20px}.at_flat_counter{cursor:pointer;font-family:helvetica,arial,sans-serif;font-weight:700;text-transform:uppercase;display:inline-block;position:relative;vertical-align:top;height:auto;margin:0 5px;padding:0 6px;left:-1px;background:#ebebeb;color:#32363b;transition:all .2s ease}.at_flat_counter:after{top:30%;left:-4px;content:"";position:absolute;border-width:5px 8px 5px 0;border-style:solid;border-color:transparent #ebebeb transparent transparent;display:block;width:0;height:0;transform:translateY(360deg)}.at_flat_counter:hover{background:#e1e2e2}</style><style type="text/css">.at4-thankyou-background{top:0;right:0;left:0;bottom:0;-webkit-overflow-scrolling:touch;z-index:9999999;background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpizCuu/sRABGBiIBKMKqSOQoAAAwC8KgJipENhxwAAAABJRU5ErkJggg==);background:hsla(217,6%,46%,.95)}.at4-thankyou-background.at-thankyou-shown{position:fixed}.at4-thankyou-inner{position:absolute;width:100%;top:10%;left:50%;margin-left:-50%;text-align:center}.at4-thankyou-mobile .at4-thankyou-inner{top:5%}.thankyou-description{font-weight:400}.at4-thankyou-background .at4lb-inner{position:relative;width:100%;height:100%}.at4-thankyou-background .at4lb-inner .at4x{position:absolute;top:15px;right:15px;display:block;width:20px;height:20px;padding:20px;margin:0;cursor:pointer;transition:opacity .25s ease-in;opacity:.4;background:url("data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAUCAYAAACNiR0NAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAABx0RVh0U29mdHdhcmUAQWRvYmUgRmlyZXdvcmtzIENTNui8sowAAAAWdEVYdENyZWF0aW9uIFRpbWUAMTEvMTMvMTKswDp5AAAAd0lEQVQ4jb2VQRLAIAgDE///Z3qqY1FAhalHMCsCIkVEAIAkkVgvp2lDBgYAnAyHkWotLccNrEd4A7X2TqIdqLfnWBAdaF5rJdyJfjtPH5GT37CaGhoVq3nOm/XflUuLUto2pY1d+vRKh0Pp+MrAVtDe2JkvYNQ+jVSEEFmOkggAAAAASUVORK5CYII=") no-repeat center center;overflow:hidden;text-indent:-99999em;border:1px solid transparent}.at4-thankyou-background .at4lb-inner .at4x:focus,.at4-thankyou-background .at4lb-inner .at4x:hover{border:1px solid #fff;border-radius:50%;outline:0}.at4-thankyou-background .at4lb-inner #at4-palogo{position:absolute;bottom:10px;display:inline-block;text-decoration:none;font-family:helvetica,arial,sans-serif;font-size:11px;cursor:pointer;-webkit-transition:opacity .25s ease-in;moz-transition:opacity .25s ease-in;transition:opacity .25s ease-in;opacity:.5;z-index:100020;color:#fff;padding:2px 0 0 13px}.at4-thankyou-background .at4lb-inner #at4-palogo .at-branding-addthis,.at4-thankyou-background .at4lb-inner #at4-palogo .at-branding-info{color:#fff}.at4-thankyou-background .at4lb-inner #at4-palogo:hover,.at4-thankyou-background.ats-dark .at4lb-inner a#at4-palogo:hover{text-decoration:none;color:#fff;opacity:1}.at4-thankyou-background.ats-dark{background-image:url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgeMZABGBiIBKMKqSOQoAAAwB+cQD6hqlbCwAAAABJRU5ErkJggg==");background:rgba(0,0,0,.85)}.at4-thankyou-background .thankyou-title{color:#fff;font-size:38.5px;margin:10px 20px;line-height:38.5px;font-family:helvetica neue,helvetica,arial,sans-serif;font-weight:300}.at4-thankyou-background.ats-dark .thankyou-description,.at4-thankyou-background.ats-dark .thankyou-title{color:#fff}.at4-thankyou-background .thankyou-description{color:#fff;font-size:18px;margin:10px 0;line-height:24px;padding:0;font-family:helvetica neue,helvetica,arial,sans-serif;font-weight:300}.at4-thankyou-background .at4-thanks-icons{padding-top:10px}.at4-thankyou-mobile *{-webkit-overflow-scrolling:touch}#at4-thankyou .at4-recommended-recommendedbox .at-logo{display:none}.at4-thankyou .at-h3{height:49px;line-height:49px;margin:0 50px 0 20px;padding:1px 0 0;font-family:helvetica neue,helvetica,arial,sans-serif;font-size:1pc;font-weight:700;color:#fff;text-shadow:0 1px #000}.at4-thanks{padding-top:50px;text-align:center}.at4-thanks label{display:block;margin:0 0 15px;font-size:1pc;line-height:1pc}.at4-thanks .at4-h2{background:none;border:none;margin:0 0 10px;padding:0;font-family:helvetica neue,helvetica,arial,sans-serif;font-size:28px;font-weight:300;color:#000}.at4-thanks .at4-thanks-icons{position:relative;height:2pc}.at4-thanks .at4-thanks-icons .at-thankyou-label{display:block;padding-bottom:10px;font-size:14px;color:#666}.at4-thankyou-layer .at-follow .at-icon-wrapper{width:2pc;height:2pc}</style><style type="text/css">.at4-recommended-toaster{position:fixed;top:auto;bottom:0;right:0;z-index:100021}.at4-recommended-toaster.ats-light{border:1px solid #c5c5c5;background:#fff}.at4-recommended-toaster.ats-gray{border:1px solid #c5c5c5;background:#f2f2f2}.at4-recommended-toaster.ats-dark{background:#262b30;color:#fff}.at4-recommended-toaster .at4-recommended-container{padding-top:0;margin:0}.at4-recommended.at4-recommended-toaster div.at-recommended-label{line-height:1pc;font-size:1pc;text-align:left;padding:20px 0 0 20px}.at4-toaster-outer .at4-recommended .at4-recommended-item .at4-recommended-item-caption .at-h4{font-size:11px;line-height:11px;margin:10px 0 6px;height:30px}.at4-recommended.at4-recommended-toaster div.at-recommended-label.ats-gray,.at4-recommended.at4-recommended-toaster div.at-recommended-label.ats-light{color:#464646}.at4-recommended.at4-recommended-toaster div.at-recommended-label.ats-dark{color:#fff}.at4-toaster-close-control{position:absolute;top:0;right:0;display:block;width:20px;height:20px;line-height:20px;margin:5px 5px 0 0;padding:0;text-indent:-9999em}.at4-toaster-open-control{position:fixed;right:0;bottom:0;z-index:100020}.at4-toaster-outer .at4-recommended-item{width:90pt;border:0;margin:9px 10px 0}.at4-toaster-outer .at4-recommended-item:first-child{margin-left:20px}.at4-toaster-outer .at4-recommended-item:last-child{margin-right:20px}.at4-toaster-outer .at4-recommended-item .at4-recommended-item-img{max-height:90pt;max-width:90pt}.at4-toaster-outer .at4-recommended-item .at4-recommended-item-img img{height:90pt;width:90pt}.at4-toaster-outer .at4-recommended-item .at4-recommended-item-caption{height:30px;padding:0;margin:0;height:initial}.at4-toaster-outer .ats-dark .at4-recommended-item .at4-recommended-item-caption{background:#262b30}.at4-toaster-outer .at4-recommended .at4-recommended-item .at4-recommended-item-caption small{width:auto;line-height:14px;margin:0}.at4-toaster-outer .at4-recommended.ats-dark .at4-recommended-item .at4-recommended-item-caption small{color:#fff}.at4-recommended-toaster .at-logo{margin:0 0 3px 20px;text-align:left}.at4-recommended-toaster .at-logo .at4-logo-container.at-sponsored-logo{position:relative}.at4-toaster-outer .at4-recommended-item .sponsored-label{text-align:right;font-size:10px;color:#666;float:right;position:fixed;bottom:6px;right:20px;top:initial;z-index:99999}</style><style type="text/css">.at4-whatsnext{position:fixed;bottom:0!important;right:0;background:#fff;border:1px solid #c5c5c5;margin:-1px;width:390px;height:90pt;overflow:hidden;font-size:9pt;font-weight:400;color:#000;z-index:1800000000}.at4-whatsnext a{color:#666}.at4-whatsnext .at-whatsnext-content{height:90pt;position:relative}.at4-whatsnext .at-whatsnext-content .at-branding{position:absolute;bottom:15px;right:10px;padding-left:9px;text-decoration:none;line-height:10px;font-family:helvetica,arial,sans-serif;font-size:10px;color:#666}.at4-whatsnext .at-whatsnext-content .at-whatsnext-content-inner{position:absolute;top:15px;right:20px;bottom:15px;left:140px;text-align:left;height:105px}.at4-whatsnext .at-whatsnext-content-inner a{display:inline-block}.at4-whatsnext .at-whatsnext-content-inner div.at-h6{text-align:left;margin:0;padding:0 0 3px;font-size:11px;color:#666;cursor:default}.at4-whatsnext .at-whatsnext-content .at-h3{text-align:left;margin:5px 0;padding:0;line-height:1.2em;font-weight:400;font-size:14px;height:3pc}.at4-whatsnext .at-whatsnext-content-inner a:link,.at4-whatsnext .at-whatsnext-content-inner a:visited{text-decoration:none;font-weight:400;color:#464646}.at4-whatsnext .at-whatsnext-content-inner a:hover{color:#000}.at4-whatsnext .at-whatsnext-content-inner small{position:absolute;bottom:15px;line-height:10px;font-size:11px;color:#666;cursor:default;text-align:left}.at4-whatsnext .at-whatsnext-content .at-whatsnext-content-img{position:absolute;top:0;left:0;width:90pt;height:90pt;overflow:hidden}.at4-whatsnext .at-whatsnext-content .at-whatsnext-content-img img{position:absolute;top:0;left:0;max-height:none;max-width:none}.at4-whatsnext .at-whatsnext-close-control{position:absolute;top:0;right:0;display:block;width:20px;height:20px;line-height:20px;margin:0 5px 0 0;padding:0;text-indent:-9999em}.at-whatsnext-open-control{position:fixed;right:0;bottom:0;z-index:100020}.at4-whatsnext.ats-dark{background:#262b30}.at4-whatsnext.ats-dark .at-whatsnext-content .at-h3,.at4-whatsnext.ats-dark .at-whatsnext-content a.at4-logo:hover,.at4-whatsnext.ats-dark .at-whatsnext-content-inner a:link,.at4-whatsnext.ats-dark .at-whatsnext-content-inner a:visited{color:#fff}.at4-whatsnext.ats-light{background:#fff}.at4-whatsnext.ats-gray{background:#f2f2f2}.at4-whatsnext.at-whatsnext-nophoto{width:270px}.at4-whatsnext.at-whatsnext-nophoto .at-whatsnext-content-img{display:none}.at4-whatsnext.at-whatsnext-nophoto .at-whatsnext-content .at-whatsnext-content-inner{top:15px;right:0;left:20px}.at4-whatsnext.at-whatsnext-nophoto .at-whatsnext-content .at-whatsnext-content-inner.addthis_32x32_style{top:0;right:0;left:0;padding:45px 20px 0;font-size:20px}.at4-whatsnext.at-whatsnext-nophoto .at-whatsnext-content .at-whatsnext-content-inner .at4-icon,.at4-whatsnext.at-whatsnext-nophoto .at-whatsnext-content .at-whatsnext-content-inner .at4-icon-fw,.at4-whatsnext.at-whatsnext-nophoto .at-whatsnext-content .at-whatsnext-content-inner .whatsnext-msg{vertical-align:middle}.at-whatsnext-img,.at-whatsnext-img-lnk{position:absolute;left:0}</style><style type="text/css">.at4-whatsnextmobile{position:fixed;bottom:0;right:0;left:0;background:#fff;z-index:9999998;height:170px;font-size:28px}.at4-whatsnextmobile .col-2{height:100%;font-size:1em}.at4-whatsnextmobile .col-2:first-child{max-width:200px;display:inline-block;float:left}.at4-whatsnextmobile .col-2:last-child{position:absolute;left:200px;right:50px;top:0;bottom:0;display:inline-block}.at4-whatsnextmobile .at-whatsnext-content-inner{font-size:1em}.at4-whatsnextmobile .at-whatsnext-content-img img{height:100%;width:100%}.at4-whatsnextmobile .at-close-control{font-size:1em;position:absolute;top:0;right:0;width:50px;height:50px}.at4-whatsnextmobile .at-close-control button{width:100%;height:100%;font-size:1em;font-weight:400;text-decoration:none;opacity:.5;padding:0;cursor:pointer;background:0 0;border:0;-webkit-appearance:none}.at4-whatsnextmobile .at-h3,.at4-whatsnextmobile .at-h6{font-size:1em;margin:0;color:#a1a1a1;margin-left:2.5%;margin-top:25px}.at4-whatsnextmobile .at-h3{font-size:1em;line-height:1em;font-weight:500;height:50%}.at4-whatsnextmobile .at-h3 a{font-size:1em;text-decoration:none}.at4-whatsnextmobile .at-h6{font-size:.8em;line-height:.8em;font-weight:500}.at4-whatsnextmobile .footer{position:absolute;bottom:2px;left:200px;right:0;padding-left:2.5%;font-size:1em;line-height:.6em}.at4-whatsnextmobile .footer small{font-size:.6em;color:#a1a1a1}.at4-whatsnextmobile .footer small:first-child{margin-right:5%;float:left}.at4-whatsnextmobile .footer small:last-child{margin-right:2.5%;float:right}.at4-whatsnextmobile .at-whatsnext-content{height:100%}.at4-whatsnextmobile.ats-dark{background:#262b30;color:#fff}.at4-whatsnextmobile .at-close-control button{color:#bfbfbf}.at4-whatsnextmobile.ats-dark a:link,.at4-whatsnextmobile.ats-dark a:visited{color:#fff}.at4-whatsnextmobile.ats-gray{background:#f2f2f2;color:#262b30}.at4-whatsnextmobile.ats-light{background:#fff;color:#262b30}.at4-whatsnextmobile.ats-dark .footer a:link,.at4-whatsnextmobile.ats-dark .footer a:visited,.at4-whatsnextmobile.ats-gray .footer a:link,.at4-whatsnextmobile.ats-gray .footer a:visited,.at4-whatsnextmobile.ats-light .footer a:link,.at4-whatsnextmobile.ats-light .footer a:visited{color:#a1a1a1}.at4-whatsnextmobile.ats-gray a:link,.at4-whatsnextmobile.ats-gray a:visited,.at4-whatsnextmobile.ats-light a:link,.at4-whatsnextmobile.ats-light a:visited{color:#262b30}@media only screen and (min-device-width:320px) and (max-device-width:480px){.at4-whatsnextmobile{height:85px;font-size:14px}.at4-whatsnextmobile .col-2:first-child{width:75pt}.at4-whatsnextmobile .col-2:last-child{right:25px;left:75pt}.at4-whatsnextmobile .footer{left:75pt}.at4-whatsnextmobile .at-close-control{width:25px;height:25px}.at4-whatsnextmobile .at-h3,.at4-whatsnextmobile .at-h6{margin-top:12.5px}}</style><style type="text/css">.at-custom-mobile-bar{left:0;right:0;width:100%;height:56px;position:fixed;text-align:center;z-index:100020;background:#fff;overflow:hidden;box-shadow:0 0 10px 0 rgba(0,0,0,.2);font:initial;line-height:normal;top:auto;bottom:0}.at-custom-mobile-bar.at-custom-mobile-bar-zindex-hide{z-index:-1!important}.at-custom-mobile-bar.atss-top{top:0;bottom:auto}.at-custom-mobile-bar.atss-bottom{top:auto;bottom:0}.at-custom-mobile-bar .at-custom-mobile-bar-btns{display:inline-block;text-align:center}.at-custom-mobile-bar .at-custom-mobile-bar-counter,.at-custom-mobile-bar .at-share-btn{margin-top:4px}.at-custom-mobile-bar .at-share-btn{display:inline-block;text-decoration:none;transition:none;box-sizing:content-box}.at-custom-mobile-bar .at-custom-mobile-bar-counter{font-family:Helvetica neue,arial;vertical-align:top;margin-left:4px;margin-right:4px;display:inline-block}.at-custom-mobile-bar .at-custom-mobile-bar-count{font-size:26px;line-height:1.25em;color:#222}.at-custom-mobile-bar .at-custom-mobile-bar-text{font-size:9pt;line-height:1.25em;color:#888;letter-spacing:1px}.at-custom-mobile-bar .at-icon-wrapper{text-align:center;height:3pc;width:3pc;margin:0 4px}.at-custom-mobile-bar .at-icon{vertical-align:top;margin:8px;width:2pc;height:2pc}.at-custom-mobile-bar.at-shfs-medium{height:3pc}.at-custom-mobile-bar.at-shfs-medium .at-custom-mobile-bar-counter{margin-top:6px}.at-custom-mobile-bar.at-shfs-medium .at-custom-mobile-bar-count{font-size:18px}.at-custom-mobile-bar.at-shfs-medium .at-custom-mobile-bar-text{font-size:10px}.at-custom-mobile-bar.at-shfs-medium .at-icon-wrapper{height:40px;width:40px}.at-custom-mobile-bar.at-shfs-medium .at-icon{margin:6px;width:28px;height:28px}.at-custom-mobile-bar.at-shfs-small{height:40px}.at-custom-mobile-bar.at-shfs-small .at-custom-mobile-bar-counter{margin-top:3px}.at-custom-mobile-bar.at-shfs-small .at-custom-mobile-bar-count{font-size:1pc}.at-custom-mobile-bar.at-shfs-small .at-custom-mobile-bar-text{font-size:10px}.at-custom-mobile-bar.at-shfs-small .at-icon-wrapper{height:2pc;width:2pc}.at-custom-mobile-bar.at-shfs-small .at-icon{margin:4px;width:24px;height:24px}</style><style type="text/css">.at-custom-sidebar{top:20%;width:58px;position:fixed;text-align:center;z-index:100020;background:#fff;overflow:hidden;box-shadow:0 0 10px 0 rgba(0,0,0,.2);font:initial;line-height:normal;top:auto;bottom:0}.at-custom-sidebar.at-custom-sidebar-zindex-hide{z-index:-1!important}.at-custom-sidebar.atss-left{left:0;right:auto;float:left;border-radius:0 4px 4px 0}.at-custom-sidebar.atss-right{left:auto;right:0;float:right;border-radius:4px 0 0 4px}.at-custom-sidebar .at-custom-sidebar-btns{display:inline-block;text-align:center;padding-top:4px}.at-custom-sidebar .at-custom-sidebar-counter{margin-bottom:8px}.at-custom-sidebar .at-share-btn{display:inline-block;text-decoration:none;transition:none;box-sizing:content-box}.at-custom-sidebar .at-custom-sidebar-counter{font-family:Helvetica neue,arial;vertical-align:top;margin-left:4px;margin-right:4px;display:inline-block}.at-custom-sidebar .at-custom-sidebar-count{font-size:21px;line-height:1.25em;color:#222}.at-custom-sidebar .at-custom-sidebar-text{font-size:10px;line-height:1.25em;color:#888;letter-spacing:1px}.at-custom-sidebar .at-icon-wrapper{text-align:center;margin:0 4px}.at-custom-sidebar .at-icon{vertical-align:top;margin:9px;width:2pc;height:2pc}.at-custom-sidebar .at-icon-wrapper{position:relative}.at-custom-sidebar .at4-share-count,.at-custom-sidebar .at4-share-count-container{line-height:1pc;font-size:10px}.at-custom-sidebar .at4-share-count{text-indent:0;font-family:Arial,Helvetica Neue,Helvetica,sans-serif;font-weight:200;width:100%;height:1pc}.at-custom-sidebar .at4-share-count-anchor .at-icon{margin-top:3px}.at-custom-sidebar .at4-share-count-container{position:absolute;left:0;right:auto;top:auto;bottom:0;width:100%;color:#fff;background:inherit}</style><style type="text/css">.at-image-sharing-mobile-icon{position:absolute;background:#000 url(https://s7.addthis.com/static/44a36d35bafef33aa9455b7d3039a771.png) no-repeat top center;background-color:rgba(0,0,0,.9);background-image:url(https://s7.addthis.com/static/10db525181ee0bbe1a515001be1c7818.svg),none;border-radius:3px;width:50px;height:40px;top:-9999px;left:-9999px}.at-image-sharing-tool{display:block;position:absolute;text-align:center;z-index:9001;background:none;overflow:hidden;top:-9999px;left:-9999px;font:initial;line-height:0}.at-image-sharing-tool.addthis-animated{animation-duration:.15s}.at-image-sharing-tool.at-orientation-vertical .at-share-btn{display:block}.at-image-sharing-tool.at-orientation-horizontal .at-share-btn{display:inline-block}.at-image-sharing-tool.at-image-sharing-tool-size-big .at-icon{width:43px;height:43px}.at-image-sharing-tool.at-image-sharing-tool-size-mobile .at-share-btn{margin:0!important}.at-image-sharing-tool.at-image-sharing-tool-size-mobile .at-icon-wrapper{height:60px;width:100%;border-radius:0!important}.at-image-sharing-tool.at-image-sharing-tool-size-mobile .at-icon{max-width:100%;height:54px!important;width:54px!important}.at-image-sharing-tool .at-custom-shape.at-image-sharing-tool-btns{margin-right:8px;margin-bottom:8px}.at-image-sharing-tool .at-custom-shape .at-share-btn{margin-top:8px;margin-left:8px}.at-image-sharing-tool .at-share-btn{line-height:0;text-decoration:none;transition:none;box-sizing:content-box}.at-image-sharing-tool .at-icon-wrapper{text-align:center;height:100%;width:100%}.at-image-sharing-tool .at-icon{vertical-align:top;width:2pc;height:2pc;margin:3px}</style><style type="text/css">.at-expanding-share-button{box-sizing:border-box;position:fixed;z-index:9999}.at-expanding-share-button[data-position=bottom-right]{bottom:10px;right:10px}.at-expanding-share-button[data-position=bottom-right] .at-expanding-share-button-toggle-bg,.at-expanding-share-button[data-position=bottom-right] .at-expanding-share-button-toggle-btn[data-name]:after,.at-expanding-share-button[data-position=bottom-right] .at-icon-wrapper,.at-expanding-share-button[data-position=bottom-right] [data-name]:after{float:right}.at-expanding-share-button[data-position=bottom-right] [data-name]:after{margin-right:10px}.at-expanding-share-button[data-position=bottom-right] .at-expanding-share-button-toggle-btn[data-name]:after{margin-right:5px}.at-expanding-share-button[data-position=bottom-right] .at-icon-wrapper{margin-right:-3px}.at-expanding-share-button[data-position=bottom-left]{bottom:10px;left:10px}.at-expanding-share-button[data-position=bottom-left] .at-expanding-share-button-toggle-bg,.at-expanding-share-button[data-position=bottom-left] .at-expanding-share-button-toggle-btn[data-name]:after,.at-expanding-share-button[data-position=bottom-left] .at-icon-wrapper,.at-expanding-share-button[data-position=bottom-left] [data-name]:after{float:left}.at-expanding-share-button[data-position=bottom-left] [data-name]:after{margin-left:10px}.at-expanding-share-button[data-position=bottom-left] .at-expanding-share-button-toggle-btn[data-name]:after{margin-left:5px}.at-expanding-share-button *,.at-expanding-share-button :after,.at-expanding-share-button :before{box-sizing:border-box}.at-expanding-share-button .at-expanding-share-button-services-list{display:none;list-style:none;margin:0 5px;overflow:visible;padding:0}.at-expanding-share-button .at-expanding-share-button-services-list>li{display:block;height:45px;position:relative;overflow:visible}.at-expanding-share-button .at-expanding-share-button-toggle-btn,.at-expanding-share-button .at-share-btn{transition:.1s;text-decoration:none}.at-expanding-share-button .at-share-btn{display:block;height:40px;padding:0 3px 0 0}.at-expanding-share-button .at-expanding-share-button-toggle-btn{position:relative;overflow:auto}.at-expanding-share-button .at-expanding-share-button-toggle-btn.at-expanding-share-button-hidden[data-name]:after{display:none}.at-expanding-share-button .at-expanding-share-button-toggle-bg{box-shadow:0 2px 4px 0 rgba(0,0,0,.3);border-radius:50%;position:relative}.at-expanding-share-button .at-expanding-share-button-toggle-bg>span{background-image:url("data:image/svg+xml,%3Csvg%20width%3D%2232px%22%20height%3D%2232px%22%20viewBox%3D%220%200%2032%2032%22%20version%3D%221.1%22%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%3Ctitle%3Eshare%3C%2Ftitle%3E%3Cg%20stroke%3D%22none%22%20stroke-width%3D%221%22%20fill%3D%22none%22%20fill-rule%3D%22evenodd%22%3E%3Cg%20fill%3D%22%23FFFFFF%22%3E%3Cpath%20d%3D%22M26%2C13.4285714%20C26%2C13.6220248%2025.9293162%2C13.7894338%2025.7879464%2C13.9308036%20L20.0736607%2C19.6450893%20C19.932291%2C19.786459%2019.7648819%2C19.8571429%2019.5714286%2C19.8571429%20C19.3779752%2C19.8571429%2019.2105662%2C19.786459%2019.0691964%2C19.6450893%20C18.9278267%2C19.5037195%2018.8571429%2C19.3363105%2018.8571429%2C19.1428571%20L18.8571429%2C16.2857143%20L16.3571429%2C16.2857143%20C15.6279725%2C16.2857143%2014.9750773%2C16.3080355%2014.3984375%2C16.3526786%20C13.8217977%2C16.3973217%2013.2488868%2C16.477306%2012.6796875%2C16.5926339%20C12.1104882%2C16.7079619%2011.6157015%2C16.8660704%2011.1953125%2C17.0669643%20C10.7749235%2C17.2678581%2010.3824423%2C17.5264121%2010.0178571%2C17.8426339%20C9.65327199%2C18.1588557%209.35565592%2C18.534596%209.125%2C18.9698661%20C8.89434408%2C19.4051361%208.71391434%2C19.9203839%208.58370536%2C20.515625%20C8.45349637%2C21.1108661%208.38839286%2C21.7842224%208.38839286%2C22.5357143%20C8.38839286%2C22.9449425%208.40699386%2C23.4025272%208.44419643%2C23.9084821%20C8.44419643%2C23.9531252%208.45349693%2C24.0405499%208.47209821%2C24.1707589%20C8.4906995%2C24.3009679%208.5%2C24.3995532%208.5%2C24.4665179%20C8.5%2C24.5781256%208.46837829%2C24.6711306%208.40513393%2C24.7455357%20C8.34188956%2C24.8199408%208.25446484%2C24.8571429%208.14285714%2C24.8571429%20C8.02380893%2C24.8571429%207.9196433%2C24.7938994%207.83035714%2C24.6674107%20C7.77827355%2C24.6004461%207.72991094%2C24.5186017%207.68526786%2C24.421875%20C7.64062478%2C24.3251483%207.59040206%2C24.2135423%207.53459821%2C24.0870536%20C7.47879436%2C23.9605648%207.43973225%2C23.87128%207.41741071%2C23.8191964%20C6.47246551%2C21.6986501%206%2C20.0208395%206%2C18.7857143%20C6%2C17.3050521%206.19717065%2C16.0662252%206.59151786%2C15.0691964%20C7.79688103%2C12.0706695%2011.0520568%2C10.5714286%2016.3571429%2C10.5714286%20L18.8571429%2C10.5714286%20L18.8571429%2C7.71428571%20C18.8571429%2C7.52083237%2018.9278267%2C7.35342333%2019.0691964%2C7.21205357%20C19.2105662%2C7.07068382%2019.3779752%2C7%2019.5714286%2C7%20C19.7648819%2C7%2019.932291%2C7.07068382%2020.0736607%2C7.21205357%20L25.7879464%2C12.9263393%20C25.9293162%2C13.067709%2026%2C13.2351181%2026%2C13.4285714%20L26%2C13.4285714%20Z%22%3E%3C%2Fpath%3E%3C%2Fg%3E%3C%2Fg%3E%3C%2Fsvg%3E");background-position:center center;background-repeat:no-repeat;transition:transform .4s ease;border-radius:50%;display:block}.at-expanding-share-button .at-icon-wrapper{box-shadow:0 2px 4px 0 rgba(0,0,0,.3);border-radius:50%;display:inline-block;height:40px;line-height:40px;text-align:center;width:40px}.at-expanding-share-button .at-icon{display:inline-block;height:34px;margin:3px 0;vertical-align:top;width:34px}.at-expanding-share-button [data-name]:after{box-shadow:0 2px 4px 0 rgba(0,0,0,.3);transform:translate(0, -50%);transition:.4s;background-color:#fff;border-radius:3px;color:#666;content:attr(data-name);font-family:Helvetica Neue,Helvetica,Arial,sans-serif;font-size:9pt;line-height:9pt;font-weight:500;opacity:0;padding:3px 5px;position:relative;top:20px;white-space:nowrap}.at-expanding-share-button.at-expanding-share-button-show-icons .at-expanding-share-button-services-list{display:block}.at-expanding-share-button.at-expanding-share-button-animate-in .at-expanding-share-button-toggle-bg>span{transform:rotate(270deg);background-image:url("data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20xmlns%3Axlink%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxlink%22%20viewBox%3D%220%200%2032%2032%22%3E%3Cg%3E%3Cpath%20d%3D%22M18%2014V8h-4v6H8v4h6v6h4v-6h6v-4h-6z%22%20fill-rule%3D%22evenodd%22%20fill%3D%22white%22%3E%3C%2Fpath%3E%3C%2Fg%3E%3C%2Fsvg%3E");background-position:center center;background-repeat:no-repeat}.at-expanding-share-button.at-expanding-share-button-animate-in [data-name]:after{opacity:1}.at-expanding-share-button.at-hide-label [data-name]:after{display:none}.at-expanding-share-button.at-expanding-share-button-desktop .at-expanding-share-button-toggle{height:50px}.at-expanding-share-button.at-expanding-share-button-desktop .at-icon-wrapper:hover{box-shadow:0 2px 5px 0 rgba(0,0,0,.5)}.at-expanding-share-button.at-expanding-share-button-desktop .at-expanding-share-button-toggle-bg{height:50px;line-height:50px;width:50px}.at-expanding-share-button.at-expanding-share-button-desktop .at-expanding-share-button-toggle-bg>span{height:50px;width:50px}.at-expanding-share-button.at-expanding-share-button-desktop .at-expanding-share-button-toggle-bg:after{box-shadow:0 2px 5px 0 rgba(0,0,0,.2);transition:opacity .2s ease;border-radius:50%;content:'';height:100%;opacity:0;position:absolute;top:0;left:0;width:100%}.at-expanding-share-button.at-expanding-share-button-desktop .at-expanding-share-button-toggle-bg:hover:after{opacity:1}.at-expanding-share-button.at-expanding-share-button-desktop .at-expanding-share-button-toggle-btn[data-name]:after{top:25px}.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-services-list{margin:0}.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-toggle-btn,.at-expanding-share-button.at-expanding-share-button-mobile .at-share-btn{outline:0}.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-toggle{height:40px;-webkit-tap-highlight-color:transparent}.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-toggle-bg,.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-toggle-bg span{height:40px;line-height:40px;width:40px}.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-click-flash{transform:scale(0);transition:transform ease,opacity ease-in;background-color:hsla(0,0%,100%,.3);border-radius:50%;height:40px;opacity:1;position:absolute;width:40px;z-index:10000}.at-expanding-share-button.at-expanding-share-button-mobile .at-expanding-share-button-click-flash.at-expanding-share-button-click-flash-animate{transform:scale(1);opacity:0}.at-expanding-share-button.at-expanding-share-button-mobile+.at-expanding-share-button-mobile-overlay{transition:opacity ease;bottom:0;background-color:hsla(0,0%,87%,.7);display:block;height:auto;left:0;opacity:0;position:fixed;right:0;top:0;width:auto;z-index:9998}.at-expanding-share-button.at-expanding-share-button-mobile+.at-expanding-share-button-mobile-overlay.at-expanding-share-button-hidden{height:0;width:0;z-index:-10000}.at-expanding-share-button.at-expanding-share-button-mobile.at-expanding-share-button-animate-in+.at-expanding-share-button-mobile-overlay{transition:opacity ease;opacity:1}</style><style type="text/css">.at-tjin-element .at300b,.at-tjin-element .at300m{display:inline-block;width:auto;padding:0;margin:0 2px 5px;outline-offset:-1px;transition:all .2s ease-in-out}.at-tjin-element .at300b:focus,.at-tjin-element .at300b:hover,.at-tjin-element .at300m:focus,.at-tjin-element .at300m:hover{transform:translateY(-4px)}.at-tjin-element .addthis_tjin_label{display:none}.at-tjin-element .addthis_vertical_style .at300b,.at-tjin-element .addthis_vertical_style .at300m{display:block}.at-tjin-element .addthis_vertical_style .at300b .addthis_tjin_label,.at-tjin-element .addthis_vertical_style .at300b .at-icon-wrapper,.at-tjin-element .addthis_vertical_style .at300m .addthis_tjin_label,.at-tjin-element .addthis_vertical_style .at300m .at-icon-wrapper{display:inline-block;vertical-align:middle;margin-right:5px}.at-tjin-element .addthis_vertical_style .at300b:focus,.at-tjin-element .addthis_vertical_style .at300b:hover,.at-tjin-element .addthis_vertical_style .at300m:focus,.at-tjin-element .addthis_vertical_style .at300m:hover{transform:none}.at-tjin-element .at-tjin-btn{margin:0 5px 5px 0;padding:0;outline-offset:-1px;display:inline-block;box-sizing:content-box;transition:all .2s ease-in-out}.at-tjin-element .at-tjin-btn:focus,.at-tjin-element .at-tjin-btn:hover{transform:translateY(-4px)}.at-tjin-element .at-tjin-title{margin:0 0 15px}</style><style type="text/css">#addthissmartlayerscssready{color:#bada55!important}.addthis-smartlayers,div#at4-follow,div#at4-share,div#at4-thankyou,div#at4-whatsnext{padding:0;margin:0}#at4-follow-label,#at4-share-label,#at4-whatsnext-label,.at4-recommended-label.hidden{padding:0;border:none;background:none;position:absolute;top:0;left:0;height:0;width:0;overflow:hidden;text-indent:-9999em}.addthis-smartlayers .at4-arrow:hover{cursor:pointer}.addthis-smartlayers .at4-arrow:after,.addthis-smartlayers .at4-arrow:before{content:none}a.at4-logo{background:url(data:image/gif;base64,R0lGODlhBwAHAJEAAP9uQf///wAAAAAAACH5BAkKAAIALAAAAAAHAAcAAAILFH6Ge8EBH2MKiQIAOw==) no-repeat left center}.at4-minimal a.at4-logo{background:url(data:image/gif;base64,R0lGODlhBwAHAJEAAP9uQf///wAAAAAAACH5BAkKAAIALAAAAAAHAAcAAAILFH6Ge8EBH2MKiQIAOw==) no-repeat left center!important}button.at4-closebutton{position:absolute;top:0;right:0;padding:0;margin-right:10px;cursor:pointer;background:transparent;border:0;-webkit-appearance:none;font-size:19px;line-height:1;color:#000;text-shadow:0 1px 0 #fff;opacity:.2}button.at4-closebutton:hover{color:#000;text-decoration:none;cursor:pointer;opacity:.5}div.at4-arrow{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFAAAAAoCAYAAABpYH0BAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAV1JREFUeNrsmesOgyAMhQfxwfrofTM3E10ME2i5Oeppwr9a5OMUCrh1XV+wcvNAAIAA+BiAzrmtUWln27dbjEcC3AdODfo0BdEPhmcO4nIDvDNELi2jggk4/k8dT7skfeKzWIEd4VUpMQKvNB7X+OZSmAZkATWC1xvipbpnLmOosbJZC08CkAeA4E6qFUEMwLAGnlSBPCE8lW8CYnZTcimH2HoT7kSFOx5HBmCnDhTIu1p5s98G+QZrxGPhZVMY1vgyAQaAAAiAAAgDQACcBOD+BvJtBWfRy7NpJK5tBe4FNzXokywV734wPHMQlxvgnSGyNoUP/2ACjv/7iSeYKO3YWKzAjvCqlBiBVxqPa3ynexNJwOsN8TJbzL6JNIYYXWpMv4lIIAZgWANPqkCeEJ7KNwExu8lpLlSpAVQarO77TyKdBsyRPuwV0h0gmoGnTWFYzVkYBoAA+I/2FmAAt6+b5XM9mFkAAAAASUVORK5CYII=);background-repeat:no-repeat;width:20px;height:20px;margin:0;padding:0;overflow:hidden;text-indent:-9999em;text-align:left;cursor:pointer}#at4-recommendedpanel-outer-container .at4-arrow.at-right,div.at4-arrow.at-right{background-position:-20px 0}#at4-recommendedpanel-outer-container .at4-arrow.at-left,div.at4-arrow.at-left{background-position:0 0}div.at4-arrow.at-down{background-position:-60px 0}div.at4-arrow.at-up{background-position:-40px 0}.ats-dark div.at4-arrow.at-right{background-position:-20px -20px}.ats-dark div.at4-arrow.at-left{background-position:0 -20px}.ats-dark div.at4-arrow.at-down{background-position:-60px -20px}.ats-dark div.at4-arrow.at-up{background-position:-40px -20}.at4-opacity-hidden{opacity:0!important}.at4-opacity-visible{opacity:1!important}.at4-visually-hidden{position:absolute;clip:rect(1px,1px,1px,1px);padding:0;border:0;overflow:hidden}.at4-hidden-off-screen,.at4-hidden-off-screen *{position:absolute!important;top:-9999px!important;left:-9999px!important}.at4-show{display:block!important;opacity:1!important}.at4-show-content{opacity:1!important;visibility:visible}.at4-hide{display:none!important;opacity:0!important}.at4-hide-content{opacity:0!important;visibility:hidden}.at4-visible{display:block!important;opacity:0!important}.at-wordpress-hide{display:none!important;opacity:0!important}.addthis-animated{animation-fill-mode:both;animation-timing-function:ease-out;animation-duration:.3s}.slideInDown.addthis-animated,.slideInLeft.addthis-animated,.slideInRight.addthis-animated,.slideInUp.addthis-animated,.slideOutDown.addthis-animated,.slideOutLeft.addthis-animated,.slideOutRight.addthis-animated,.slideOutUp.addthis-animated{animation-duration:.4s}@keyframes fadeIn{0%{opacity:0}to{opacity:1}}.fadeIn{animation-name:fadeIn}@keyframes fadeInUp{0%{opacity:0;transform:translateY(20px)}to{opacity:1;transform:translateY(0)}}.fadeInUp{animation-name:fadeInUp}@keyframes fadeInDown{0%{opacity:0;transform:translateY(-20px)}to{opacity:1;transform:translateY(0)}}.fadeInDown{animation-name:fadeInDown}@keyframes fadeInLeft{0%{opacity:0;transform:translateX(-20px)}to{opacity:1;transform:translateX(0)}}.fadeInLeft{animation-name:fadeInLeft}@keyframes fadeInRight{0%{opacity:0;transform:translateX(20px)}to{opacity:1;transform:translateX(0)}}.fadeInRight{animation-name:fadeInRight}@keyframes fadeOut{0%{opacity:1}to{opacity:0}}.fadeOut{animation-name:fadeOut}@keyframes fadeOutUp{0%{opacity:1;transform:translateY(0)}to{opacity:0;transform:translateY(-20px)}}.fadeOutUp{animation-name:fadeOutUp}@keyframes fadeOutDown{0%{opacity:1;transform:translateY(0)}to{opacity:0;transform:translateY(20px)}}.fadeOutDown{animation-name:fadeOutDown}@keyframes fadeOutLeft{0%{opacity:1;transform:translateX(0)}to{opacity:0;transform:translateX(-20px)}}.fadeOutLeft{animation-name:fadeOutLeft}@keyframes fadeOutRight{0%{opacity:1;transform:translateX(0)}to{opacity:0;transform:translateX(20px)}}.fadeOutRight{animation-name:fadeOutRight}@keyframes slideInUp{0%{transform:translateY(1500px)}0%,to{opacity:1}to{transform:translateY(0)}}.slideInUp{animation-name:slideInUp}.slideInUp.addthis-animated{animation-duration:.4s}@keyframes slideInDown{0%{transform:translateY(-850px)}0%,to{opacity:1}to{transform:translateY(0)}}.slideInDown{animation-name:slideInDown}@keyframes slideOutUp{0%{transform:translateY(0)}0%,to{opacity:1}to{transform:translateY(-250px)}}.slideOutUp{animation-name:slideOutUp}@keyframes slideOutUpFast{0%{transform:translateY(0)}0%,to{opacity:1}to{transform:translateY(-1250px)}}#at4m-menu.slideOutUp{animation-name:slideOutUpFast}@keyframes slideOutDown{0%{transform:translateY(0)}0%,to{opacity:1}to{transform:translateY(350px)}}.slideOutDown{animation-name:slideOutDown}@keyframes slideOutDownFast{0%{transform:translateY(0)}0%,to{opacity:1}to{transform:translateY(1250px)}}#at4m-menu.slideOutDown{animation-name:slideOutDownFast}@keyframes slideInLeft{0%{opacity:0;transform:translateX(-850px)}to{transform:translateX(0)}}.slideInLeft{animation-name:slideInLeft}@keyframes slideInRight{0%{opacity:0;transform:translateX(1250px)}to{transform:translateX(0)}}.slideInRight{animation-name:slideInRight}@keyframes slideOutLeft{0%{transform:translateX(0)}to{opacity:0;transform:translateX(-350px)}}.slideOutLeft{animation-name:slideOutLeft}@keyframes slideOutRight{0%{transform:translateX(0)}to{opacity:0;transform:translateX(350px)}}.slideOutRight{animation-name:slideOutRight}.at4win{margin:0 auto;background:#fff;border:1px solid #ebeced;width:25pc;box-shadow:0 0 10px rgba(0,0,0,.3);border-radius:8px;font-family:helvetica neue,helvetica,arial,sans-serif;text-align:left;z-index:9999}.at4win .at4win-header{position:relative;border-bottom:1px solid #f2f2f2;background:#fff;height:49px;-webkit-border-top-left-radius:8px;-webkit-border-top-right-radius:8px;-moz-border-radius-topleft:8px;-moz-border-radius-topright:8px;border-top-left-radius:8px;border-top-right-radius:8px;cursor:default}.at4win .at4win-header .at-h3,.at4win .at4win-header h3{height:49px;line-height:49px;margin:0 50px 0 0;padding:1px 0 0;margin-left:20px;font-family:helvetica neue,helvetica,arial,sans-serif;font-size:1pc;font-weight:700;text-shadow:0 1px #fff;color:#333}.at4win .at4win-header .at-h3 img,.at4win .at4win-header h3 img{display:inline-block;margin-right:4px}.at4win .at4win-header .at4-close{display:block;position:absolute;top:0;right:0;background:url("data:image/gif;base64,R0lGODlhFAAUAIABAAAAAP///yH5BAEAAAEALAAAAAAUABQAAAIzBIKpG+YMm5Enpodw1HlCfnkKOIqU1VXk55goVb2hi7Y0q95lfG70uurNaqLgTviyyUoFADs=") no-repeat center center;background-repeat:no-repeat;background-position:center center;border-left:1px solid #d2d2d1;width:49px;height:49px;line-height:49px;overflow:hidden;text-indent:-9999px;text-shadow:none;cursor:pointer;opacity:.5;border:0;transition:opacity .15s ease-in}.at4win .at4win-header .at4-close::-moz-focus-inner{border:0;padding:0}.at4win .at4win-header .at4-close:hover{opacity:1;background-color:#ebeced;border-top-right-radius:7px}.at4win .at4win-content{position:relative;background:#fff;min-height:220px}#at4win-footer{position:relative;background:#fff;border-top:1px solid #d2d2d1;-webkit-border-bottom-right-radius:8px;-webkit-border-bottom-left-radius:8px;-moz-border-radius-bottomright:8px;-moz-border-radius-bottomleft:8px;border-bottom-right-radius:8px;border-bottom-left-radius:8px;height:11px;line-height:11px;padding:5px 20px;font-size:11px;color:#666;-ms-box-sizing:content-box;-o-box-sizing:content-box;box-sizing:content-box}#at4win-footer a{margin-right:10px;text-decoration:none;color:#666}#at4win-footer a:hover{text-decoration:none;color:#000}#at4win-footer a.at4-logo{top:5px;padding-left:10px}#at4win-footer a.at4-privacy{position:absolute;top:5px;right:10px;padding-right:14px}.at4win.ats-dark{border-color:#555;box-shadow:none}.at4win.ats-dark .at4win-header{background:#1b1b1b;-webkit-border-top-left-radius:6px;-webkit-border-top-right-radius:6px;-moz-border-radius-topleft:6px;-moz-border-radius-topright:6px;border-top-left-radius:6px;border-top-right-radius:6px}.at4win.ats-dark .at4win-header .at4-close{background:url("data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAUCAYAAACNiR0NAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAABx0RVh0U29mdHdhcmUAQWRvYmUgRmlyZXdvcmtzIENTNui8sowAAAAWdEVYdENyZWF0aW9uIFRpbWUAMTEvMTMvMTKswDp5AAAAd0lEQVQ4jb2VQRLAIAgDE///Z3qqY1FAhalHMCsCIkVEAIAkkVgvp2lDBgYAnAyHkWotLccNrEd4A7X2TqIdqLfnWBAdaF5rJdyJfjtPH5GT37CaGhoVq3nOm/XflUuLUto2pY1d+vRKh0Pp+MrAVtDe2JkvYNQ+jVSEEFmOkggAAAAASUVORK5CYII=") no-repeat center center;background-image:url(https://s7.addthis.com/static/fb08f6d50887bd0caacc86a62bcdcf68.svg),none;border-color:#333}.at4win.ats-dark .at4win-header .at4-close:hover{background-color:#000}.at4win.ats-dark .at4win-header .at-h3,.at4win.ats-dark .at4win-header h3{color:#fff;text-shadow:0 1px #000}.at4win.ats-gray .at4win-header{background:#fff;border-color:#d2d2d1;-webkit-border-top-left-radius:6px;-webkit-border-top-right-radius:6px;-moz-border-radius-topleft:6px;-moz-border-radius-topright:6px;border-top-left-radius:6px;border-top-right-radius:6px}.at4win.ats-gray .at4win-header a.at4-close{border-color:#d2d2d1}.at4win.ats-gray .at4win-header a.at4-close:hover{background-color:#ebeced}.at4win.ats-gray #at4win-footer{border-color:#ebeced}.at4win .clear{clear:both}.at4win ::selection{background:#fe6d4c;color:#fff}.at4win ::-moz-selection{background:#fe6d4c;color:#fff}.at4-icon-fw{display:inline-block;background-repeat:no-repeat;background-position:0 0;margin:0 5px 0 0;overflow:hidden;text-indent:-9999em;cursor:pointer;padding:0;border-radius:50%;-moz-border-radius:50%;-webkit-border-radius:50%}.at44-follow-container a.aticon{height:2pc;margin:0 5px 5px 0}.at44-follow-container .at4-icon-fw{margin:0}</style></head>

<body class="" id="articles_controller">
<div class="off-canvas-wrap" data-offcanvas="">
<div class="inner-wrap">
<div class="fixed show-for-large-up">
<div class="row menu-align" id="logo-bar">
<div class="small-12 columns">
<div class="cross-journal-container">
Go to
<a href="http://insight.jci.org/">JCI Insight</a>
</div>
<a href="https://www.jci.org/"><img src="jci-spelled-out-white-on-transparent.png"></a>
</div>
</div>

<div class="row menu-align" id="journal-bar">
<div class="small-12 columns">
<ul class="inline-list">
<li><a href="https://www.jci.org/kiosks/about">About</a></li>
<li><a href="https://www.jci.org/kiosks/editorial-board">Editors</a></li>
<li><a href="https://www.jci.org/kiosks/about/consulting-editors">Consulting Editors</a></li>
<li><a href="https://www.jci.org/kiosks/authors">For authors</a></li>
<li><a href="https://www.jci.org/kiosks/connect">Alerts</a></li>
<li><a href="https://www.jci.org/kiosks/advertise">Advertising/recruitment</a></li>
<li><a href="https://www.jci.org/kiosks/subscriptions">Subscribe</a></li>
<li><a href="https://www.jci.org/kiosks/contact">Contact</a></li>

</ul>
</div>
</div>

<div id="content-bar">
<nav class="top-bar" data-topbar="">

<section class="top-bar-section">
<ul class="left">
<li class="not-click">
<a id="topmenu_current_issue" href="https://www.jci.org/current">Current Issue</a>
</li>
<li class="not-click">
<a href="https://www.jci.org/archive">Past Issues</a>
</li>
<li class="has-dropdown not-click">
<a>By specialty</a>
<ul class="dropdown"><li class="title back js-generated"><h5><a href="javascript:void(0)">Back</a></h5></li>
<li><a href="https://www.jci.org/tags/15">Cardiology</a></li>
<li><a href="https://www.jci.org/tags/21">Gastroenterology</a></li>
<li><a href="https://www.jci.org/tags/25">Immunology</a></li>
<li><a href="https://www.jci.org/tags/28">Metabolism</a></li>
<li><a href="https://www.jci.org/tags/31">Nephrology</a></li>
<li><a href="https://www.jci.org/tags/32">Neuroscience</a></li>
<li><a href="https://www.jci.org/tags/33">Oncology</a></li>
<li><a href="https://www.jci.org/tags/36">Pulmonology</a></li>
<li><a href="https://www.jci.org/tags/42">Vascular biology</a></li>
<li><a href="https://www.jci.org/specialties">All...</a></li>
</ul>
</li>
<li class="has-dropdown not-click">
<a href="https://www.jci.org/videos">Videos</a>
<ul class="dropdown"><li class="title back js-generated"><h5><a href="javascript:void(0)">Back</a></h5></li><li class="parent-link hide-for-medium-up"><a class="parent-link js-generated" href="https://www.jci.org/videos">Videos</a></li>
<li><a href="https://www.jci.org/videos/cgms">Conversations with Giants in Medicine</a></li>
<li><a href="https://www.jci.org/videos/authors_takes">Author's Takes</a></li>
</ul>
</li>
<li class="has-dropdown not-click">
<a href="https://www.jci.org/tags/reviews">Reviews</a>
<ul class="dropdown"><li class="title back js-generated"><h5><a href="javascript:void(0)">Back</a></h5></li><li class="parent-link hide-for-medium-up"><a class="parent-link js-generated" href="https://www.jci.org/tags/reviews">Reviews</a></li>
<li>
<label>Reviews</label>
</li>
<li><a href="https://www.jci.org/tags/reviews">View all reviews...</a></li>
<li class="divider"></li>
<li>
<label>Review Series</label>
</li>
<li><a href="https://www.jci.org/review_series/109">Immunotherapy in Hematological Cancers (Upcoming)</a></li>
<li><a href="https://www.jci.org/review_series/108">Big Data's Future in Medicine (Feb 2020)</a></li>
<li><a href="https://www.jci.org/review_series/107">Mechanisms Underlying the Metabolic Syndrome (Oct 2019)</a></li>
<li><a href="https://www.jci.org/review_series/106">Reparative Immunology (Jul 2019)</a></li>
<li><a href="https://www.jci.org/review_series/105">Allergy (Apr 2019)</a></li>
<li><a href="https://www.jci.org/review_series/104">Biology of familial cancer predisposition syndromes (Feb 2019)</a></li>
<li><a href="https://www.jci.org/review_series/103">Mitochondrial dysfunction in disease (Aug 2018)</a></li>
<li>
<a href="https://www.jci.org/review_series">View all review series...</a>
</li>
</ul>
</li>
<li class="has-dropdown not-click">
<a>Collections</a>
<ul class="dropdown"><li class="title back js-generated"><h5><a href="javascript:void(0)">Back</a></h5></li>
<li><a href="https://www.jci.org/recently-published">Recently published</a></li>
<li><a href="https://www.jci.org/in-press-preview">In-Press Preview</a></li>
<li><a href="https://www.jci.org/tags/44">Commentaries</a></li>
<li><a href="https://www.jci.org/tags/concise_communications">Concise Communication</a></li>
<li><a href="https://www.jci.org/tags/56">Editorials</a></li>
<li><a href="https://www.jci.org/tags/111">Viewpoint</a></li>
<li><a href="https://www.jci.org/top_articles">Top read articles</a></li>

</ul>
</li>
<li><a href="https://www.jci.org/tags/3">Clinical Medicine</a></li>
<li class="has-dropdown not-click">
<a href="https://www.jci.org/this-month">JCI This Month</a>
<ul class="dropdown"><li class="title back js-generated"><h5><a href="javascript:void(0)">Back</a></h5></li><li class="parent-link hide-for-medium-up"><a class="parent-link js-generated" href="https://www.jci.org/this-month">JCI This Month</a></li>
<li><a href="https://www.jci.org/this-month/current">Current issue</a></li>
<li><a href="https://www.jci.org/this-month">Past issues</a></li>
</ul>
</li>
</ul>
<ul class="right">
<li class="has-form">
<div id="search-area">
<form action="/search/results" accept-charset="UTF-8" method="get"><input name="utf8" value="✓" type="hidden">
<input name="q" id="q" placeholder="Search the JCI" type="text">
<input src="search-black-867f68b5b717d00fb9c106b8c637cfd33ea8ee8b2ff37a9.png" value="" type="image">
</form>

</div>
</li>
</ul>
</section></nav>
</div>

</div>
<!--[if gt IE 8]><!--><nav class="tab-bar hide-for-large-up fixed" id="small-navbar">
<section class="left-small">
<a class="left-off-canvas-toggle menu-icon">
<span></span>
</a>
</section>
<section class="middle tab-bar-section">
<h1 class="title"><a href="https://www.jci.org/"><img src="jci-only-white-8a7e75c924e8f4e2d61f98952aa688ca36f76c9e55ac7.png" width="40"></a></h1>
</section>
</nav>
<aside class="left-off-canvas-menu">
<ul class="off-canvas-list">
<li>
<label>The Journal of Clinical Investigation</label>
</li>
<li><form action="/search/results" accept-charset="UTF-8" method="get"><input name="utf8" value="✓" type="hidden">
<div class="row collapse" id="search-div-offcanvas">
<div class="small-8 columns">
<input name="q" placeholder="Search the JCI" type="text">
</div>
<div class="small-4 columns">
<input src="search-white-cc4a29c31d1a1a75e19da4c773d8175e78de1ac330be7aa.png" id="search-icon-offcanvas" type="image">
</div>
</div>
</form>

</li>
<li><a id="offcanvas_current_issue" href="https://www.jci.org/current">Current issue</a></li>
<li><a href="https://www.jci.org/archive">Past issues</a></li>
<li><a href="https://www.jci.org/specialties">Specialties</a></li>
<li><a href="https://www.jci.org/tags/reviews">Reviews</a></li>
<li><a href="https://www.jci.org/review_series">Review series</a></li>
<li>
<label>Videos</label>
</li>
<li><a href="https://www.jci.org/videos/cgms">Conversations with Giants in Medicine</a></li>
<li><a href="https://www.jci.org/videos/authors_takes">Author's Takes</a></li>
<li>
<label>Collections</label>
</li>
<li><a href="https://www.jci.org/recently-published">Recently published</a></li>
<li><a href="https://www.jci.org/in-press-preview">In-Press Preview</a></li>
<li><a href="https://www.jci.org/tags/44">Commentaries</a></li>
<li><a href="https://www.jci.org/tags/concise_communications">Concise Communication</a></li>
<li><a href="https://www.jci.org/tags/56">Editorials</a></li>
<li><a href="https://www.jci.org/tags/111">Viewpoint</a></li>
<li><a href="https://www.jci.org/top_articles">Top read articles</a></li>

<li>
<label>Journal Details</label>
</li>
<li><a href="https://www.jci.org/kiosks/about">About</a></li>
<li><a href="https://www.jci.org/kiosks/editorial-board">Editors</a></li>
<li><a href="https://www.jci.org/kiosks/about/consulting-editors">Consulting Editors</a></li>
<li><a href="https://www.jci.org/kiosks/authors">For authors</a></li>
<li><a href="https://www.jci.org/kiosks/connect">Alerts</a></li>
<li><a href="https://www.jci.org/kiosks/advertise">Advertising/recruitment</a></li>
<li><a href="https://www.jci.org/kiosks/subscriptions">Subscribe</a></li>
<li><a href="https://www.jci.org/kiosks/contact">Contact</a></li>

</ul>
</aside>
<a class="exit-off-canvas"></a><!--<![endif]-->

	<!-- Provides top level banner in small view -->
<nav class="fixed hide-for-large-up" id="article-tools-nav">
<a class="article-menu-button" href="#top" id="top-button" title="Go to top">
<i class="fi-arrow-up"></i>
Top
</a>
<button aria-controls="tools-menu" aria-expanded="false" class="article-menu-button" data-dropdown="tools-menu" href="#">
<i class="fi-list"></i>
<span>Tools</span>
</button>
<div class="f-dropdown medium content" data-dropdown-content="" id="tools-menu">
<ul class="side-nav" id="article-tools">
<li class="hide-for-small">
<a href="https://www.jci.org/articles/view/44423/pdf">View PDF <img class="article-tools-icon" src="adobe_pdf_file_icon.png"></a>
</li>
<li><a href="https://www.jci.org/articles/view/44423/cite">Download citation information</a></li>
<li><a href="https://www.jci.org/eletters/submit/44423">Send a letter</a></li>
<li><a href="http://www.addthis.com/bookmark.php?v=250&amp;pubid=ra-4d8389db4b0bb592">Share this article</a></li>
<li><a href="https://www.jci.org/kiosks/terms">Terms of use</a></li>
<li><a href="https://www.jci.org/kiosks/publish/abbreviations">Standard abbreviations</a></li>
<li><a href="https://www.jci.org/feedback?reference=44423">Need Help? E-mail the JCI</a></li>
<script>
var addthis_share = {
	email_template: 'jci_share_article',
	email_vars: {
		short_title: '#&lt;#&lt;Class:0x00000000070796b0&gt;:0x00007fade57672b8&gt;',
		author_list: 'Peter D. Crompton, Susan K. Pierce, Louis H. Miller',
	}
}
</script>
<div class="addthis_sharing_toolbox" data-title="JCI - Advances and challenges in malaria vaccine development" style="clear: both;" data-url="https://www.jci.org/articles/view/44423"><div id="atstbx" class="at-share-tbx-element addthis-smartlayers at4-hide" aria-labelledby="at-aad3694c-ce84-4c1d-a6e5-83ceb9597126" role="region"><span id="at-aad3694c-ce84-4c1d-a6e5-83ceb9597126" class="at4-visually-hidden">AddThis Sharing Buttons</span><div class="at-share-btn-elements"><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-facebook" style="background-color: rgb(59, 89, 152); border-radius: 2%;"><span class="at4-visually-hidden">Share to Facebook</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-facebook-1" class="at-icon at-icon-facebook" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-facebook-1">Facebook</title><g><path d="M22 5.16c-.406-.054-1.806-.16-3.43-.16-3.4 0-5.733 1.825-5.733 5.17v2.882H9v3.913h3.837V27h4.604V16.965h3.823l.587-3.913h-4.41v-2.5c0-1.123.347-1.903 2.198-1.903H22V5.16z" fill-rule="evenodd"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-twitter" style="background-color: rgb(29, 161, 242); border-radius: 2%;"><span class="at4-visually-hidden">Share to Twitter</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-twitter-2" class="at-icon at-icon-twitter" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-twitter-2">Twitter</title><g><path d="M27.996 10.116c-.81.36-1.68.602-2.592.71a4.526 4.526 0 0 0 1.984-2.496 9.037 9.037 0 0 1-2.866 1.095 4.513 4.513 0 0 0-7.69 4.116 12.81 12.81 0 0 1-9.3-4.715 4.49 4.49 0 0 0-.612 2.27 4.51 4.51 0 0 0 2.008 3.755 4.495 4.495 0 0 1-2.044-.564v.057a4.515 4.515 0 0 0 3.62 4.425 4.52 4.52 0 0 1-2.04.077 4.517 4.517 0 0 0 4.217 3.134 9.055 9.055 0 0 1-5.604 1.93A9.18 9.18 0 0 1 6 23.85a12.773 12.773 0 0 0 6.918 2.027c8.3 0 12.84-6.876 12.84-12.84 0-.195-.005-.39-.014-.583a9.172 9.172 0 0 0 2.252-2.336" fill-rule="evenodd"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-print" style="background-color: rgb(115, 138, 141); border-radius: 2%;"><span class="at4-visually-hidden">Share to Print</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-print-3" class="at-icon at-icon-print" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-print-3">Print</title><g><path d="M24.67 10.62h-2.86V7.49H10.82v3.12H7.95c-.5 0-.9.4-.9.9v7.66h3.77v1.31L15 24.66h6.81v-5.44h3.77v-7.7c-.01-.5-.41-.9-.91-.9zM11.88 8.56h8.86v2.06h-8.86V8.56zm10.98 9.18h-1.05v-2.1h-1.06v7.96H16.4c-1.58 0-.82-3.74-.82-3.74s-3.65.89-3.69-.78v-3.43h-1.06v2.06H9.77v-3.58h13.09v3.61zm.75-4.91c-.4 0-.72-.32-.72-.72s.32-.72.72-.72c.4 0 .72.32.72.72s-.32.72-.72.72zm-4.12 2.96h-6.1v1.06h6.1v-1.06zm-6.11 3.15h6.1v-1.06h-6.1v1.06z"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-email" style="background-color: rgb(132, 132, 132); border-radius: 2%;"><span class="at4-visually-hidden">Share to Email</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-email-4" class="at-icon at-icon-email" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-email-4">Email</title><g><g fill-rule="evenodd"></g><path d="M27 22.757c0 1.24-.988 2.243-2.19 2.243H7.19C5.98 25 5 23.994 5 22.757V13.67c0-.556.39-.773.855-.496l8.78 5.238c.782.467 1.95.467 2.73 0l8.78-5.238c.472-.28.855-.063.855.495v9.087z"></path><path d="M27 9.243C27 8.006 26.02 7 24.81 7H7.19C5.988 7 5 8.004 5 9.243v.465c0 .554.385 1.232.857 1.514l9.61 5.733c.267.16.8.16 1.067 0l9.61-5.733c.473-.283.856-.96.856-1.514v-.465z"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-compact" style="background-color: rgb(255, 101, 80); border-radius: 2%;"><span class="at4-visually-hidden">Share to More</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-addthis-5" class="at-icon at-icon-addthis" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-addthis-5">AddThis</title><g><path d="M18 14V8h-4v6H8v4h6v6h4v-6h6v-4h-6z" fill-rule="evenodd"></path></g></svg></span></a></div></div></div>

</ul>

</div>
<button aria-controls="goto-menu" aria-expanded="false" class="article-menu-button" data-dropdown="goto-menu" href="#">
<i class="fi-list"></i>
<span>Go to</span>
</button>
<div class="f-dropdown content" data-dropdown-content="" id="goto-menu">
<ul class="side-nav">
<li><a href="#top">Top</a></li>
<li><a href="#ABS">Abstract</a></li>
<li><a href="#SEC1">Introduction</a></li>
<li><a href="#SEC2">The P. falciparum life cycle and vaccine targets
         </a></li>
<li><a href="#SEC3">Pre-erythrocytic vaccines</a></li>
<li><a href="#SEC4">Asexual blood-stage vaccines</a></li>
<li><a href="#SEC5">Combining pre-erythrocytic and blood-stage vaccines</a></li>
<li><a href="#SEC6">Transmission-blocking vaccines</a></li>
<li><a href="#SEC7">Summary</a></li>
<li><a href="#FN">Footnotes</a></li>
<li><a href="#BIBL">References</a></li>
<li><a href="#version_history">Version history</a></li>
</ul>

</div>
<button class="article-menu-button" data-pdf-url="/articles/view/44423/pdf" id="article-tools-pdf-button">
<span>
<img class="article-tools-icon" src="adobe_pdf_file_icon.png">
PDF
</span>
</button>
<button aria-controls="metrics-menu" aria-expanded="false" class="article-menu-button" data-dropdown="metrics-menu" href="#">
<i class="fi-list"></i>
<span>Metrics</span>
</button>
<div class="f-dropdown medium content" data-dropdown-content="" id="metrics-menu">
<div class="altmetric-embed" data-badge-details="right" data-badge-type="medium-donut" data-doi="10.1172/JCI44423" style="background-color: white;" data-uuid="874ac8d8-d3d0-c744-d3f9-1421c28a709a"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194" style="display:inline-block;">
                <img alt="Article has an altmetric score of 11" src="a" style="border:0; margin:0; max-width: none;" width="120px" height="120px">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_874ac8d8-d3d0-c744-d3f9-1421c28a709a" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container" id="_altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right" id="_altmetric_popover_inner">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=twitter">
          Tweeted by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=patents">
          Referenced in <b>10</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>416</b> readers on Mendeley
          </div>
          <div class="altmetric-embed tip_citeulike" style="padding-left: 10px; line-height:18px; border-left: 16px solid #BCD2EF;">
              <b>1</b> readers on CiteULike
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<ul class="side-nav" id="article-metrics">
<li><a href="https://www.jci.org/articles/view/44423/usage">Article usage</a></li>
<li>
<a href="https://www.jci.org/articles/view/44423/citations">Citations to this article
<span class="article-citation-count">(168)</span>
</a></li>
</ul>

</div>
</nav>



<!--[if (lt IE 9)]>
<div class='alert-box info' data-alert=''>
Please note that the JCI no longer supports your version of Internet Explorer. We recommend upgrading to the latest version of
<a href="http://windows.microsoft.com/en-us/internet-explorer/download-ie">Internet Explorer</a>,
<a href="https://www.google.com/chrome/browser/desktop/index.html">Google Chrome</a>, or
<a href="https://www.mozilla.org/en-US/firefox/new/">Firefox</a>
<a class='close' href='#'>&times;</a>
</div>
<![endif]-->

<div class="row content-wrapper" style="padding-bottom: 140px;">
<div class="small-12 columns">
<div class="menu-align">
<div class="row">
<div class="large-10 medium-9 small-12 columns">



<div class="row">
	<div class="ad-leaderboard-wrapper">
<div class="ad-leaderboard" id="jci-article-interior-leaderboard-top" style="display: none;" data-google-query-id="CIvCir2isegCFZMN4AodQ20AkQ">
<span class="secondary label">
<p>
Advertisement
</p>
</span>
<script>
  try {
    googletag.cmd.push(function() {
      googletag.display('jci-article-interior-leaderboard-top');
    })
  } catch(e){}
</script>
<div id="google_ads_iframe_/82117132/jci-article-interior-leaderboard-top_0__container__" style="border: 0pt none; width: 320px; height: 50px;"></div></div>
</div>

</div>

<div class="row">
	<div class="small-12 large-9 columns">
		<div id="subscriber_label"></div>
		
<p class="tag-list">
<a href="https://www.jci.org/tags/53"><span style="margin-right: 6px" class="label-article-type">Science in Medicine</span></a>
<span class="license">
Free access    |    <a href="https://doi.org/10.1172/JCI44423">10.1172/JCI44423</a>
</span>
</p>

<p>
<b></b>
</p>
<h1 class="article-title">Advances and challenges in malaria vaccine development</h1>


<h4 class="author-list">
	<a class="author-affiliation show-more" href="javascript:void(0);" data-dropdown="author-affiliation-0">
		Peter D. Crompton,<sup>1</sup> 
	</a>
	<a class="author-affiliation show-more" href="javascript:void(0);" data-dropdown="author-affiliation-1">
		Susan K. Pierce,<sup>1</sup> and 
	</a>
	<a class="author-affiliation show-more" href="javascript:void(0);" data-dropdown="author-affiliation-2">
		Louis H. Miller<sup>2</sup>
	</a>
</h4>
	<div class="f-dropdown content large" data-dropdown-content="" id="author-affiliation-0">
		<p></p><p class="affiliations"><sup>1</sup>Laboratory of Immunogenetics and 
<sup>2</sup>Laboratory of Malaria and Vector Research, National 
Institute of Allergy and Infectious Disease (NIAID), NIH, Rockville, 
Maryland, USA.</p><p></p>
			
  <p>Address correspondence to: Louis H. Miller, Laboratory of Malaria 
and Vector Research, NIAID, NIH, 12735 Twinbrook Parkway, Rockville, 
Maryland 20852, USA. Phone: 301.496.2183; Fax: 301.402.2201; E-mail: 
               <a href="mailto:lmiller@niaid.nih.gov">lmiller@niaid.nih.gov</a>.
            </p>


			<p>
				Find articles by
				Crompton, P.
				in:
				<a target="_blank" href="https://www.jci.org/search/results?q=author.first_name%3A%22Peter%20D.%22+author.last_name%3A%22Crompton%22&amp;search_type=advanced">JCI
				</a> |
				<a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=pubmed&amp;term=Crompton+P[au]&amp;dispmax=50">PubMed
				</a> |
				<a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AP+Crompton%22">Google Scholar
				</a> 
			</p>
	</div>
	<div class="f-dropdown content large" data-dropdown-content="" id="author-affiliation-1">
		<p></p><p class="affiliations"><sup>1</sup>Laboratory of Immunogenetics and 
<sup>2</sup>Laboratory of Malaria and Vector Research, National 
Institute of Allergy and Infectious Disease (NIAID), NIH, Rockville, 
Maryland, USA.</p><p></p>
			
  <p>Address correspondence to: Louis H. Miller, Laboratory of Malaria 
and Vector Research, NIAID, NIH, 12735 Twinbrook Parkway, Rockville, 
Maryland 20852, USA. Phone: 301.496.2183; Fax: 301.402.2201; E-mail: 
               <a href="mailto:lmiller@niaid.nih.gov">lmiller@niaid.nih.gov</a>.
            </p>


			<p>
				Find articles by
				Pierce, S.
				in:
				<a target="_blank" href="https://www.jci.org/search/results?q=author.first_name%3A%22Susan%20K.%22+author.last_name%3A%22Pierce%22&amp;search_type=advanced">JCI
				</a> |
				<a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=pubmed&amp;term=Pierce+S[au]&amp;dispmax=50">PubMed
				</a> |
				<a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AS+Pierce%22">Google Scholar
				</a> 
			</p>
	</div>
	<div class="f-dropdown content large" data-dropdown-content="" id="author-affiliation-2">
		<p></p><p class="affiliations"><sup>1</sup>Laboratory of Immunogenetics and 
<sup>2</sup>Laboratory of Malaria and Vector Research, National 
Institute of Allergy and Infectious Disease (NIAID), NIH, Rockville, 
Maryland, USA.</p><p></p>
			
  <p>Address correspondence to: Louis H. Miller, Laboratory of Malaria 
and Vector Research, NIAID, NIH, 12735 Twinbrook Parkway, Rockville, 
Maryland 20852, USA. Phone: 301.496.2183; Fax: 301.402.2201; E-mail: 
               <a href="mailto:lmiller@niaid.nih.gov">lmiller@niaid.nih.gov</a>.
            </p>


			<p>
				Find articles by
				Miller, L.
				in:
				<a target="_blank" href="https://www.jci.org/search/results?q=author.first_name%3A%22Louis%20H.%22+author.last_name%3A%22Miller%22&amp;search_type=advanced">JCI
				</a> |
				<a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=pubmed&amp;term=Miller+L[au]&amp;dispmax=50">PubMed
				</a> |
				<a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AL+Miller%22">Google Scholar
				</a> 
			</p>
	</div>

<p class="publication_date">
First published December 1, 2010
-
<a class="show-more" data-dropdown="full-publication-dropdown" href="javascript:void(0);">
More info
</a>
</p>
<div class="f-dropdown content large" data-dropdown-content="" id="full-publication-dropdown">
<div class="copyright">
Published in
<a href="https://www.jci.org/120/12">Volume 120, Issue 12</a>
on
December 1, 2010
<br>
<i>
J Clin Invest.
</i>
2010;120(12):4168–4178.
<a href="https://doi.org/10.1172/JCI44423">https://doi.org/10.1172/JCI44423</a>.
<br>
©
2010 The American Society for Clinical Investigation
</div>

<div class="publication_date">
First published December 1, 2010
-
<a href="#version_history">Version history</a>
</div>

</div>




			<div class="content_well">
<a class="in-page" name="ABS"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-abstract" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Abstract</span></a><div id="section-abstract" class="content active"><p>Malaria caused by <i>Plasmodium falciparum</i>
 remains a major public health threat, especially among children and 
pregnant women in Africa. An effective malaria vaccine would be a 
valuable tool to reduce the disease burden and could contribute to 
elimination of malaria in some regions of the world. Current malaria 
vaccine candidates are directed against human and mosquito stages of the
 parasite life cycle, but thus far, relatively few proteins have been 
studied for potential vaccine development. The most advanced vaccine 
candidate, RTS,S, conferred partial protection against malaria in phase 
II clinical trials and is currently being evaluated in a phase III trial
 in Africa. New vaccine targets need to be identified to improve the 
chances of developing a highly effective malaria vaccine. A better 
understanding of the mechanisms of naturally acquired immunity to 
malaria may lead to insights for vaccine development.
            </p></div>
</dd></dl>
<a class="in-page" name="SEC1"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-1" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Introduction</span></a><div id="section-1" class="content active">
<p>There are over 500 million cases of malaria annually among the world’s poorest populations (<span class="xref"><a id="#B1-link" href="#B1" onclick="showRefSection();">1</a></span>). Malaria claims the lives of nearly a million children each year in Africa alone (<span class="xref"><span class="gen"></span><a id="#B2-link" href="#B2" onclick="showRefSection();">2</a></span>). The parasite that causes the most deadly form of malaria, <i>Plasmodium falciparum</i>, is spread by the highly prevalent mosquitoes <i>Anopheles gambiae</i> and <i>An. funestus</i>.
 After decades of neglect, funding from the international community to 
fight malaria has increased substantially in recent years (<span class="xref"><a id="#B3-link" href="#B3" onclick="showRefSection();">3</a></span>).
 Increased funding has supported the scale-up of malaria control 
interventions such as the procurement and distribution of 
artemisinin-based combination therapy (ACT), the antimalarial drug class
 of choice, and insecticide-treated bed nets (ITNs), as well as other 
mosquito vector control strategies (<span class="xref"><span class="gen"></span><a id="#B3-link" href="#B3" onclick="showRefSection();">3</a></span>).
 In certain areas of Africa, these interventions have been linked 
temporally to recent declines in the incidence of malaria of more than 
50% (<span class="xref"><span class="gen"></span><a id="#B4-link" href="#B4" onclick="showRefSection();">4</a></span>);
 however, the incidence of malaria in other areas of Africa and other 
regions of the world, such as Amazonia, is static or increasing (<span class="xref"><span class="gen"></span><a id="#B4-link" href="#B4" onclick="showRefSection();">4</a></span>, <span class="xref"><span class="gen"></span><a id="#B5-link" href="#B5" onclick="showRefSection();">5</a></span>).
 Unfortunately, the widespread implementation of ACTs and ITNs is 
hampered by the poor health care infrastructure of many malaria-endemic 
countries. Moreover, <i>P. falciparum</i> has proven adept at acquiring 
and rapidly spreading resistance to antimalarial drugs, and even now 
resistance may have been acquired in Asia to the artemisinin derivatives
 (<span class="xref"><a id="#B6-link" href="#B6" onclick="showRefSection();">6</a></span>). Vector control is also threatened by the inevitability of the emergence of insecticide-resistant mosquitoes (<span class="xref"><span class="gen"></span><a id="#B7-link" href="#B7" onclick="showRefSection();">7</a></span>).
 There is no question that a key tool for the control, elimination, or 
even possible eradication of malaria, in addition to antimalarial drugs 
and vector control, is an effective vaccine.
         </p>
<p>Thus far, we have no malaria vaccine, and it is not clear that a 
highly effective vaccine is in the pipeline. This may be due in part to a
 relative scarcity of research funding; in recent years global funding 
for malaria vaccine development has barely reached 25% of the 
approximately $684 million invested in the development of a 
still-elusive HIV/AIDS vaccine (<span class="xref"><a id="#B8-link" href="#B8" onclick="showRefSection();">8</a></span>). In addition, malaria vaccine development is hindered by the sheer complexity of the parasite and its life cycle (<span class="xref"><span class="gen"></span><a id="#B9-link" href="#B9" onclick="showRefSection();">9</a></span>, <span class="xref"><span class="gen"></span><a id="#B10-link" href="#B10" onclick="showRefSection();">10</a></span>), extensive antigenic variation (<span class="xref"><span class="gen"></span><a id="#B11-link" href="#B11" onclick="showRefSection();">11</a></span>), and a poor understanding of the interaction between <i>P. falciparum</i> and the human immune system (<span class="xref"><a id="#B12-link" href="#B12" onclick="showRefSection();">12</a></span>).
         </p>
<p>The bright spot in terms of vaccine development is that <i>P. falciparum</i> infection induces something that HIV does not: clinical immunity. In areas of intense <i>P. falciparum</i>
 transmission, where individuals are infected by hundreds of mosquito 
bites each year, immunity to severe, life-threatening disease is usually
 acquired early in childhood, whereas immunity to mild disease is not 
typically acquired until late adolescence (<span class="xref"><a id="#B13-link" href="#B13" onclick="showRefSection();">13</a></span>, <span class="xref"><span class="gen"></span><a id="#B14-link" href="#B14" onclick="showRefSection();">14</a></span>). Data from transmigrant studies suggest that adults may acquire immunity more rapidly than children (<span class="xref"><span class="gen"></span><a id="#B15-link" href="#B15" onclick="showRefSection();">15</a></span>, <span class="xref"><span class="gen"></span><a id="#B16-link" href="#B16" onclick="showRefSection();">16</a></span>); however, even in adults who have had decades of <i>P. falciparum</i> exposure, sterile immunity to blood-stage infection rarely develops, and an occasional episode of fever can occur (<span class="xref"><a id="#B13-link" href="#B13" onclick="showRefSection();">13</a></span>). Thus, the immunity ultimately acquired by adults confers protection against the disease caused by the blood stages of <i>P. falciparum</i>, and not protection from infection per se. The hope is that knowledge of the immune mechanisms and their <i>P. falciparum</i>
 targets that ultimately provide protection from disease in adults can 
be used to develop a vaccine that would induce in a child a facsimile of
 adult immunity. Alternatively, by understanding the clinically silent 
stages that precede the blood-stage infection (i.e., sporozoite and 
hepatocyte stages), it might be possible to evoke, by vaccination, 
protective immune responses that do not normally develop in natural 
infection, namely, responses that prevent the blood-stage infection from
 occurring at all. Both broad approaches to vaccine development are 
being taken, but given the enormous complexity of <i>P. falciparum</i> infections, the effort is relatively small, targeting less than 0.5% of the thousands of potential <i>P. falciparum</i> antigens (refs. <span class="xref"><a id="#B9-link" href="#B9" onclick="showRefSection();">9</a></span>, <span class="xref"><span class="gen"></span><a id="#B10-link" href="#B10" onclick="showRefSection();">10</a></span>, and Tables <a href="#T1">1</a>, <a href="#T2">2</a>, and <a href="#T3">3</a>). Compounding the difficulty of the vaccine effort are the large gaps in our understanding of <i>P. falciparum</i> infection biology — how <i>P. falciparum</i>
 invades its target cells and causes disease. These gaps can be closed, 
but only with adequate research support and the recruitment of experts 
in all facets of <i>P. falciparum</i> immunology and biology. With 
increased funding, vaccinologists can broaden their scope of 
exploration, increasing the probability of success.
         </p>
<a class="in-page" name="T1" id="T1-target"></a><div class="figure">
<a href="https://www.jci.org/articles/view/44423/table/1"><img class="table_thumbnail" src="JCI44423_004.gif" align="left"></a><a class="figure_number" href="https://www.jci.org/articles/view/44423/table/1">Table 1
</a><p>Sporozoite and liver-stage malaria vaccines in clinical development</p>
</div>
<a class="in-page" name="T2" id="T2-target"></a><div class="figure">
<a href="https://www.jci.org/articles/view/44423/table/2"><img class="table_thumbnail" src="JCI44423.gif" align="left"></a><a class="figure_number" href="https://www.jci.org/articles/view/44423/table/2">Table 2
</a><p>Blood-stage malaria vaccines in clinical development</p>
</div>
<a class="in-page" name="T3" id="T3-target"></a><div class="figure">
<a href="https://www.jci.org/articles/view/44423/table/3"><img class="table_thumbnail" src="JCI44423_002.gif" align="left"></a><a class="figure_number" href="https://www.jci.org/articles/view/44423/table/3">Table 3
</a><p>Transmission-blocking, multistage, and <i>P. vivax</i> vaccines in clinical development
   </p>
</div>
<p>In this review we discuss the stages in the <i>P. falciparum</i> life cycle that are targeted for vaccine development (Figure <a id="#F1-link" href="#F1" onclick="showFigSection(this);">1</a>),
 the progress to date in this effort, and last, the gaps in knowledge 
that, if filled, would have the greatest impact on the development of an
 effective vaccine.
         </p>
<a class="in-page" name="F1" id="F1-target"></a><div class="figure">
<a href="https://www.jci.org/articles/view/44423/figure/1"><img class="figure_thumbnail" src="JCI44423_005.gif" alt="The P. falciparum life cycle." title="The P. falciparum life cycle." align="left"></a><a class="figure_number" href="https://www.jci.org/articles/view/44423/figure/1">Figure 1</a><p><span class="figure_title">The <i>P. falciparum</i> life cycle.
   </span> The <i>P. falciparum</i> life cycle in humans includes the 
pre-erythrocytic stage, which initiates the infection; the asexual blood
 stage, which causes disease; and the gametocyte stage, which infects 
mosquitoes that transmit the parasite. At each of these stages, the 
parasite expresses proteins that are targets of malaria vaccine 
candidates (Tables <a href="#T1">1</a>–<a href="#T3">3</a>). The pre-erythrocytic stage begins when a female <i>Anopheles</i>
 mosquito inoculates sporozoites into the skin or directly into the 
bloodstream. Sporozoites migrate to the liver and infect a small number 
of hepatocytes. A single sporozoite gives rise to tens of thousands of 
asexual parasites called merozoites. Merozoites exit the liver into the 
bloodstream approximately one week later, leaving no residual parasites 
in the liver. The pre-erythrocytic stage does not cause disease, and 
complete immunity to this stage is not induced through natural <i>P. falciparum</i>
 infection. Merozoites entering the bloodstream begin a cycle of 
erythrocyte invasion, replication, erythrocyte rupture, and merozoite 
release that repeats approximately every 48 hours. Symptoms of malaria 
only occur during the blood stage of infection. Immunity that protects 
against disease but not infection per se can be acquired by individuals 
who are repeatedly infected in endemic areas. A small percentage of 
blood-stage asexual parasites convert to sexual forms, or gametocytes, 
which can infect mosquitoes. The mosquito stage is a potential target 
for transmission-blocking vaccines, as the parasite in the mosquito 
midgut is present extracellularly and in relatively small numbers. 
Possible immune mechanisms at each stage are indicated.
   </p>
</div>
</div>
</dd></dl>
<a class="in-page" name="SEC2"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-2" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">The <i>P. falciparum</i> life cycle and vaccine targets
         </span></a><div id="section-2" class="content active">
<p>The <i>P. falciparum</i> life cycle in humans includes the 
pre-erythrocytic stage, which initiates the infection; the asexual 
erythrocytic stage, which causes disease; and the gametocyte stage, 
which infects mosquitoes that transmit the parasite (Figure <a id="#F1-link" href="#F1" onclick="showFigSection(this);">1</a>). The pre-erythrocytic cycle begins when a female <i>Anopheles</i> mosquito inoculates a small number of <i>P. falciparum</i>
 sporozoites into the skin or directly into the bloodstream. Sporozoites
 travel to the liver and infect a small number of hepatocytes. A single 
sporozoite gives rise to tens of thousands of asexual parasites called 
merozoites (<span class="xref"><a id="#B17-link" href="#B17" onclick="showRefSection();">17</a></span>).
 Merozoites are released into the bloodstream around one week after the 
initial liver infection, when infected hepatocytes burst, leaving no 
residual parasites in the liver. The pre-erythrocytic stage does not 
cause clinical disease (<span class="xref"><span class="gen"></span><a id="#B18-link" href="#B18" onclick="showRefSection();">18</a></span>),
 and there is no convincing evidence for naturally acquired protective 
immunity to this stage in individuals living in malaria-endemic areas (<span class="xref"><span class="gen"></span><a id="#B13-link" href="#B13" onclick="showRefSection();">13</a></span>).
 Thus, this stage would appear to be an unattractive vaccine target. 
Nonetheless, as will be detailed below, the most advanced vaccine in 
development is a protein expressed at this stage that covers the 
parasite surface, the circumsporozoite (CS) protein (<span class="xref"><span class="gen"></span><a id="#B19-link" href="#B19" onclick="showRefSection();">19</a></span>).
         </p>
<p>Each merozoite exiting the liver into the bloodstream can invade an 
erythrocyte and multiply up to 20-fold every two days in cycles of 
erythrocyte invasion, replication, erythrocyte rupture, and release of 
infectious merozoites. In a nonimmune person, this results in as many as
 10<sup>8</sup> asexual blood-stage parasites per milliliter of blood in
 a matter of a week, and symptoms can occur as early as three days after
 the blood-stage infection begins (<span class="xref"><a id="#B18-link" href="#B18" onclick="showRefSection();">18</a></span>, <span class="xref"><span class="gen"></span><a id="#B20-link" href="#B20" onclick="showRefSection();">20</a></span>).
 The rapid increase in parasites that the host suddenly experiences 
suggests that clinically immune individuals control the rapidly 
progressive blood-stage infection by high levels of preexisting 
antibodies (<span class="xref"><span class="gen"></span><a id="#B21-link" href="#B21" onclick="showRefSection();">21</a></span>) or possibly effector CD4<sup>+</sup> T cells (<span class="xref"><a id="#B22-link" href="#B22" onclick="showRefSection();">22</a></span>, <span class="xref"><span class="gen"></span><a id="#B23-link" href="#B23" onclick="showRefSection();">23</a></span>), since there may not be time for memory B or T cells to differentiate into effector cells before the onset of symptoms (<span class="xref"><span class="gen"></span><a id="#B24-link" href="#B24" onclick="showRefSection();">24</a></span>).
 It appears that adults in endemic areas do maintain levels of 
circulating antibodies sufficient to control the blood-stage disease, as
 shown by the ability to rapidly resolve fevers and reduce parasite 
levels to below detection via the transferral of IgG from 
malaria-experienced adults to children with fevers and high parasitemias
 (<span class="xref"><span class="gen"></span><a id="#B25-link" href="#B25" onclick="showRefSection();">25</a></span>).
         </p>
<p>A small percentage of blood-stage asexual parasites convert to sexual forms, or gametocytes, by poorly understood mechanisms (<span class="xref"><a id="#B26-link" href="#B26" onclick="showRefSection();">26</a></span>), and these forms are able to infect female <i>Anopheles</i> mosquitoes. The <i>P. falciparum</i>
 male and female gametes undergo fertilization in the mosquito midgut, 
the only time in the life cycle when the parasites are diploid. 
Approximately 24 hours later, a small number of parasites (ookinetes) 
invade the midgut epithelial cells and travel through the cells to the 
hemolymph, where they replicate and form an oocyst containing thousands 
of sporozoites. This is the only stage in the life cycle in which the 
parasite replicates extracellularly. After the oocyst ruptures, 
sporozoites invade salivary glands and migrate to the salivary duct, 
from which they are injected into humans by blood-feeding mosquitoes, 
initiating a new human infection. The mosquito stage is an attractive 
target for a transmission-blocking vaccine, as the parasite in the 
mosquito midgut is present extracellularly and in very small numbers. 
Thus, one vaccine strategy is to immunize humans with mosquito-stage <i>P. falciparum</i> proteins, eliciting antibodies that would be taken up with the blood meal and disrupt <i>P. falciparum</i> development in the mosquito midgut (<span class="xref"><a id="#B27-link" href="#B27" onclick="showRefSection();">27</a></span>).
         </p>
</div>
</dd></dl>
<a class="in-page" name="SEC3"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-3" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Pre-erythrocytic vaccines</span></a><div id="section-3" class="content active">
<p>As described above, complete immunity to the pre-erythrocytic stage 
does not appear to be acquired naturally in endemic areas, as clinically
 immune adults are commonly infected with blood-stage parasites (<span class="xref"><a id="#B13-link" href="#B13" onclick="showRefSection();">13</a></span>).
 However, experimental data suggest that it might be possible to induce 
immunity to the pre-erythrocytic stage. Roestenberg et al. (<span class="xref"><span class="gen"></span><a id="#B28-link" href="#B28" onclick="showRefSection();">28</a></span>) inoculated volunteers with sporozoites by the bites of <i>P. falciparum</i>–infected
 mosquitoes three times at 28-day intervals. During this period 
volunteers received chloroquine prophylaxis, which only has activity 
against blood-stage parasites, resulting in transient blood-stage 
infections. After 28 days without chloroquine, the volunteers were 
inoculated again with sporozoites through exposure to infected 
mosquitoes. Volunteers previously exposed to infected mosquitoes did not
 become infected, as monitored by the appearance of parasites in the 
blood, whereas all volunteers in the control group initially exposed to 
uninfected mosquitoes developed blood-stage infections. Protection was 
associated with a pluripotent effector memory T cell response (<span class="xref"><a id="#B28-link" href="#B28" onclick="showRefSection();">28</a></span>).
 If the observed protection was due to an immune-mediated block of the 
pre-erythrocytic infection, this predicts that live attenuated 
sporozoite-based vaccines targeting the pre-erythrocytic stage might be 
effective. However, the possibility that blood-stage immunity induced by
 the transient blood-stage infection may have contributed to protection 
in this study cannot be ruled out.
         </p>
<p>The idea of a pre-erythrocytic vaccine took shape with the landmark 
observation by Ruth Nussenzweig that vaccination of mice with irradiated
 sporozoites resulted in protection (<span class="xref"><a id="#B29-link" href="#B29" onclick="showRefSection();">29</a></span>) and, further, that protection could be achieved by immunization with the CS protein (CSP) alone (<span class="xref"><span class="gen"></span><a id="#B30-link" href="#B30" onclick="showRefSection();">30</a></span>). Development of human pre-erythrocytic vaccines began with the cloning of the <i>P. falciparum</i> CSP (<span class="xref"><a id="#B31-link" href="#B31" onclick="showRefSection();">31</a></span>)
 and the entry of SmithKline with the Walter Reed Army Institute of 
Research (WRAIR) into vaccine development in 1985. This research led to 
the development of the RTS,S vaccine, which consists of hepatitis B 
surface antigen (HBsAg) particles with 25% of the HBsAg fused to the 
central repeat and thrombospondin domain of the CSP formulated in the 
adjuvant AS01 (<span class="xref"><span class="gen"></span><a id="#B19-link" href="#B19" onclick="showRefSection();">19</a></span>, <span class="xref"><span class="gen"></span><a id="#B32-link" href="#B32" onclick="showRefSection();">32</a></span>) (Figure <a id="#F2-link" href="#F2" onclick="showFigSection(this);">2</a>).
 In a series of phase II clinical trials, 30%–50% of malaria-naive 
adults immunized with RTS,S were protected against challenge by 
mosquitoes infected with the homologous <i>P. falciparum</i> clone (<span class="xref"><a id="#B32-link" href="#B32" onclick="showRefSection();">32</a></span>–<span class="xref"><span class="gen"></span><a id="#B37-link" href="#B37" onclick="showRefSection();">37</a></span>). Protection correlated with CS-specific antibody and CD4<sup>+</sup> T cell responses (<span class="xref"><a id="#B37-link" href="#B37" onclick="showRefSection();">37</a></span>), although reanalysis of the data suggests that the contribution of T cell immunity to protection may be minimal (<span class="xref"><span class="gen"></span><a id="#B38-link" href="#B38" onclick="showRefSection();">38</a></span>). In phase II field trials in the Gambia (<span class="xref"><span class="gen"></span><a id="#B39-link" href="#B39" onclick="showRefSection();">39</a></span>) and Kenya (<span class="xref"><span class="gen"></span><a id="#B40-link" href="#B40" onclick="showRefSection();">40</a></span>),
 RTS,S conferred short-lived protection against malaria infection in 
approximately 35% of adults, although results from the Kenya trial did 
not reach statistical significance. Approximately 30%–50% of children 
and infants immunized with RTS,S in phase II trials conducted in 
Mozambique, Tanzania, and Kenya were protected from clinical malaria (<span class="xref"><span class="gen"></span><a id="#B41-link" href="#B41" onclick="showRefSection();">41</a></span>–<span class="xref"><span class="gen"></span><a id="#B45-link" href="#B45" onclick="showRefSection();">45</a></span>);
 however, protection was generally short-lived. In field trials, 
immunization with RTS,S induced antibodies that correlate with 
protection from <i>P. falciparum</i> infection (<span class="xref"><a id="#B46-link" href="#B46" onclick="showRefSection();">46</a></span>, <span class="xref"><span class="gen"></span><a id="#B47-link" href="#B47" onclick="showRefSection();">47</a></span>) but not clinical disease (<span class="xref"><span class="gen"></span><a id="#B41-link" href="#B41" onclick="showRefSection();">41</a></span>, <span class="xref"><span class="gen"></span><a id="#B45-link" href="#B45" onclick="showRefSection();">45</a></span>, <span class="xref"><span class="gen"></span><a id="#B46-link" href="#B46" onclick="showRefSection();">46</a></span>).
         </p>
<a class="in-page" name="F2" id="F2-target"></a><div class="figure">
<a href="https://www.jci.org/articles/view/44423/figure/2"><img class="figure_thumbnail" src="JCI44423_003.gif" alt="Schematic representation of the CSP and the RTS,S vaccine." title="Schematic representation of the CSP and the RTS,S vaccine." align="left"></a><a class="figure_number" href="https://www.jci.org/articles/view/44423/figure/2">Figure 2</a><p><span class="figure_title">Schematic representation of the CSP and the RTS,S vaccine.</span>
 The CSP is the predominant surface antigen on sporozoites. CSP is 
composed of an N-terminal region that binds heparin sulfate 
proteoglycans (RI), a central region containing a four-amino-acid (NANP)
 repeat, and a GPI-anchored C-terminal region containing a 
thrombospondin-like domain (RII). The region of the CSP included in the 
RTS,S vaccine includes the last 16 NANP repeats and the entire flanking 
C-terminus. HBsAg particles serve as the matrix carrier for RTS,S, 25% 
of which is fused to the CSP segment. The central repeat region contains
 the immunodominant B cell epitope, which induces antibodies that block 
sporozoite infection of liver cells in vitro (<span class="xref"><a id="#B111-link" href="#B111" onclick="showRefSection();">111</a></span>, <span class="xref"><span class="gen"></span><a id="#B112-link" href="#B112" onclick="showRefSection();">112</a></span>). RTS,S immunization induces antibodies to the central repeat region that correlate with protection from <i>P. falciparum</i> infection (<span class="xref"><a id="#B46-link" href="#B46" onclick="showRefSection();">46</a></span>, <span class="xref"><span class="gen"></span><a id="#B47-link" href="#B47" onclick="showRefSection();">47</a></span>) but not clinical disease (<span class="xref"><span class="gen"></span><a id="#B41-link" href="#B41" onclick="showRefSection();">41</a></span>, <span class="xref"><span class="gen"></span><a id="#B45-link" href="#B45" onclick="showRefSection();">45</a></span>, <span class="xref"><span class="gen"></span><a id="#B46-link" href="#B46" onclick="showRefSection();">46</a></span>). RTS,S also includes the thrombospondin domain, which binds receptors on liver cells (<span class="xref"><span class="gen"></span><a id="#B113-link" href="#B113" onclick="showRefSection();">113</a></span>).
 Monoclonal antibodies to the thrombospondin domain also block 
sporozoite invasion of liver cells, but to a lesser degree than 
antibodies to the repeat region (<span class="xref"><span class="gen"></span><a id="#B112-link" href="#B112" onclick="showRefSection();">112</a></span>). The CSP contains three known T cell epitopes: a highly variable CD4<sup>+</sup> T cell epitope before the thrombospondin domain (<span class="xref"><a id="#B114-link" href="#B114" onclick="showRefSection();">114</a></span>), a highly variable CD8<sup>+</sup> T cell epitope within the thrombospondin domain (<span class="xref"><a id="#B115-link" href="#B115" onclick="showRefSection();">115</a></span>), and a conserved “universal” CD4<sup>+</sup> T cell epitope at the C-terminus (<span class="xref"><a id="#B116-link" href="#B116" onclick="showRefSection();">116</a></span>). RTS,S induces a moderate CS-specific CD4<sup>+</sup> T cell response that weakly correlates with protection from infection (<span class="xref"><a id="#B37-link" href="#B37" onclick="showRefSection();">37</a></span>, <span class="xref"><span class="gen"></span><a id="#B38-link" href="#B38" onclick="showRefSection();">38</a></span>), but RTS,S does not appear to induce a substantial CS-specific CD8<sup>+</sup> T cell response (<span class="xref"><a id="#B37-link" href="#B37" onclick="showRefSection();">37</a></span>, <span class="xref"><span class="gen"></span><a id="#B117-link" href="#B117" onclick="showRefSection();">117</a></span>, <span class="xref"><span class="gen"></span><a id="#B118-link" href="#B118" onclick="showRefSection();">118</a></span>).
   </p>
</div>
<p>The mechanism by which a vaccine that targets the sporozoite and 
liver stages protects against blood-stage disease remains unclear. It is
 possible that RTS,S induces protection against clinical malaria by 
temporarily reducing the number of merozoites emerging from the liver. 
This may lead to prolonged exposure to subclinical levels of asexual 
blood-stage parasites, which in turn allows boosting of naturally 
acquired blood-stage immunity (<span class="xref"><a id="#B46-link" href="#B46" onclick="showRefSection();">46</a></span>). The RTS,S vaccine entered a phase III clinical trial in 2009 (Table <a href="#T1">1</a>).
 Based on results from phase II trials, RTS,S is likely to provide only 
partial protection. However, barring any unpredictable adverse effects, 
the vaccine could benefit millions of children by reducing the disease 
burden. It is also possible that the vaccine, if widely used, could have
 a greater impact on disease than predicted from the phase II trials in 
unforeseen ways by, for example, decreasing <i>P. falciparum</i> 
transmission. Conversely, disrupting the normal acquisition of malaria 
immunity through natural infection without providing complete protection
 could leave older children at risk of severe disease. Efforts to 
improve the efficacy of CSP-based vaccines with alternative adjuvants (<span class="xref"><a id="#B48-link" href="#B48" onclick="showRefSection();">48</a></span>) or viral vectors (<span class="xref"><span class="gen"></span><a id="#B49-link" href="#B49" onclick="showRefSection();">49</a></span>, <span class="xref"><span class="gen"></span><a id="#B50-link" href="#B50" onclick="showRefSection();">50</a></span>) have been unsuccessful to date; however, several studies are still ongoing (Table <a href="#T1">1</a>). Preclinical research efforts are going toward inducing higher levels of CSP-specific antibody (<span class="xref"><span class="gen"></span><a id="#B51-link" href="#B51" onclick="showRefSection();">51</a></span>).
 In one study the CS repeat peptide conjugated to the mosquito stage 
ookinete surface protein Pfs25 induced high levels of uncommonly 
long-lasting antibodies to both vaccine components in mice (<span class="xref"><span class="gen"></span><a id="#B51-link" href="#B51" onclick="showRefSection();">51</a></span>).
 In principle, this vaccine strategy could confer protection against 
liver infection and block transmission by the mosquito vector.
         </p>
<p>Efforts are also going toward developing vaccines that induce T cell 
immunity to the pre-erythrocytic stage through either irradiated (<span class="xref"><a id="#B52-link" href="#B52" onclick="showRefSection();">52</a></span>) or genetically attenuated (<span class="xref"><span class="gen"></span><a id="#B53-link" href="#B53" onclick="showRefSection();">53</a></span>) sporozoites or through expression of <i>P. falciparum</i> liver-stage proteins in viral vectors (<span class="xref"><a id="#B54-link" href="#B54" onclick="showRefSection();">54</a></span>) (Table <a href="#T1">1</a>).
 The irradiated sporozoite strategy is based on the observation that the
 bites of irradiated infected mosquitoes protected humans from challenge
 with unirradiated infected mosquitoes (<span class="xref"><span class="gen"></span><a id="#B55-link" href="#B55" onclick="showRefSection();">55</a></span>), suggesting that irradiated sporozoites in humans could be an effective vaccine, as they were first shown to be in mice (<span class="xref"><span class="gen"></span><a id="#B29-link" href="#B29" onclick="showRefSection();">29</a></span>). This approach is challenging, as protection required the bites of more than 1,000 infected, irradiated mosquitoes (<span class="xref"><span class="gen"></span><a id="#B56-link" href="#B56" onclick="showRefSection();">56</a></span>).
 However, this difficulty may be overcome, as it is possible to purify 
and cryopreserve irradiated sporozoites from aseptic mosquitoes in the 
quantities necessary for vaccination (<span class="xref"><span class="gen"></span><a id="#B52-link" href="#B52" onclick="showRefSection();">52</a></span>).
 In the first clinical trial, the irradiated, purified, cryopreserved 
sporozoite vaccine was safe and well tolerated, but only modestly 
immunogenic and protected only a few individuals. The next clinical 
trial will attempt to improve efficacy by optimizing the route of 
administration (S.L. Hoffman, personal communication). Studies are also 
in progress to determine whether sporozoites can be attenuated for use 
as vaccines by methods other than irradiation (<span class="xref"><span class="gen"></span><a id="#B53-link" href="#B53" onclick="showRefSection();">53</a></span>, <span class="xref"><span class="gen"></span><a id="#B57-link" href="#B57" onclick="showRefSection();">57</a></span>). Recent studies in a mouse model provided evidence that infection with parasites attenuated by knockout of <i>Plasmodium yoelii</i> genes required for liver-stage development resulted in aborted hepatocyte development and induced CD8<sup>+</sup> T cells that mediated killing of infected hepatocytes through secretion of perforin and IFN-γ (<span class="xref"><a id="#B57-link" href="#B57" onclick="showRefSection();">57</a></span>). A phase II trial to test this strategy in humans is underway (Table <a href="#T1">1</a>).
         </p>
<p>In mouse models of malaria, immunization with irradiated sporozoites induces CD8<sup>+</sup> T cells that kill parasite-infected hepatocytes. The known targets of CD8<sup>+</sup>
 T cell killing, in addition to CSP, include thrombospondin-related 
adhesion protein (TRAP) and liver-stage antigen (LSA). Immunization with
 viral vectors containing TRAP peptides led to partial protection in <i>P. falciparum</i>–naive
 adults from challenge by infected mosquitoes by mechanisms that 
involved the induction of large numbers of TRAP-specific IFN-γ–producing
 T cells (<span class="xref"><a id="#B58-link" href="#B58" onclick="showRefSection();">58</a></span>). However, disappointingly, this vaccine did not induce protection in children in Africa (<span class="xref"><span class="gen"></span><a id="#B59-link" href="#B59" onclick="showRefSection();">59</a></span>).
 For unknown reasons, the level of TRAP-specific IFN-γ–producing T cells
 was considerably lower in vaccinated African children as compared with <i>P. falciparum</i>–naive adults (<span class="xref"><a id="#B58-link" href="#B58" onclick="showRefSection();">58</a></span>, <span class="xref"><span class="gen"></span><a id="#B59-link" href="#B59" onclick="showRefSection();">59</a></span>). Efforts to improve the T cell immunogenicity of TRAP with simian adenovirus vectors are ongoing (<span class="xref"><span class="gen"></span><a id="#B54-link" href="#B54" onclick="showRefSection();">54</a></span>) (Table <a href="#T1">1</a>).
         </p>
</div>
</dd></dl>
<a class="in-page" name="SEC4"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-4" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Asexual blood-stage vaccines</span></a><div id="section-4" class="content active">
<p>The asexual blood stage begins with the release of merozoites into 
the bloodstream from ruptured infected hepatocytes. The blood stage is 
the only stage in the parasite life cycle that causes disease (<span class="xref"><a id="#B18-link" href="#B18" onclick="showRefSection();">18</a></span>). Since immunity to disease develops with repeated <i>P. falciparum</i>
 infections, it may be possible to mimic and accelerate the acquisition 
of naturally acquired immunity by a vaccine. What do we know about the 
mechanism of this immunity? One key component of blood-stage immunity is
 antibodies, as demonstrated by experiments in which the transfer of IgG
 from immune adult Africans to partially immune African (<span class="xref"><a id="#B25-link" href="#B25" onclick="showRefSection();">25</a></span>) or Thai (<span class="xref"><span class="gen"></span><a id="#B60-link" href="#B60" onclick="showRefSection();">60</a></span>)
 children rapidly reduced parasitemia and fever. Thus, it is 
theoretically possible to develop a vaccine that would elicit in 
children the antibodies that protect against disease in adults. At 
present, the specificity of antibodies that confer protection against 
malaria is not fully characterized, and as is the case for many 
infectious diseases, the precise mechanisms of antibody-mediated 
protection are unknown. The transferred IgG from malaria-immune adults 
did not block merozoite invasion of erythrocytes or growth of the 
parasites within erythrocytes in vitro (<span class="xref"><span class="gen"></span><a id="#B61-link" href="#B61" onclick="showRefSection();">61</a></span>),
 although this may not reflect events in vivo. However, the IgGs were 
shown to kill in vitro by antibody-dependent cell-mediated cytotoxicity (<span class="xref"><span class="gen"></span><a id="#B61-link" href="#B61" onclick="showRefSection();">61</a></span>),
 suggesting that inducing antibody responses of IgG1 and IgG3 isotypes 
that interact with activating Fc receptors may be desirable. Antibodies 
may also confer protection against blood-stage infection by blocking the
 binding of infected erythrocytes to endothelial cells (<span class="xref"><span class="gen"></span><a id="#B62-link" href="#B62" onclick="showRefSection();">62</a></span>); promoting the opsonization and destruction of merozoites and infected erythrocytes by phagocytic cells (<span class="xref"><span class="gen"></span><a id="#B63-link" href="#B63" onclick="showRefSection();">63</a></span>–<span class="xref"><span class="gen"></span><a id="#B65-link" href="#B65" onclick="showRefSection();">65</a></span>); and neutralizing <i>P. falciparum</i>–derived proinflammatory molecules such as glycosylphosphatidylinositol (GPI) (<span class="xref"><a id="#B66-link" href="#B66" onclick="showRefSection();">66</a></span>, <span class="xref"><span class="gen"></span><a id="#B67-link" href="#B67" onclick="showRefSection();">67</a></span>).
         </p>
<p>Antibody-independent mechanisms may also play a role in blood-stage 
immunity, although there are far less data from human studies to support
 this possibility. Volunteers repeatedly inoculated with <i>P. falciparum</i>–infected erythrocytes and then cured early in infection with antimalarial drugs were protected from reinfection (<span class="xref"><a id="#B23-link" href="#B23" onclick="showRefSection();">23</a></span>). Although antibodies to <i>P. falciparum</i> were not observed in the protected volunteers, there was a Th1-biased CD4<sup>+</sup> and CD8<sup>+</sup>
 T cell response after exposure to malarial antigens ex vivo. However, 
the interpretation of this result is clouded by the possibility that the
 antimalarial drugs persisted at the time of challenge (<span class="xref"><a id="#B68-link" href="#B68" onclick="showRefSection();">68</a></span>).
         </p>
<p>Thus far, relatively few blood-stage antigens are in clinical development as vaccines (Table <a href="#T2">2</a>). These include apical membrane antigen 1 (AMA1) (<span class="xref"><span class="gen"></span><a id="#B69-link" href="#B69" onclick="showRefSection();">69</a></span>), erythrocyte-binding antigen–175 (EBA-175) (<span class="xref"><span class="gen"></span><a id="#B70-link" href="#B70" onclick="showRefSection();">70</a></span>), glutamate-rich protein (GLURP) (<span class="xref"><span class="gen"></span><a id="#B71-link" href="#B71" onclick="showRefSection();">71</a></span>, <span class="xref"><span class="gen"></span><a id="#B72-link" href="#B72" onclick="showRefSection();">72</a></span>), merozoite surface protein 1 (MSP1) (<span class="xref"><span class="gen"></span><a id="#B73-link" href="#B73" onclick="showRefSection();">73</a></span>), MSP2 (<span class="xref"><span class="gen"></span><a id="#B74-link" href="#B74" onclick="showRefSection();">74</a></span>), MSP3 (<span class="xref"><span class="gen"></span><a id="#B71-link" href="#B71" onclick="showRefSection();">71</a></span>, <span class="xref"><span class="gen"></span><a id="#B75-link" href="#B75" onclick="showRefSection();">75</a></span>–<span class="xref"><span class="gen"></span><a id="#B77-link" href="#B77" onclick="showRefSection();">77</a></span>), and serine-repeat antigen 5 (SERA5) (<span class="xref"><span class="gen"></span><a id="#B78-link" href="#B78" onclick="showRefSection();">78</a></span>),
 all of which are highly expressed on the surface of the merozoite. 
Unfortunately, recent phase II trials of the most advanced blood-stage 
candidates, AMA1 and MSP1, did not demonstrate efficacy in African 
children (<span class="xref"><span class="gen"></span><a id="#B69-link" href="#B69" onclick="showRefSection();">69</a></span>, <span class="xref"><span class="gen"></span><a id="#B73-link" href="#B73" onclick="showRefSection();">73</a></span>). Efforts to enhance the vaccine efficacy of AMA1 and MSP1 with novel adjuvants (<span class="xref"><span class="gen"></span><a id="#B79-link" href="#B79" onclick="showRefSection();">79</a></span>, <span class="xref"><span class="gen"></span><a id="#B80-link" href="#B80" onclick="showRefSection();">80</a></span>), with viral vector prime-boost strategies (<span class="xref"><span class="gen"></span><a id="#B54-link" href="#B54" onclick="showRefSection();">54</a></span>), or by combining AMA1 and MSP1 (<span class="xref"><span class="gen"></span><a id="#B81-link" href="#B81" onclick="showRefSection();">81</a></span>) are ongoing (Table <a href="#T2">2</a>).
 However, extensive parasite genetic diversity due to the selective 
pressure exerted by the human immune response presents a major hurdle 
for blood-stage vaccine development (<span class="xref"><span class="gen"></span><a id="#B82-link" href="#B82" onclick="showRefSection();">82</a></span>, <span class="xref"><span class="gen"></span><a id="#B83-link" href="#B83" onclick="showRefSection();">83</a></span>).
 For example, AMA1 is highly polymorphic, with hundreds of haplotypes 
that affect the ability of antibodies specific for one haplotype to 
block invasion by other haplotypes (<span class="xref"><span class="gen"></span><a id="#B84-link" href="#B84" onclick="showRefSection();">84</a></span>). Unless strategies are developed to overcome such genetic diversity, highly polymorphic <i>P. falciparum</i> antigens such as AMA1 are unlikely to be useful (<span class="xref"><a id="#B82-link" href="#B82" onclick="showRefSection();">82</a></span>, <span class="xref"><span class="gen"></span><a id="#B84-link" href="#B84" onclick="showRefSection();">84</a></span>). Another major challenge, considering that <i>P. falciparum</i> encodes approximately 5,300 genes (<span class="xref"><a id="#B9-link" href="#B9" onclick="showRefSection();">9</a></span>),
 is the identification of new potential blood-stage vaccine candidates. 
One approach that takes advantage of the completion of the <i>P. falciparum</i> genome (<span class="xref"><a id="#B9-link" href="#B9" onclick="showRefSection();">9</a></span>) is the use of high-throughput protein expression systems to construct microarrays of large numbers of <i>P. falciparum</i> proteins (<span class="xref"><a id="#B21-link" href="#B21" onclick="showRefSection();">21</a></span>, <span class="xref"><span class="gen"></span><a id="#B85-link" href="#B85" onclick="showRefSection();">85</a></span>, <span class="xref"><span class="gen"></span><a id="#B86-link" href="#B86" onclick="showRefSection();">86</a></span>). In a recent study, an array containing 1,204 <i>P. falciparum</i> proteins was probed with plasma from <i>P. falciparum</i>–exposed children in Mali to identify antibody profiles associated with naturally acquired malaria immunity (<span class="xref"><a id="#B21-link" href="#B21" onclick="showRefSection();">21</a></span>).
 An inherent drawback to this high-throughput approach is that not all 
proteins on the array will be properly folded and display all possible 
antigenic epitopes. Thus, this approach may serve as a starting point to
 “rule in” but not necessarily “rule out” <i>P. falciparum</i> proteins 
or combinations of proteins that induce protective antibodies. Another 
approach being taken to circumvent concerns related to protein folding 
and complex conformational epitopes is to screen for protective 
antibodies directed against predicted α-helical coiled-coil peptides 
derived from putative <i>P. falciparum</i> blood-stage antigens (<span class="xref"><a id="#B87-link" href="#B87" onclick="showRefSection();">87</a></span>).
 Regardless of the approach, the analogous proteins determined by 
homology and synteny in rodent malaria could be tested for vaccine 
efficacy in preclinical vaccine trials.
         </p>
<p>Another starting point to search for new asexual blood-stage vaccine 
candidates is to focus on the parasite proteins that are required for 
erythrocyte invasion. However, there are a number of hurdles to this 
approach, as <i>P. falciparum</i> uses highly redundant, 
receptor-mediated pathways to invade erythrocytes, presenting an 
ever-moving target to the host immune response (<span class="xref"><a id="#B88-link" href="#B88" onclick="showRefSection();">88</a></span>, <span class="xref"><span class="gen"></span><a id="#B89-link" href="#B89" onclick="showRefSection();">89</a></span>).
 To initiate invasion, the merozoite first attaches to erythrocytes in a
 random orientation and then reorients to attach apically. The parasite 
ligands for initial attachment have yet to be identified and may be good
 targets for invasion-blocking antibodies. Two families of <i>P. falciparum</i>
 proteins have been identified that create the tight junction between 
the apical end of the parasite and the erythrocyte: the Duffy 
binding–like (DBL) and the reticulocytes homology (Rh) ligands. <i>P. falciparum</i> has multiple, functionally redundant members of each family (<span class="xref"><a id="#B88-link" href="#B88" onclick="showRefSection();">88</a></span>, <span class="xref"><span class="gen"></span><a id="#B89-link" href="#B89" onclick="showRefSection();">89</a></span>).
 As a consequence, it is likely that a vaccine that successfully blocks 
erythrocyte invasion would need to target multiple parasite ligands. By 
selecting conditions whereby the <i>P. falciparum</i> ligand under study
 is the only one available for invasion, it may be possible to determine
 whether an antibody will block invasion against multiple <i>P. falciparum</i> clones.
         </p>
<p>Another potential target for blood-stage vaccines is the <i>P. falciparum</i> erythrocyte membrane protein 1 (PfEMP1) family, which is encoded by 60 or more <i>var</i> genes present in each parasite clone, with polymorphism between clones (<span class="xref"><a id="#B11-link" href="#B11" onclick="showRefSection();">11</a></span>).
 The PfEMP1s are expressed on the surface of infected erythrocytes and 
are essential for the sequestration of the parasite in vascular 
endothelium to avoid destruction in the spleen (<span class="xref"><span class="gen"></span><a id="#B90-link" href="#B90" onclick="showRefSection();">90</a></span>).
 As one parasite clone expressing one PfEMP1 is detected by the immune 
system, another parasite clone expressing another PfEMP1 takes over (<span class="xref"><span class="gen"></span><a id="#B91-link" href="#B91" onclick="showRefSection();">91</a></span>, <span class="xref"><span class="gen"></span><a id="#B92-link" href="#B92" onclick="showRefSection();">92</a></span>).
 PfEMP1-mediated sequestration of parasitized erythrocytes in vital 
organs is also thought to be responsible for severe disease such as 
cerebral and placental malaria. Despite the diversity of the PfEMP1, 
there is evidence for conservation in function and in sequences that 
might provide vaccine targets among this protein family. For example, 
only one PfEMP1, VAR2CSA, is thought to mediate parasite sequestration 
in the placenta (<span class="xref"><span class="gen"></span><a id="#B93-link" href="#B93" onclick="showRefSection();">93</a></span>), through binding of placental chondroitin sulfate A (<span class="xref"><span class="gen"></span><a id="#B94-link" href="#B94" onclick="showRefSection();">94</a></span>),
 causing pregnancy-associated malaria that can result in the mother’s 
death and low birth weight or death of the fetus or newborn. Efforts to 
identify antibodies to domains of VAR2CSA that are broadly 
cross-reactive and block sequestration are ongoing (<span class="xref"><span class="gen"></span><a id="#B95-link" href="#B95" onclick="showRefSection();">95</a></span>).
 It is possible that other severe malaria syndromes such as cerebral 
malaria may result from a single, relatively conserved PfEMP1 that 
mediates sequestration of parasitized erythrocytes in the brain, a 
hallmark of cerebral malaria (<span class="xref"><span class="gen"></span><a id="#B96-link" href="#B96" onclick="showRefSection();">96</a></span>).
 To identify such PfEMP1s, convalescent sera from patients who survive 
severe disease can be probed against a protein array of PfEMP1 domains 
to identify antibody reactivity against domains that are associated with
 the various syndromes of severe malaria. In addition, some members of 
the PfEMP1 family, encoded by the so-called Type 3 Ups A <i>var</i> genes, are more structurally conserved than other PfEMP1s (<span class="xref"><a id="#B97-link" href="#B97" onclick="showRefSection();">97</a></span>, <span class="xref"><span class="gen"></span><a id="#B98-link" href="#B98" onclick="showRefSection();">98</a></span>), although their function remains unknown. Understanding the function of PfEMP1s encoded by group A <i>var</i> genes could indicate their potential as vaccine candidates.
         </p>
</div>
</dd></dl>
<a class="in-page" name="SEC5"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-5" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Combining pre-erythrocytic and blood-stage vaccines</span></a><div id="section-5" class="content active"><p>According
 to the WHO’s guidelines, the efficacy of malaria vaccines in field 
trials is assessed as the time to first clinical malaria episode (<span class="xref"><a id="#B99-link" href="#B99" onclick="showRefSection();">99</a></span>).
 By this criterion, the RTS,S vaccine is showing 30%–50% efficacy, as 
described above. However, an important unanswered question remains: How 
does partial pre-erythrocytic immunity influence the time to onset of 
clinical malaria, which occurs during the erythrocytic stage? As 
commented on above, one possibility is that a partially effective 
pre-erythrocytic vaccine reduces the number of infected hepatocytes, 
thus decreasing the number of merozoites released into the bloodstream, 
and allowing more time for blood-stage immunity to develop before the 
fever threshold is reached. If so, combining <i>P. falciparum</i> 
antigens that target the pre-erythrocytic and blood stages may further 
decrease the probability of reaching the disease threshold. This 
possibility provides the rationale for several multistage vaccine 
candidates that are currently under evaluation in clinical trials (Table
 <a href="#T3">3</a>).
         </p></div>
</dd></dl>
<a class="in-page" name="SEC6"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-6" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Transmission-blocking vaccines</span></a><div id="section-6" class="content active">
<p>Transmission-blocking vaccines would target antigens on gametes, 
zygotes or ookinites, and the antibodies ingested as part of the blood 
meal would prevent parasite development in the mosquito midgut (<span class="xref"><a id="#B27-link" href="#B27" onclick="showRefSection();">27</a></span>). These vaccines could be important tools for malaria elimination and could protect against epidemics if <i>P. falciparum</i>
 parasites are reintroduced after a period of elimination. The 
feasibility of this approach is supported by the observation of 
transmission-blocking antibodies in individuals living in endemic areas (<span class="xref"><a id="#B100-link" href="#B100" onclick="showRefSection();">100</a></span>, <span class="xref"><span class="gen"></span><a id="#B101-link" href="#B101" onclick="showRefSection();">101</a></span>).
 However, the vaccine would need to be used in the entire population to 
block transmission. The vaccine would confer no protection to the 
vaccinated individual unless combined with an effective pre-erythrocytic
 (<span class="xref"><span class="gen"></span><a id="#B51-link" href="#B51" onclick="showRefSection();">51</a></span>) or erythrocytic vaccine. Transmission-blocking vaccines are not predicted to be effective in areas of intense <i>P. falciparum</i> transmission unless other measures to reduce transmission such as ITNs and insecticide spraying are employed (<span class="xref"><a id="#B27-link" href="#B27" onclick="showRefSection();">27</a></span>).
         </p>
<p><i>P. falciparum</i> proteins expressed only in the mosquito, such as
 Pfs25, are not polymorphic, as they are under no adaptive immune 
pressure in the human host (<span class="xref"><a id="#B102-link" href="#B102" onclick="showRefSection();">102</a></span>).
 Gamete proteins such as Pfs48/45 and Pfs230 that are expressed in the 
human host are more polymorphic, but still have conserved domains 
present in all parasite clones studied to date. These two proteins have a
 six-cysteine structure unique to <i>Plasmodium</i> that presented a problem for recombinant protein production, which has now been solved (<span class="xref"><a id="#B103-link" href="#B103" onclick="showRefSection();">103</a></span>). Pfs230 has the additional advantage of being the target of antibody-dependent complement lysis (<span class="xref"><span class="gen"></span><a id="#B104-link" href="#B104" onclick="showRefSection();">104</a></span>). In a mouse model, antibodies to HAP2, a <i>Plasmodium</i> protein thought to be involved in the fusion of male and female gametes in the mosquito midgut (<span class="xref"><a id="#B105-link" href="#B105" onclick="showRefSection();">105</a></span>), also have transmission-blocking activity in vivo and in vitro (<span class="xref"><span class="gen"></span><a id="#B106-link" href="#B106" onclick="showRefSection();">106</a></span>).
         </p>
<p>Although the approach seems reasonable, transmission-blocking 
vaccines may be difficult to develop and implement. First, current 
evidence suggests that the levels of antibody in blood that would be 
required to significantly affect mosquito development may need to be 
extremely high (<span class="xref"><a id="#B107-link" href="#B107" onclick="showRefSection();">107</a></span>). Conjugation of Pfs25 to a carrier such as outer membrane protein complex (OMPC) of <i>Neisseria meningitides</i>
 serogroup B may overcome this problem, as the conjugate induces 
high-titer antibody in rhesus monkeys that persists for at least two 
years (<span class="xref"><a id="#B108-link" href="#B108" onclick="showRefSection();">108</a></span>).
 Second, it may be difficult to widely implement a vaccine that has no 
direct benefit to the individual receiving the vaccine but only to the 
vaccinated community. The combination of a pre-erythrocytic vaccine to 
prevent infection, such as the repeat region of the CSP, with a 
transmission-blocking vaccine, such as Pfs25 (<span class="xref"><span class="gen"></span><a id="#B51-link" href="#B51" onclick="showRefSection();">51</a></span>),
 may be an ideal vaccine strategy because, if effective, it would reduce
 transmission and provide some protection to vaccinated individuals. 
Despite the theoretical problems cited above, preclinical and clinical 
development of transmission-blocking vaccines is underway (Table <a href="#T3">3</a>) because of its promise for malaria elimination.
         </p>
<p>Although less virulent than <i>P. falciparum</i>, the capacity of <i>Plasmodium vivax</i>
 to cause severe, life-threatening disease is increasingly recognized, 
and its global burden has been historically underestimated (<span class="xref"><a id="#B109-link" href="#B109" onclick="showRefSection();">109</a></span>). While not the focus of this review, it is important to note that efforts to develop a <i>P. vivax</i> vaccine are underway but still in the early stages (Table <a href="#T3">3</a>).

         </p>
</div>
</dd></dl>
<a class="in-page" name="SEC7"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#section-7" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Summary</span></a><div id="section-7" class="content active">
<p>Malaria is a complex parasitic disease that imposes an enormous 
disease burden for which we currently have no vaccine. Optimism that a 
vaccine can be developed comes from the observations that malaria 
immunity can be acquired through natural and experimental infection. 
However, many <i>P. falciparum</i> proteins are highly polymorphic and 
their functions are redundant, which presents significant challenges for
 vaccine design. Nevertheless, we remain optimistic that with adequate 
research support and the recruitment of experts in all aspects of <i>P. falciparum</i> infection biology and immunity to work on this problem, a highly effective vaccine is possible.
         </p>
<p><span class="level-4">Note added in proof.</span> Dhingra et al. have now reported that the burden of malaria in India has been underestimated (<span class="xref"><a id="#B110-link" href="#B110" onclick="showRefSection();">110</a></span>).
            </p>
</div>
</dd></dl>
<a class="in-page" name="FN"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#footnotes" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">Footnotes</span></a><div id="footnotes" class="content active">
<p><b>Conflict of interest:</b>The authors have declared that no conflict of interest exists.
            </p>
<p><b>Reference information:</b><i> J Clin Invest.</i> 2010;120(12):4168–4178. doi:10.1172/JCI44423
            </p>
</div>
</dd></dl>
<a class="in-page" name="BIBL" id="BIBL-target"></a><dl class="article-section" data-accordion=""><dd class="accordion-navigation active">
<a href="#references" aria-expanded="true"><span class="toggle-icon"></span><span class="section-title">References</span></a><div id="references" class="content active"><ol compact="compact">
<a class="in-page" name="B1"></a><li class="reference" value="1">Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. <i>Nature.</i> 2005;434(7030):214–217.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15759000"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/nature03342"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B1">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B2"></a><li class="reference" value="2">
<a target="_blank" href="http://www.who.int/malaria/publications/atoz/9789241563697/en/%0Aindex.html">
http://www.who.int/malaria/publications/atoz/9789241563697/en/index.html</a>.
	</li>
<a class="in-page" name="B3"></a><li class="reference" value="3">
      Johansson EW, Cibulskis R, Steketee RW. Malaria funding and 
resource utilization: the first decade of roll back malaria. In: <i>Roll Back Malaria Progress &amp; Impact Series</i>
      . Number 1. Geneva, Switzerland: World Health Organization; 2010.
    </li>
<a class="in-page" name="B4"></a><li class="reference" value="4">O’Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. <i>Lancet Infect Dis.</i> 2009;10(8):545–555.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20637696"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/S1473-3099(10)70096-7"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B4">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B5"></a><li class="reference" value="5">Cabral 
AC, Fe NF, Suarez-Mutis MC, Boia MN, Carvalho-Costa FA. Increasing 
incidence of malaria in the Negro River basin, Brazilian Amazon. <i>Trans R Soc Trop Med Hyg.</i> 2010;104(8):556–562.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20462621"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.trstmh.2010.03.008"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B5">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B6"></a><li class="reference" value="6">Dondorp AM, et al. Artemisinin resistance: current status and scenarios for containment. <i>Nat Rev Microbiol.</i> 2010;8(4):272–280.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20208550"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B6">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B7"></a><li class="reference" value="7">N’Guessan
 R, Corbel V, Akogbeto M, Rowland M. Reduced efficacy of 
insecticide-treated nets and indoor residual spraying for malaria 
control in pyrethroid resistance area, Benin. <i>Emerg Infect Dis.</i> 2007;13(2):199–206.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17479880"> PubMed </a><a target="_blank" href="https://doi.org/10.3201/eid1302.060631"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B7">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B8"></a><li class="reference" value="8">
<a target="_blank" href="http://www.thegeorgeinstitute.org/">
http://www.thegeorgeinstitute.org/</a>.
	</li>
<a class="in-page" name="B9"></a><li class="reference" value="9">Gardner MJ, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. <i>Nature.</i> 2002;419(6906):498–511.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/12368864"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/nature01097"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B9">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B10"></a><li class="reference" value="10">Florens L, et al. A proteomic view of the Plasmodium falciparum life cycle. <i>Nature.</i> 2002;419(6906):520–526.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/12368866"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B10">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B11"></a><li class="reference" value="11">Scherf A, Lopez-Rubio JJ, Riviere L. Antigenic variation in Plasmodium falciparum. <i>Annu Rev Microbiol.</i> 2008;62:445–470.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18785843"> PubMed </a><a target="_blank" href="https://doi.org/10.1146/annurev.micro.61.080706.093134"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B11">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B12"></a><li class="reference" value="12">Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. <i>Nat Immunol.</i> 2008;9(7):725–732.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18563083"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/ni.f.205"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B12">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B13"></a><li class="reference" value="13">Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. <i>Parasite Immunol.</i> 2006;28(1–2):51–60.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16438676"> PubMed </a><a target="_blank" href="https://doi.org/10.1111/j.1365-3024.2006.00808.x"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B13">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B14"></a><li class="reference" value="14">Gupta
 S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral 
severe malaria is acquired after one or two infections. <i>Nat Med.</i> 1999;5(3):340–343.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/10086393"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B14">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B15"></a><li class="reference" value="15">Baird
 JK, et al. Age-dependent acquired protection against Plasmodium 
falciparum in people having two years exposure to hyperendemic malaria. <i>Am J Trop Med Hyg.</i> 1991;45(1):65–76.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/1867349"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B15">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B16"></a><li class="reference" value="16">Baird
 JK, et al. Age-specific prevalence of Plasmodium falciparum among six 
populations with limited histories of exposure to endemic malaria. <i>Am J Trop Med Hyg.</i> 1993;49(6):707–719.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/8279639"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B16">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B17"></a><li class="reference" value="17">Shortt HE, Fairley NH, Covell G, Shute PG, Garnham PC. The pre-erythrocytic stage of Plasmodium falciparum. <i>Trans R Soc Trop Med Hyg.</i> 1951;44(4):405–419.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/14817818"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B17">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B18"></a><li class="reference" value="18">Fairley NH. Sidelights on malaria in man obtained by subinoculation experiments. <i>Trans R Soc Trop Med Hyg.</i> 1947;40(5):621–676.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20243883"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/0035-9203(47)90025-4"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B18">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B19"></a><li class="reference" value="19">Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. <i>Vaccine.</i> 2010;28(31):4880–4894.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20553771"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2010.05.033"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B19">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B20"></a><li class="reference" value="20">Simpson
 JA, Aarons L, Collins WE, Jeffery GM, White NJ. Population dynamics of 
untreated Plasmodium falciparum malaria within the adult human host 
during the expansion phase of the infection. <i>Parasitology.</i> 2002;124(pt 3):247–263.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/11922427"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B20">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B21"></a><li class="reference" value="21">Crompton
 PD, et al. A prospective analysis of the Ab response to Plasmodium 
falciparum before and after a malaria season by protein microarray. <i>Proc Natl Acad Sci U S A.</i> 2010;107(15):6958–6963.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20351286"> PubMed </a><a target="_blank" href="https://doi.org/10.1073/pnas.1001323107"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B21">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B22"></a><li class="reference" value="22">Pinzon-Charry
 A, et al. Low doses of killed parasite in CpG elicit vigorous CD4+ T 
cell responses against blood-stage malaria in mice. <i>J Clin Invest.</i> 2010;120(8):2967–2978.<div class="reference_linkouts">View this article via: <a class="self-reference" href="https://www.jci.org/content/vol120/page2967">
						JCI
					</a><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20628205"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B22">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B23"></a><li class="reference" value="23">Pombo DJ, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. <i>Lancet.</i> 2002;360(9333):610–617.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/12241933"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B23">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B24"></a><li class="reference" value="24">Weiss
 GE, et al. The Plasmodium falciparum-specific human memory B cell 
compartment expands gradually with repeated malaria infections. <i>PLoS Pathog.</i> 2010;6(5):e1000912.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20502681"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.ppat.1000912"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B24">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B25"></a><li class="reference" value="25">Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. <i>Nature.</i> 1961;192:733–737.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/13880318"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/192733a0"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B25">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B26"></a><li class="reference" value="26">Carter R, Miller LH. Evidence for environmental modulation of gametocytogenesis in Plasmodium falciparum in continuous culture. <i>Bull World Health Organ.</i> 1979;57(suppl 1):37–52.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/397008"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B26">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B27"></a><li class="reference" value="27">Carter
 R, Mendis KN, Miller LH, Molineaux L, Saul A. Malaria 
transmission-blocking vaccines — how can their development be supported?
 <i>Nat Med.</i> 2000;6(3):241–244.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/10700212"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B27">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B28"></a><li class="reference" value="28">Roestenberg M, et al. Protection against a malaria challenge by sporozoite inoculation. <i>N Engl J Med.</i> 2009;361(5):468–477.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19641203"> PubMed </a><a target="_blank" href="https://doi.org/10.1056/NEJMoa0805832"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B28">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B29"></a><li class="reference" value="29">Nussenzweig
 RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the 
injection of x-irradiated sporozoites of plasmodium berghei. <i>Nature.</i> 1967;216(5111):160–162.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/6057225"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/216160a0"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B29">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B30"></a><li class="reference" value="30">Nussenzweig V, Nussenzweig RS. Development of a sporozoite malaria vaccine. <i>Am J Trop Med Hyg.</i> 1986;35(4):678–688.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2425647"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B30">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B31"></a><li class="reference" value="31">Dame 
JB, et al. Structure of the gene encoding the immunodominant surface 
antigen on the sporozoite of the human malaria parasite Plasmodium 
falciparum. <i>Science.</i> 1984;225(4662):593–599.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/6204383"> PubMed </a><a target="_blank" href="https://doi.org/10.1126/science.6204383"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B31">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B32"></a><li class="reference" value="32">Gordon
 DM, et al. Safety, immunogenicity, and efficacy of a recombinantly 
produced Plasmodium falciparum circumsporozoite protein-hepatitis B 
surface antigen subunit vaccine. <i>J Infect Dis.</i> 1995;171(6):1576–1585.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/7769295"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B32">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B33"></a><li class="reference" value="33">Stoute
 JA, et al. A preliminary evaluation of a recombinant circumsporozoite 
protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria 
Vaccine Evaluation Group. <i>N Engl J Med.</i> 1997;336(2):86–91.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/8988885"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B33">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B34"></a><li class="reference" value="34">Kester
 KE, et al. Efficacy of recombinant circumsporozoite protein vaccine 
regimens against experimental Plasmodium falciparum malaria. <i>J Infect Dis.</i> 2001;183(4):640–647.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/11170991"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B34">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B35"></a><li class="reference" value="35">Kester
 KE, et al. A phase I/IIa safety, immunogenicity, and efficacy bridging 
randomized study of a two-dose regimen of liquid and lyophilized 
formulations of the candidate malaria vaccine RTS,S/AS02A in 
malaria-naive adults. <i>Vaccine.</i> 2007;25(29):5359–5366.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17574311"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2007.05.005"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B35">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B36"></a><li class="reference" value="36">Kester
 KE, et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day 
immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive 
adults at the Walter Reed Army Institute of Research. <i>Vaccine.</i> 2008;26(18):2191–2202.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18387719"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2008.02.048"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B36">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B37"></a><li class="reference" value="37">Kester
 KE, et al. Randomized, double-blind, phase 2a trial of falciparum 
malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: 
safety, efficacy, and immunologic associates of protection. <i>J Infect Dis.</i> 2009;200(3):337–346.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19569965"> PubMed </a><a target="_blank" href="https://doi.org/10.1086/600120"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B37">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B38"></a><li class="reference" value="38">Olotu
 AI, Fegan G, Bejon P. Further analysis of correlates of protection from
 a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and 
RTS,S/AS02A in malaria-naive adults. <i>J Infect Dis.</i> 2009;201(6):970–971.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20170369"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B38">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B39"></a><li class="reference" value="39">Bojang
 KA, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium 
falciparum infection in semi-immune adult men in The Gambia: a 
randomised trial. <i>Lancet.</i> 2001;358(9297):1927–1934.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/11747915"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/S0140-6736(01)06957-4"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B39">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B40"></a><li class="reference" value="40">Polhemus ME, et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. <i>PLoS One.</i> 2009;4(7):e6465.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19649245"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0006465"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B40">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B41"></a><li class="reference" value="41">Alonso
 PL, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium 
falciparum infection and disease in young African children: randomised 
controlled trial. <i>Lancet.</i> 2004;364(9443):1411–1420.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15488216"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/S0140-6736(04)17223-1"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B41">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B42"></a><li class="reference" value="42">Alonso
 PL, et al. Duration of protection with RTS,S/AS02A malaria vaccine in 
prevention of Plasmodium falciparum disease in Mozambican children: 
single-blind extended follow-up of a randomised controlled trial. <i>Lancet.</i> 2005;366(9502):2012–2018.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16338450"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/S0140-6736(05)67669-6"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B42">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B43"></a><li class="reference" value="43">Sacarlal J, et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. <i>J Infect Dis.</i> 2009;200(3):329–336.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19569964"> PubMed </a><a target="_blank" href="https://doi.org/10.1086/600119"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B43">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B44"></a><li class="reference" value="44">Abdulla S, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. <i>N Engl J Med.</i> 2008;359(24):2533–2544.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19064623"> PubMed </a><a target="_blank" href="https://doi.org/10.1056/NEJMoa0807773"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B44">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B45"></a><li class="reference" value="45">Bejon P, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. <i>N Engl J Med.</i> 2008;359(24):2521–2532.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19064627"> PubMed </a><a target="_blank" href="https://doi.org/10.1056/NEJMoa0807381"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B45">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B46"></a><li class="reference" value="46">Guinovart
 C, et al. Insights into long-lasting protection induced by RTS,S/AS02A 
malaria vaccine: further results from a phase IIb trial in Mozambican 
children. <i>PLoS One.</i> 2009;4(4):e5165.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19365567"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0005165"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B46">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B47"></a><li class="reference" value="47">Aponte
 JJ, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in 
infants living in a highly endemic area of Mozambique: a double blind 
randomised controlled phase I/IIb trial. <i>Lancet.</i> 2007;370(9598):1543–1551.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17949807"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/S0140-6736(07)61542-6"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B47">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B48"></a><li class="reference" value="48">Genton
 B, et al. Randomized double-blind controlled Phase I/IIa trial to 
assess the efficacy of malaria vaccine PfCS102 to protect against 
challenge with P. falciparum. <i>Vaccine.</i> 2010;28(40):6573–6580.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20691266"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2010.07.067"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B48">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B49"></a><li class="reference" value="49">Walther
 M, et al. Safety, immunogenicity, and efficacy of prime-boost 
immunization with recombinant poxvirus FP9 and modified vaccinia virus 
Ankara encoding the full-length Plasmodium falciparum circumsporozoite 
protein. <i>Infect Immun.</i> 2006;74(5):2706–2716.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16622207"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B49">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B50"></a><li class="reference" value="50">Walther
 M, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic 
malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. <i>Vaccine.</i> 2005;23(7):857–864.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15603885"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2004.08.020"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B50">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B51"></a><li class="reference" value="51">Kubler-Kielb J, et al. A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. <i>Proc Natl Acad Sci U S A.</i> 2010;107(3):1172–1177.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20080619"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B51">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B52"></a><li class="reference" value="52">Hoffman
 SL, et al. Development of a metabolically active, non-replicating 
sporozoite vaccine to prevent Plasmodium falciparum malaria. <i>Hum Vaccin.</i> 2010;6(1):97–106.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19946222"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B52">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B53"></a><li class="reference" value="53">Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. <i>Hum Vaccin.</i> 2010;6(1):107–113.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19838068"> PubMed </a><a target="_blank" href="https://doi.org/10.4161/hv.6.1.9654"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B53">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B54"></a><li class="reference" value="54">Hill AV, et al. Prime-boost vectored malaria vaccines: progress and prospects. <i>Hum Vaccin.</i> 2010;6(1):78–83.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20061802"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B54">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B55"></a><li class="reference" value="55">Clyde
 DF. Immunity to falciparum and vivax malaria induced by irradiated 
sporozoites: a review of the University of Maryland studies, 1971-75. <i>Bull World Health Organ.</i> 1990;68(suppl):9–12.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2094597"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B55">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B56"></a><li class="reference" value="56">Hoffman
 SL, et al. Protection of humans against malaria by immunization with 
radiation-attenuated Plasmodium falciparum sporozoites. <i>J Infect Dis.</i> 2002;185(8):1155–1164.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/11930326"> PubMed </a><a target="_blank" href="https://doi.org/10.1086/339409"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B56">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B57"></a><li class="reference" value="57">Trimnell
 A, Takagi A, Gupta M, Richie TL, Kappe SH, Wang R. Genetically 
attenuated parasite vaccines induce contact-dependent CD8+ T cell 
killing of Plasmodium yoelii liver stage-infected hepatocytes. <i>J Immunol.</i> 2009;183(9):5870–5878.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19812194"> PubMed </a><a target="_blank" href="https://doi.org/10.4049/jimmunol.0900302"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B57">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B58"></a><li class="reference" value="58">Webster
 DP, et al. Enhanced T cell-mediated protection against malaria in human
 challenges by using the recombinant poxviruses FP9 and modified 
vaccinia virus Ankara. <i>Proc Natl Acad Sci U S A.</i> 2005;102(13):4836–4841.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15781866"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B58">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B59"></a><li class="reference" value="59">Bejon
 P, et al. A phase 2b randomised trial of the candidate malaria vaccines
 FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. <i>PLoS Clin Trials.</i> 2006;1(6):e29.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17053830"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pctr.0010029"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B59">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B60"></a><li class="reference" value="60">Sabchareon A, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. <i>Am J Trop Med Hyg.</i> 1991;45(3):297–308.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/1928564"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B60">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B61"></a><li class="reference" value="61">Bouharoun-Tayoun
 H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. 
Antibodies that protect humans against Plasmodium falciparum blood 
stages do not on their own inhibit parasite growth and invasion in 
vitro, but act in cooperation with monocytes. <i>J Exp Med.</i> 1990;172(6):1633–1641.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2258697"> PubMed </a><a target="_blank" href="https://doi.org/10.1084/jem.172.6.1633"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B61">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B62"></a><li class="reference" value="62">Baruch
 DI, Gormely JA, Ma C, Howard RJ, Pasloske BL. Plasmodium falciparum 
erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for
 adherence to CD36, thrombospondin, and intercellular adhesion molecule 
1. <i>Proc Natl Acad Sci U S A.</i> 1996;93(8):3497–3502.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/8622965"> PubMed </a><a target="_blank" href="https://doi.org/10.1073/pnas.93.8.3497"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B62">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B63"></a><li class="reference" value="63">Celada
 A, Cruchaud A, Perrin LH. Opsonic activity of human immune serum on in 
vitro phagocytosis of Plasmodium falciparum infected red blood cells by 
monocytes. <i>Clin Exp Immunol.</i> 1982;47(3):635–644.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/7044626"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B63">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B64"></a><li class="reference" value="64">Groux
 H, Gysin J. Opsonization as an effector mechanism in human protection 
against asexual blood stages of Plasmodium falciparum: functional role 
of IgG subclasses. <i>Res Immunol.</i> 1990;141(6):529–542.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/1704637"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B64">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B65"></a><li class="reference" value="65">Bull 
PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite 
antigens on the infected red cell surface are targets for naturally 
acquired immunity to malaria. <i>Nat Med.</i> 1998;4(3):358–360.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/9500614"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/nm0398-358"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B65">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B66"></a><li class="reference" value="66">Naik 
RS, Krishnegowda G, Ockenhouse CF, Gowda DC. Naturally elicited 
antibodies to glycosylphosphatidylinositols (GPIs) of Plasmodium 
falciparum require intact GPI structures for binding and are directed 
primarily against the conserved glycan moiety. <i>Infect Immun.</i> 2006;74(2):1412–1415.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16428795"> PubMed </a><a target="_blank" href="https://doi.org/10.1128/IAI.74.2.1412-1415.2006"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B66">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B67"></a><li class="reference" value="67">Schofield
 L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a 
candidate anti-toxic vaccine in a model of malaria. <i>Nature.</i> 2002;418(6899):785–789.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/12181569"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B67">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B68"></a><li class="reference" value="68">Edstein MD, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. <i>Antimicrob Agents Chemother.</i> 2005;49(10):4421–4422.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16189139"> PubMed </a><a target="_blank" href="https://doi.org/10.1128/AAC.49.10.4421-4422.2005"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B68">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B69"></a><li class="reference" value="69">Sagara
 I, et al. A randomized controlled phase 2 trial of the blood stage 
AMA1-C1/Alhydrogel malaria vaccine in children in Mali. <i>Vaccine.</i> 2009;27(23):3090–3098.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19428923"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B69">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B70"></a><li class="reference" value="70">El 
Sahly HM, et al. The safety and immunogenicity of recombinant EBA 
175-RII NG malaria vaccine in healthy adults living in a non-endemic 
area. <i>Clin Vaccine Immunol.</i> 2010;17(10):1552–1559.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20702657"> PubMed </a><a target="_blank" href="https://doi.org/10.1128/CVI.00082-10"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B70">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B71"></a><li class="reference" value="71">Esen M, et al. Safety and immunogenicity of GMZ2 — a MSP3-GLURP fusion protein malaria vaccine candidate. <i>Vaccine.</i> 2009;27(49):6862–6868.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19755144"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2009.09.011"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B71">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B72"></a><li class="reference" value="72">Hermsen
 CC, et al. Glutamate-rich protein (GLURP) induces antibodies that 
inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria 
vaccine trial. <i>Vaccine.</i> 2007;25(15):2930–2940.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16914240"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2006.06.081"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B72">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B73"></a><li class="reference" value="73">Ogutu
 BR, et al. Blood stage malaria vaccine eliciting high antigen-specific 
antibody concentrations confers no protection to young children in 
Western Kenya. <i>PLoS One.</i> 2009;4(3):e4708.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19262754"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0004708"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B73">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B74"></a><li class="reference" value="74">Genton
 B, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium 
falciparum density and exerts selective pressure on parasite populations
 in a phase 1-2b trial in Papua New Guinea.  <i>J Infect Dis.</i> 2002;185(6):820–827.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/11920300"> PubMed </a><a target="_blank" href="https://doi.org/10.1086/339342"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B74">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B75"></a><li class="reference" value="75">Audran
 R, et al. Phase I malaria vaccine trial with a long synthetic peptide 
derived from the merozoite surface protein 3 antigen. <i>Infect Immun.</i> 2005;73(12):8017–8026.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16299295"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B75">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B76"></a><li class="reference" value="76">Sirima
 SB, et al. Safety and immunogenicity of the malaria vaccine candidate 
MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. <i>PLoS One.</i> 2009;4(10):e7549.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19855847"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0007549"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B76">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B77"></a><li class="reference" value="77">Druilhe P, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. <i>PLoS Med.</i> 2005;2(11):e344.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16262450"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pmed.0020344"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B77">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B78"></a><li class="reference" value="78">Horii
 T, et al. Evidences of protection against blood-stage infection of 
Plasmodium falciparum by the novel protein vaccine SE36. <i>Parasitol Int.</i> 2010;59(3):380–386.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20493274"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B78">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B79"></a><li class="reference" value="79">Ellis
 RD, et al. Phase 1 trial of the Plasmodium falciparum blood stage 
vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria 
naive adults. <i>PLoS One.</i> 2010;5(1):e8787.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20107498"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0008787"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B79">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B80"></a><li class="reference" value="80">Sagara
 I, et al. A randomized and controlled Phase 1 study of the safety and 
immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for 
Plasmodium falciparum malaria in semi-immune Malian adults. <i>Vaccine.</i> 2009;27(52):7292–7298.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19874925"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2009.10.087"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B80">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B81"></a><li class="reference" value="81">Malkin
 E, et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant
 protein vaccine for Plasmodium falciparum malaria. <i>Vaccine.</i> 2008;26(52):6864–6873.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18930094"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B81">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B82"></a><li class="reference" value="82">Weedall GD, Conway DJ. Detecting signatures of balancing selection to identify targets of anti-parasite immunity. <i>Trends Parasitol.</i> 2010;26(7):363–369.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20466591"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.pt.2010.04.002"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B82">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B83"></a><li class="reference" value="83">Takala
 SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and
 efficacy: preventing and overcoming ‘vaccine resistant malaria.’. <i>Parasite Immunol.</i> 2009;31(9):560–573.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19691559"> PubMed </a><a target="_blank" href="https://doi.org/10.1111/j.1365-3024.2009.01138.x"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B83">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B84"></a><li class="reference" value="84">Takala SL, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. <i>Sci Transl Med.</i> 2009;1(2):2ra5.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20165550"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B84">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B85"></a><li class="reference" value="85">Doolan DL, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. <i>Proteomics.</i> 2008;8(22):4680–4694.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18937256"> PubMed </a><a target="_blank" href="https://doi.org/10.1002/pmic.200800194"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B85">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B86"></a><li class="reference" value="86">Tsuboi T, et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. <i>Infect Immun.</i> 2008;76(4):1702–1708.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18268027"> PubMed </a><a target="_blank" href="https://doi.org/10.1128/IAI.01539-07"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B86">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B87"></a><li class="reference" value="87">Agak 
GW, et al. Longitudinal analyses of immune responses to Plasmodium 
falciparum derived peptides corresponding to novel blood stage antigens 
in coastal Kenya. <i>Vaccine.</i> 2008;26(16):1963–1971.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18342997"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2008.02.020"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B87">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B88"></a><li class="reference" value="88">Gaur 
D, Mayer DC, Miller LH. Parasite ligand-host receptor interactions 
during invasion of erythrocytes by Plasmodium merozoites. <i>Int J Parasitol.</i> 2004;34(13–14):1413–1429.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15582519"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B88">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B89"></a><li class="reference" value="89">Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. <i>Cell.</i> 2006;124(4):755–766.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16497586"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.cell.2006.02.006"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B89">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B90"></a><li class="reference" value="90">Langreth
 SG, Peterson E. Pathogenicity, stability, and immunogenicity of a 
knobless clone of Plasmodium falciparum in Colombian owl monkeys. <i>Infect Immun.</i> 1985;47(3):760–766.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/3882566"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B90">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B91"></a><li class="reference" value="91">Hommel
 M, David PH, Oligino LD. Surface alterations of erythrocytes in 
Plasmodium falciparum malaria. Antigenic variation, antigenic diversity,
 and the role of the spleen. <i>J Exp Med.</i> 1983;157(4):1137–1148.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/6187885"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B91">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B92"></a><li class="reference" value="92">Leech
 JH, Barnwell JW, Miller LH, Howard RJ. Identification of a 
strain-specific malarial antigen exposed on the surface of Plasmodium 
falciparum-infected erythrocytes. <i>J Exp Med.</i> 1984;159(6):1567–1575.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/6374009"> PubMed </a><a target="_blank" href="https://doi.org/10.1084/jem.159.6.1567"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B92">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B93"></a><li class="reference" value="93">Salanti
 A, et al. Selective upregulation of a single distinctly structured var 
gene in chondroitin sulphate A-adhering Plasmodium falciparum involved 
in pregnancy-associated malaria. <i>Mol Microbiol.</i> 2003;49(1):179–191.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/12823820"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B93">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B94"></a><li class="reference" value="94">Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. <i>Science.</i> 1996;272(5267):1502–1504.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/8633247"> PubMed </a><a target="_blank" href="https://doi.org/10.1126/science.272.5267.1502"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B94">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B95"></a><li class="reference" value="95">Avril
 M, et al. Immunization with VAR2CSA-DBL5 recombinant protein elicits 
broadly cross-reactive antibodies to placental Plasmodium 
falciparum-infected erythrocytes. <i>Infect Immun.</i> 2010;78(5):2248–2256.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20194590"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B95">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B96"></a><li class="reference" value="96">Taylor TE, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. <i>Nat Med.</i> 2004;10(2):143–145.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/14745442"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B96">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B97"></a><li class="reference" value="97">Kraemer
 SM, Smith JD. Evidence for the importance of genetic structuring to the
 structural and functional specialization of the Plasmodium falciparum 
var gene family. <i>Mol Microbiol.</i> 2003;50(5):1527–1538.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/14651636"> PubMed </a><a target="_blank" href="https://doi.org/10.1046/j.1365-2958.2003.03814.x"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B97">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B98"></a><li class="reference" value="98">Jensen
 AT, et al. Plasmodium falciparum associated with severe childhood 
malaria preferentially expresses PfEMP1 encoded by group A var genes.  <i>J Exp Med.</i> 2004;199(9):1179–1190.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/15123742"> PubMed </a><a target="_blank" href="https://doi.org/10.1084/jem.20040274"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B98">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B99"></a><li class="reference" value="99">Moorthy V, Reed Z, Smith PG. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. <i>Vaccine.</i> 2007;25(28):5115–5123.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17577487"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2007.01.085"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B99">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B100"></a><li class="reference" value="100">Graves
 PM, Carter R, Burkot TR, Quakyi IA, Kumar N. Antibodies to Plasmodium 
falciparum gamete surface antigens in Papua New Guinea sera. <i>Parasite Immunol.</i> 1988;10(2):209–218.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/3287282"> PubMed </a><a target="_blank" href="https://doi.org/10.1111/j.1365-3024.1988.tb00215.x"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B100">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B101"></a><li class="reference" value="101">Bousema JT, Drakeley CJ, Sauerwein RW. Sexual-stage antibody responses to P. falciparum in endemic populations. <i>Curr Mol Med.</i> 2006;6(2):223–229.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16515512"> PubMed </a><a target="_blank" href="https://doi.org/10.2174/156652406776055140"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B101">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B102"></a><li class="reference" value="102">Kaslow DC, Quakyi IA, Keister DB. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. <i>Mol Biochem Parasitol.</i> 1989;32(1):101–103.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2643034"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/0166-6851(89)90134-5"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B102">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B103"></a><li class="reference" value="103">Chowdhury
 DR, Angov E, Kariuki T, Kumar N. A potent malaria transmission blocking
 vaccine based on codon harmonized full length Pfs48/45 expressed in 
Escherichia coli. <i>PLoS One.</i> 2009;4(7):e6352.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19623257"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0006352"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B103">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B104"></a><li class="reference" value="104">Quakyi
 IA, Carter R, Rener J, Kumar N, Good MF, Miller LH. The 230-kDa gamete 
surface protein of Plasmodium falciparum is also a target for 
transmission-blocking antibodies. <i>J Immunol.</i> 1987;139(12):4213–4217.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2447164"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B104">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B105"></a><li class="reference" value="105">Liu
 Y, et al. The conserved plant sterility gene HAP2 functions after 
attachment of fusogenic membranes in Chlamydomonas and Plasmodium 
gametes. <i>Genes Dev.</i> 2008;22(8):1051–1068.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18367645"> PubMed </a><a target="_blank" href="https://doi.org/10.1101/gad.1656508"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B105">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B106"></a><li class="reference" value="106">Blagborough AM, Sinden RE. Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. <i>Vaccine.</i> 2009;27(38):5187–5194.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19596419"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B106">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B107"></a><li class="reference" value="107">Saul A. Efficacy model for mosquito stage transmission blocking vaccines for malaria. <i>Parasitology.</i> 2008;135(13):1497–1506.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18257944"> PubMed </a><a target="_blank" href="https://doi.org/10.1017/S0031182008000280"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B107">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B108"></a><li class="reference" value="108">Wu 
Y, et al. Sustained high-titer antibody responses induced by conjugating
 a malarial vaccine candidate to outer-membrane protein complex. <i>Proc Natl Acad Sci U S A.</i> 2006;103(48):18243–18248.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17110440"> PubMed </a><a target="_blank" href="https://doi.org/10.1073/pnas.0608545103"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B108">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B109"></a><li class="reference" value="109">Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. <i>Am J Trop Med Hyg.</i> 2007;77(6 suppl):79–87.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18165478"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B109">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B110"></a><li class="reference" value="110">Dhingra
 N, et al. Adult and child malaria mortality in India: a nationally 
representative mortality survey [published online ahead of print October
 21, 2010]. <i>Lancet.</i> doi:10.1016/S0140-6736(10)60831-8. <div class="reference_linkouts">View this article via: <a target="_blank" href="https://doi.org/10.1016/S0140-6736(10)60831-8"> CrossRef </a><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20970179"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B110">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B111"></a><li class="reference" value="111">Gysin
 J, Barnwell J, Schlesinger DH, Nussenzweig V, Nussenzweig RS. 
Neutralization of the infectivity of sporozoites of Plasmodium knowlesi 
by antibodies to a synthetic peptide. <i>J Exp Med.</i> 1984;160(3):935–940.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/6470623"> PubMed </a><a target="_blank" href="https://doi.org/10.1084/jem.160.3.935"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B111">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B112"></a><li class="reference" value="112">Plassmeyer ML, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. <i>J Biol Chem.</i> 2009;284(39):26951–26963.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19633296"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B112">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B113"></a><li class="reference" value="113">Sinnis
 P, Clavijo P, Fenyo D, Chait BT, Cerami C, Nussenzweig V. Structural 
and functional properties of region II-plus of the malaria 
circumsporozoite protein. <i>J Exp Med.</i> 1994;180(1):297–306.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/8006589"> PubMed </a><a target="_blank" href="https://doi.org/10.1084/jem.180.1.297"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B113">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B114"></a><li class="reference" value="114">Guttinger
 M, et al. Human T cells recognize polymorphic and non-polymorphic 
regions of the Plasmodium falciparum circumsporozoite protein. <i>EMBO J.</i> 1988;7(8):2555–2558.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2461298"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B114">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B115"></a><li class="reference" value="115">Kumar S, et al. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. <i>Nature.</i> 1988;334(6179):258–260.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2456467"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/334258a0"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B115">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B116"></a><li class="reference" value="116">Sinigaglia F, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. <i>Nature.</i> 1988;336(6201):778–780.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/2462673"> PubMed </a><a target="_blank" href="https://doi.org/10.1038/336778a0"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B116">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B117"></a><li class="reference" value="117">Lalvani
 A, et al. Potent induction of focused Th1-type cellular and humoral 
immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum 
malaria vaccine. <i>J Infect Dis.</i> 1999;180(5):1656–1664.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/10515829"> PubMed </a><a target="_blank" href="https://doi.org/10.1086/315074"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B117">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B118"></a><li class="reference" value="118">Sun
 P, et al. Protective immunity induced with malaria vaccine, RTS,S, is 
linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ 
and CD8+ T cells producing IFN-gamma.  <i>J Immunol.</i> 2003;171(12):6961–6967.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/14662904"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B118">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B119"></a><li class="reference" value="119">Cummings
 JF, et al. Recombinant liver stage antigen-1 (LSA-1) formulated with 
AS01 or AS02 is safe, elicits high titer antibody and induces 
IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental 
Plasmodium falciparum infection. <i>Vaccine.</i> 2010;28(31):5135–5144.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19737527"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/j.vaccine.2009.08.046"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B119">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B120"></a><li class="reference" value="120">Spring
 MD, et al. Phase 1/2a study of the malaria vaccine candidate apical 
membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or 
AS02A. <i>PLoS One.</i> 2009;4(4):e5254.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19390585"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0005254"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B120">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B121"></a><li class="reference" value="121">Roestenberg
 M, et al. Safety and immunogenicity of a recombinant Plasmodium 
falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide 
ISA 720 or AS02. <i>PLoS One.</i> 2008;3(12):e3960.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19093004"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0003960"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B121">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B122"></a><li class="reference" value="122">Lawrence
 G, et al. Effect of vaccination with 3 recombinant asexual-stage 
malaria antigens on initial growth rates of Plasmodium falciparum in 
non-immune volunteers. <i>Vaccine.</i> 2000;18(18):1925–1931.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/10699342"> PubMed </a><a target="_blank" href="https://doi.org/10.1016/S0264-410X(99)00444-2"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B122">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B123"></a><li class="reference" value="123">Wu 
Y, et al. Phase 1 trial of malaria transmission blocking vaccine 
candidates Pfs25 and Pvs25 formulated with montanide ISA 51. <i>PLoS One.</i> 2008;3(7):e2636.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18612426"> PubMed </a><a href="https://www.jci.org/references/scholar/28551/B123">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B124"></a><li class="reference" value="124">Okitsu
 SL, et al. A virosomal malaria peptide vaccine elicits a long-lasting 
sporozoite-inhibitory antibody response in a phase 1a clinical trial. <i>PLoS One.</i> 2007;2(12):e1278.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18060072"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0001278"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B124">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B125"></a><li class="reference" value="125">Genton
 B, et al. A randomized placebo-controlled phase Ia malaria vaccine 
trial of two virosome-formulated synthetic peptides in healthy adult 
volunteers. <i>PLoS One.</i> 2007;2(10):e1018.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/17925866"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0001018"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B125">Google Scholar</a>
</div>
</li>
<a class="in-page" name="B126"></a><li class="reference" value="126">Thompson FM, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. <i>PLoS One.</i> 2008;3(1):e1493.<div class="reference_linkouts">View this article via: <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/18231580"> PubMed </a><a target="_blank" href="https://doi.org/10.1371/journal.pone.0001493"> CrossRef </a><a href="https://www.jci.org/references/scholar/28551/B126">Google Scholar</a>
</div>
</li>
</ol></div>
</dd></dl>
</div>

			<dl class="article-section" data-accordion="">
<dd class="accordion-navigation active">
<a href="#version_history" aria-expanded="true">
<span class="toggle-icon"></span>
<span class="section-title">Version history</span>
</a>
<div class="content active" id="version_history">
<ul>
<li>
Version
1
(December 1, 2010):
No description
</li>
</ul>
</div>
</dd>
</dl>

		<div id="trendmd-suggestions"></div>
	</div>

	<div class="large-3 columns show-for-large-up">
		<div id="sidebar-container">
<div id="sidebar">
<div class="non-sticky-content">
<h4 class="subheader">Article tools</h4>
<ul class="side-nav" id="article-tools">
<li class="hide-for-small">
<a href="https://www.jci.org/articles/view/44423/pdf">View PDF <img class="article-tools-icon" src="adobe_pdf_file_icon.png"></a>
</li>
<li><a href="https://www.jci.org/articles/view/44423/cite">Download citation information</a></li>
<li><a href="https://www.jci.org/eletters/submit/44423">Send a letter</a></li>
<li><a href="http://www.addthis.com/bookmark.php?v=250&amp;pubid=ra-4d8389db4b0bb592">Share this article</a></li>
<li><a href="https://www.jci.org/kiosks/terms">Terms of use</a></li>
<li><a href="https://www.jci.org/kiosks/publish/abbreviations">Standard abbreviations</a></li>
<li><a href="https://www.jci.org/feedback?reference=44423">Need Help? E-mail the JCI</a></li>
<script>
var addthis_share = {
	email_template: 'jci_share_article',
	email_vars: {
		short_title: '#&lt;#&lt;Class:0x00000000070796b0&gt;:0x00007fade4b37c90&gt;',
		author_list: 'Peter D. Crompton, Susan K. Pierce, Louis H. Miller',
	}
}
</script>
<div class="addthis_sharing_toolbox" data-title="JCI - Advances and challenges in malaria vaccine development" style="clear: both;" data-url="https://www.jci.org/articles/view/44423"><div id="atstbx2" class="at-share-tbx-element addthis-smartlayers at4-hide" aria-labelledby="at-79a96629-d0d2-4bd0-a5ca-03310501cf92" role="region"><span id="at-79a96629-d0d2-4bd0-a5ca-03310501cf92" class="at4-visually-hidden">AddThis Sharing Buttons</span><div class="at-share-btn-elements"><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-facebook" style="background-color: rgb(59, 89, 152); border-radius: 2%;"><span class="at4-visually-hidden">Share to Facebook</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-facebook-6" class="at-icon at-icon-facebook" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-facebook-6">Facebook</title><g><path d="M22 5.16c-.406-.054-1.806-.16-3.43-.16-3.4 0-5.733 1.825-5.733 5.17v2.882H9v3.913h3.837V27h4.604V16.965h3.823l.587-3.913h-4.41v-2.5c0-1.123.347-1.903 2.198-1.903H22V5.16z" fill-rule="evenodd"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-twitter" style="background-color: rgb(29, 161, 242); border-radius: 2%;"><span class="at4-visually-hidden">Share to Twitter</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-twitter-7" class="at-icon at-icon-twitter" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-twitter-7">Twitter</title><g><path d="M27.996 10.116c-.81.36-1.68.602-2.592.71a4.526 4.526 0 0 0 1.984-2.496 9.037 9.037 0 0 1-2.866 1.095 4.513 4.513 0 0 0-7.69 4.116 12.81 12.81 0 0 1-9.3-4.715 4.49 4.49 0 0 0-.612 2.27 4.51 4.51 0 0 0 2.008 3.755 4.495 4.495 0 0 1-2.044-.564v.057a4.515 4.515 0 0 0 3.62 4.425 4.52 4.52 0 0 1-2.04.077 4.517 4.517 0 0 0 4.217 3.134 9.055 9.055 0 0 1-5.604 1.93A9.18 9.18 0 0 1 6 23.85a12.773 12.773 0 0 0 6.918 2.027c8.3 0 12.84-6.876 12.84-12.84 0-.195-.005-.39-.014-.583a9.172 9.172 0 0 0 2.252-2.336" fill-rule="evenodd"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-print" style="background-color: rgb(115, 138, 141); border-radius: 2%;"><span class="at4-visually-hidden">Share to Print</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-print-8" class="at-icon at-icon-print" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-print-8">Print</title><g><path d="M24.67 10.62h-2.86V7.49H10.82v3.12H7.95c-.5 0-.9.4-.9.9v7.66h3.77v1.31L15 24.66h6.81v-5.44h3.77v-7.7c-.01-.5-.41-.9-.91-.9zM11.88 8.56h8.86v2.06h-8.86V8.56zm10.98 9.18h-1.05v-2.1h-1.06v7.96H16.4c-1.58 0-.82-3.74-.82-3.74s-3.65.89-3.69-.78v-3.43h-1.06v2.06H9.77v-3.58h13.09v3.61zm.75-4.91c-.4 0-.72-.32-.72-.72s.32-.72.72-.72c.4 0 .72.32.72.72s-.32.72-.72.72zm-4.12 2.96h-6.1v1.06h6.1v-1.06zm-6.11 3.15h6.1v-1.06h-6.1v1.06z"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-email" style="background-color: rgb(132, 132, 132); border-radius: 2%;"><span class="at4-visually-hidden">Share to Email</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-email-9" class="at-icon at-icon-email" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-email-9">Email</title><g><g fill-rule="evenodd"></g><path d="M27 22.757c0 1.24-.988 2.243-2.19 2.243H7.19C5.98 25 5 23.994 5 22.757V13.67c0-.556.39-.773.855-.496l8.78 5.238c.782.467 1.95.467 2.73 0l8.78-5.238c.472-.28.855-.063.855.495v9.087z"></path><path d="M27 9.243C27 8.006 26.02 7 24.81 7H7.19C5.988 7 5 8.004 5 9.243v.465c0 .554.385 1.232.857 1.514l9.61 5.733c.267.16.8.16 1.067 0l9.61-5.733c.473-.283.856-.96.856-1.514v-.465z"></path></g></svg></span></a><a role="button" tabindex="0" class="at-icon-wrapper at-share-btn at-svc-compact" style="background-color: rgb(255, 101, 80); border-radius: 2%;"><span class="at4-visually-hidden">Share to More</span><span class="at-icon-wrapper" style="line-height: 32px; height: 32px; width: 32px;"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 32 32" version="1.1" role="img" aria-labelledby="at-svg-addthis-10" class="at-icon at-icon-addthis" style="fill: rgb(255, 255, 255); width: 32px; height: 32px;"><title id="at-svg-addthis-10">AddThis</title><g><path d="M18 14V8h-4v6H8v4h6v6h4v-6h6v-4h-6z" fill-rule="evenodd"></path></g></svg></span></a></div></div></div>

</ul>




<h4 class="subheader">Metrics</h4>
<div class="altmetric-embed centered" data-badge-popover="left" data-badge-type="medium-donut" data-doi="10.1172/JCI44423" data-uuid="7aecdc73-893d-023b-8a81-03415b42b23d"><a target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194" rel="popover" data-content="&lt;div&gt;    &lt;div style='padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;'&gt;
      &lt;a class='link-to-altmetric-details-tab' target='_self' href='https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=twitter'&gt;
          Tweeted by &lt;b&gt;2&lt;/b&gt;
      &lt;/a&gt;
    &lt;/div&gt;
    &lt;div style='padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;'&gt;
      &lt;a class='link-to-altmetric-details-tab' target='_self' href='https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=patents'&gt;
          Referenced in &lt;b&gt;10&lt;/b&gt; patents
      &lt;/a&gt;
    &lt;/div&gt;
    &lt;div style='padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;'&gt;
      &lt;a class='link-to-altmetric-details-tab' target='_self' href='https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=facebook'&gt;
          On &lt;b&gt;2&lt;/b&gt; Facebook pages
      &lt;/a&gt;
    &lt;/div&gt;
    &lt;div style='padding-left: 10px; line-height:18px; border-left: 16px solid #958899;'&gt;
      &lt;a class='link-to-altmetric-details-tab' target='_self' href='https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=wikipedia'&gt;
          Referenced in &lt;b&gt;1&lt;/b&gt; Wikipedia pages
      &lt;/a&gt;
    &lt;/div&gt;

    &lt;div class='altmetric-embed readers' style='margin-top: 10px;'&gt;
          &lt;div class='altmetric-embed tip_mendeley'
               style='padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;'&gt;
              &lt;b&gt;416&lt;/b&gt; readers on Mendeley
          &lt;/div&gt;
          &lt;div class='altmetric-embed tip_citeulike'
               style='padding-left: 10px; line-height:18px; border-left: 16px solid #BCD2EF;'&gt;
              &lt;b&gt;1&lt;/b&gt; readers on CiteULike
          &lt;/div&gt;
    &lt;/div&gt;
    &lt;div style='margin-top: 10px; text-align: center;'&gt;
        &lt;a class='altmetric_details' target='_self' href='https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194'&gt;
            See more details
        &lt;/a&gt;
    &lt;/div&gt;
&lt;/div&gt;" style="display:inline-block;" data-badge-popover="left">
        <img alt="Article has an altmetric score of 11" src="a" style="border:0; margin:0; max-width: none;" width="120px" height="120px">
</a></div>
<ul class="side-nav" id="article-metrics">
<li><a href="https://www.jci.org/articles/view/44423/usage">Article usage</a></li>
<li>
<a href="https://www.jci.org/articles/view/44423/citations">Citations to this article
<span class="article-citation-count">(168)</span>
</a></li>
</ul>

</div>
<div class="sticky-content">
<div id="goto">
<h4 class="subheader">Go to</h4>
<ul class="side-nav">
<li><a href="#top">Top</a></li>
<li><a href="#ABS">Abstract</a></li>
<li><a href="#SEC1">Introduction</a></li>
<li><a href="#SEC2">The P. falciparum life cycle and vaccine targets
         </a></li>
<li><a href="#SEC3">Pre-erythrocytic vaccines</a></li>
<li><a href="#SEC4">Asexual blood-stage vaccines</a></li>
<li><a href="#SEC5">Combining pre-erythrocytic and blood-stage vaccines</a></li>
<li><a href="#SEC6">Transmission-blocking vaccines</a></li>
<li><a href="#SEC7">Summary</a></li>
<li><a href="#FN">Footnotes</a></li>
<li><a href="#BIBL">References</a></li>
<li><a href="#version_history">Version history</a></li>
</ul>

</div>
</div>
</div>
</div>

	</div>
</div>
<div class="row hide-for-small">
	<div class="medium-12 columns">
		<div style="width:100%; text-align: center;">
<div id="jci-article-interior-leaderboard-bottom" style="display: none;" data-google-query-id="CNnTir2isegCFUmiewodOIIF_w">
<span class="secondary label">Advertisement</span>
<script>
  try {
    googletag.cmd.push(function() {
      googletag.display('jci-article-interior-leaderboard-bottom');
    })
  } catch(e){}
</script>
<div id="google_ads_iframe_/82117132/jci-article-interior-leaderboard-bottom_0__container__" style="border: 0pt none; width: 728px; height: 90px;"></div></div>
</div>

	</div>
</div>

</div>
<div class="large-2 medium-3 hide-for-small columns" style="padding: 12px 9px 12px 9px;">
<div style="width:100%; text-align: center;">
<div class="ad-interior-r-sideboard" id="jci-article-interior-skyscraper-right-col" style="" data-google-query-id="CJHVir2isegCFZK73goduW8D7g">


<div id="google_ads_iframe_/82117132/jci-article-interior-skyscraper-right-col_0__container__" style="border: 0pt none;"><iframe id="google_ads_iframe_/82117132/jci-article-interior-skyscraper-right-col_0" title="3rd party ad content" name="google_ads_iframe_/82117132/jci-article-interior-skyscraper-right-col_0" scrolling="no" marginwidth="0" marginheight="0" style="border: 0px none; vertical-align: bottom;" srcdoc="" data-google-container-id="a6bdedaa2fd8c488b7c620aa1adfff1c" data-load-complete="true" width="160" height="600" frameborder="0"></iframe></div></div>
</div>

</div>
</div>
</div>

</div>
</div>
</div>
<div id="footer">
<div class="row panel-padding">
<div class="small-6 columns">
Follow JCI:
<span id="social-links">
<a onclick="trackOutboundLink('/facebook?ref=footer');" href="https://www.jci.org/facebook"><img title="Facebook" src="facebook_logo_white-8549cbbdd5755c8d81d1ab2fdea8326c3ec2963a.png"></a>
<a onclick="trackOutboundLink('/twitter?ref=footer');" href="https://www.jci.org/twitter"><img title="Twitter" src="twitter_logo_v2-60ea0c72387950663c0b04fc251455a5a04ed832e929.png"></a>
<a href="https://www.jci.org/rss"><img title="RSS" src="rss_icon-cd21b1126f247087e91b0bc6c9d4acc3968c4ecb46461efba52.png"></a>
</span>

<br>
Copyright © 2020
<a href="http://www.the-asci.org/">American Society for Clinical Investigation</a>
<br>
ISSN: 0021-9738 (print), 1558-8238 (online)
</div>
<div class="small-6 columns">
<div class="row">
<div class="small-12 columns">
<h4 class="notices-signup">Sign up for email alerts</h4>
<form action="https://notices.jci.org/subscribers/new" method="get">
<input name="utm_source" value="jci" type="hidden">
<input name="utm_medium" value="web" type="hidden">
<input name="utm_campaign" value="email_signup" type="hidden">
<input name="utm_content" value="footer" type="hidden">
<div class="row">
<div class="small-12 medium-9 columns">
<input name="email_address" placeholder="Your email address" type="text">
</div>
<div class="small-12 medium-3 columns">
<input class="button tiny orange" value="Sign up" type="submit">
</div>
</div>
</form>
</div>
</div>

</div>
</div>
</div>

</div>
<!--[if gt IE 8]><!--><script src="application-706c98b653f31722e63102b0a408f2efaabf527722156d74b.js"></script><!--<![endif]-->
<!--[if (lt IE 9)]>
<script src="/assets/ie8/application-56fa2dadb4a7c0b757c9323e2baa810348c2052533f460b704e8627525d49783.js"></script>
<![endif]-->
<script src="addthis_widget.js" async="async"></script>
<script src="embed.js" async="async"></script>

	<script type="text/javascript" src="trendmd.js"></script><div style="visibility: hidden; height: 1px; width: 1px; position: absolute; top: -9999px; z-index: 100000;" id="_atssh"><iframe id="_atssh176" title="AddThis utility frame" style="height: 1px; width: 1px; position: absolute; top: 0px; z-index: 100000; border: 0px none; left: 0px;" src="https://s7.addthis.com/static/sh.f48a1a04fe8dbf021b4cda1d.html#rand=0.037830748894040256&amp;iit=1584989625881&amp;tmr=load%3D1584989625765%26core%3D1584989625783%26main%3D1584989625877%26ifr%3D1584989625885&amp;cb=0&amp;cdn=0&amp;md=0&amp;kw=&amp;ab=-&amp;dh=www.jci.org&amp;dr=&amp;du=https%3A%2F%2Fwww.jci.org%2Farticles%2Fview%2F44423&amp;href=https%3A%2F%2Fwww.jci.org%2Farticles%2Fview%2F44423&amp;dt=JCI%20-%20Advances%20and%20challenges%20in%20malaria%20vaccine%20development&amp;dbg=0&amp;cap=tc%3D0%26ab%3D0&amp;inst=1&amp;jsl=1&amp;prod=undefined&amp;lng=en&amp;ogt=&amp;pc=men&amp;pub=ra-4d8389db4b0bb592&amp;ssl=1&amp;sid=5e7905b9d370c11d&amp;srf=0.01&amp;ver=300&amp;xck=0&amp;xtr=0&amp;og=&amp;csi=undefined&amp;rev=v8.28.3-wp&amp;ct=1&amp;xld=1&amp;xd=1"></iframe></div><style id="service-icons-0"></style>
	<script type="text/javascript">
		jQuery(document).ready(function() {
			ArticleStickyNav.init();
			display_citation_count(44423);
			setMaxGaSize(jQuery('div.inner-wrap .fixed.show-for-large-up'), jQuery('div#section-graphical-abstract img'));
		});

		TrendMD.register({element: '#trendmd-suggestions', journal_id: 44412});
	</script>

<!--[if lt IE 9]>
<script src="/assets/ie8/ie8-b06973a49582971e782acad6ffd4ed088fc75a69416e7b71a48175f8ad303474.js"></script>
<![endif]-->



<script type="text/javascript" src="jci44423"></script><script type="text/javascript" src="jci44423"></script><script type="text/javascript" id="">"173.10.39.249"==google_tag_manager["GTM-WTNK8H9"].macro(3)||"production"!=google_tag_manager["GTM-WTNK8H9"].macro(4)?dataLayer.push({internal:"true"}):dataLayer.push({internal:"false"});dataLayer.push({event:"ipComplete"});</script>
<div class="altmetric-embed altmetric-popover altmetric-left" data-uuid="7aecdc73-893d-023b-8a81-03415b42b23d" id="_altmetric_popover_el_7aecdc73-893d-023b-8a81-03415b42b23d" style="margin: 0px; display: none;"><div class="altmetric_container" id="_altmetric_container"><div class="altmetric_arrow altmetric-left"></div><div id="_altmetric_popover_inner" class="altmetric-embed altmetric-popover-inner altmetric-floating altmetric-left" data-uuid="7aecdc73-893d-023b-8a81-03415b42b23d"><div class="altmetric-embed altmetric-popover-content altmetric-floating"><div>    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=twitter">
          Tweeted by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=patents">
          Referenced in <b>10</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>416</b> readers on Mendeley
          </div>
          <div class="altmetric-embed tip_citeulike" style="padding-left: 10px; line-height:18px; border-left: 16px solid #BCD2EF;">
              <b>1</b> readers on CiteULike
          </div>
    </div>
    <div style="margin-top: 10px; text-align: center;">
        <a class="altmetric_details" target="_self" href="https://www.altmetric.com/details.php?domain=www.jci.org&amp;citation_id=1009194">
            See more details
        </a>
    </div>
</div></div></div></div></div></body></html>